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HIV/AIDS still remains to be a challenging epidemic infecting millions of individuals 
worldwide. The morbidity and mortality rates of HIV-infected patients has been well 
documented over the years. Despite on-going HIV/AIDS research and access to antiretroviral 
therapy, to date still no cure exists for this deliberating disease.  
In recent years, computational approaches have emerged as close counterparts to experiments in 
modern drug discovery process and in understanding complex biological phenomena. An array 
of in-silico computational techniques were implemented ranging from molecular dynamic (MD) 
simulations, de-novo design, hybrid structure-based and pharmacophore-based virtual screening, 
quantitative structure-activity relationship (QSAR), homology modeling, principle component 
analysis (PCA), residue interaction network analysis (RIN), substrate envelope analysis (SEA), 
to molecular mechanics and quantum mechanics.  
The first report (Chapter 4), demonstrated a unique strategy for developing dual acting inhibitors 
against HIV-1 protease (PR) and reverse transcriptase (RT). The designed targets exhibited 
binding affinities and dual inhibiting activity comparable to, and in some cases better than, 
known active reference drugs. 
The second study (Chapter 5), reported the activity of flexible hydroquinone-based compounds 
as non-nucleoside reverse transcriptase inhibitors (NNRTIs), as proposed by Bruccoleri, where 
no experimental or computational work supported his proposal. Results concluded that the novel 
flexible hydroquinone-based compounds showed improved binding affinity as compared to 
FDA-approved prototype drugs and more specifically potent potential mutant-resistant NNRT 
inhibitor activity. 
The third report (Chapter 6), explored the activity of novel CCR5 antagonists as potential    HIV-
1 entry inhibitors. Ten scaffolds were identified as novel CCR5 antagonists or potential HIV-1 
entry inhibitors. Furthermore, from the generated atom-based 3D-QSAR model, all of the 
parameters showed certain reliability and feasible predictability to help us design new and high 
selectivity CCR5 inhibitors.  
 
The fourth study (Chapter 7), explored the atomistic basis of why the M184I single mutation 
renders complete resistance of HIV-1 RT to lamivudine. Multiple molecular dynamics 
simulations, binding free energy calculations, principle component analysis (PCA) and residue 
interaction network (RIN) analyses adequately clarified the effect of the M184I mutation on drug 
resistance to lamvudine. Results presented in this study verified that M184I mutation decreased 
drug binding affinity, distorted ligand optimum orientation in RT active site and affected the 
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overall protein conformational landscape. The results also provided some potential clues for 
further design of novel inhibitors that are less susceptible to drug resistance.  
In the fifth study (Chapter 8), we identified potential HIV-Nef inhibitors by exploiting the 
structural features of B9 using an integrated computational tools framework. The top identified 
hit compounds demonstrated comparatively better binding affinities and relatable binding modes 
compared to the prototype antagonist, B9. Top identified hits were proposed as new potential 
novel leads targeting HIV-Nef with a detailed analysis of their respective binding modes. 
 
The sixth report (Chapter 9), aimed to reveal the dimer packing and unpacking phenomena of 
HIV-Nef in its apo and inhibitor bound conformations using molecular dynamic simulations. 
Results verified a more conformational flexible nature of HIV-Nef dimer in the absence of an 
inhibitor.as compared to B9 bound conformation of HIV-Nef, which was found to be more 
conformationally rigid with a lesser inter-dimeric association. 
 
We believe that the results obtained from these several studies could be of great benefit in the 
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1.1. Background and rationale for this study   
HIV/AIDS still remains a challenging epidemic that is rapidly characterized by high mortality 
and morbidity rates. Stringent control of this “global killer” is now perhaps the foremost 
development imperative for the world. It has been reported that 34 million people live with 
HIV/AIDS globally 1, 2. In sub-Saharan Africa, an approximated 22.9 million individuals 
constitute the overall global estimate 3. 
 
Despite the fact that Highly-Active Antiretroviral Therapy (HAART) has proved successful in 
order to ensure the efficacy of such a primary therapeutic regimen for AIDS, the benefits of this 
tactic are more than often compromised by problems, such as patient compliance, complicated 
dosing, intolerable acute and chronic toxicity profiles that leads to the failure of complete 
adherence and which in turn results in multi-drug resistance.  
In recent years, computational approaches have emerged as close counterparts to experiments in 
modern drug discovery process and in understanding complex biological phenomena.  
 
Therefore, in one report, a unique strategy was generated for developing dual acting inhibitors 
against HIV-1 protease (PR) and reverse transcriptase (RT) that may result in lower toxicity 
profiles, easier dosing regimens and lower or no multi-drug resistance. The unique strategy 
encompassed “loop-docking” and molecular dynamics simulations.  
 
Although an array of inhibitors haven been approved for targeting RT, their therapeutic effects 
are hampered by several complications, such as NRTIs exhibit high levels of cellular toxicity 4, 
compared to NNRTIs, which are severely weakened by the rapid emergence of drug-resistant 
strains 29, 30. Therefore, it is suggested that more flexible NNRTIs may be more effective against 
drug-resistant strains. Bruccoleri 5 proposed the conception of utilizing flexible hydroquinone-
based compounds as potential mutant-resistant NNRT inhibitors, however, no experimental or 
computational evidence supported this proposal. Thus, a study presented herein, provided the 
computational framework support by querying chemical databases, screening and verifying the 
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activity of a set of flexible hydroquinone-based compounds as mutant –resistant non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), 
 
In an effort to combat HIV-1, depends on targeting the critical stages of the viral life cycle, such 
as viral entry, replication and maturation. Because of the high genetic variability of HIV-1 
acquired mutations accumulated during the viral replicative process, this has often resulted in 
drug resistance. Thus, a better understanding of the mutational effect on the binding 
conformation is of urgent importance. This may lead to development of antiretroviral drugs that 
are less prone to resistance. 
 
An important constituent of triple-drug anti-AIDS therapy is the NRTI, lamivudine. It has been 
proven that single mutations at residue 184 of RT in HIV cause high-level resistance to 3TC and 
contribute to the failure of anti-AIDS combination therapy. Thus, molecular dynamics (MD) 
simulations, binding free energy calculations, principle component analysis (PCA) and residue 
interaction network (RIN) analysis were used in a report herein to provide useful information for 
understanding the drug resistance mechanism against lamivudine. Also, the comprehensive 
analysis could also provide potential cues for the further design of novel inhibitors that are less 
susceptible to drug resistance. 
 
Recently acquired knowledge about the HIV entry process points to new strategies to block viral 
entry. To this end, the homology model of the chemokine co-receptor 5 protein (CCR5) was 
generated and chemical databases were queried in order to identify novel CCR5 antagonists as 
potential HIV-1 entry inhibitors.  
 
Because of its major role in HIV-1 pathogenicity, Nef protein has proven to be a very important 
target in anti-HIV drug design and discovery process. To date, only one small molecule, B9, has 
been reported as a potent Nef inhibitor. Herewith, exploiting the structural features of B9 and 
relatable binding modes by using an integrated computational tools framework to identify more 




Understanding Nef dimerization process and its inhibition mechanism is crucial for the design of 
more potent inhibitors as anti-HIV antagonists.  Molecular dynamic simulations could be used to 
reveal the dimer packing and unpacking phenomena of HIV-Nef in its apo and inhibitor bound 
conformations.  
 
The results obtained from these several studies could of great benefit in the development of more 
effective therapeutic interventions for the treatment and cure of HIV/AIDS. 
 
1.2. Aims and objectives 
This study has six major aims: 
1. To design novel inhibitors with potential dual activity against HIV Protease (PR) and 
Reverse transcriptase (RT) enzymes. To accomplish this, the following objectives were 
outlined: 
1.1.  To design dual inhibitors using an integrated “tough” in silico rational design 
strategy that exploits the structural features of both the inhibitor and enzyme active 
site using a “loop docking/MD strategy”. 
1.2.  To initially design novel leads based on the pharmacophoric features conserved 
in most potent FDA-approved PR and NRT inhibitors. 
1.3.  To subject the pharmacophore-based leads and search the Zinc Database for 
structure-based scaffolds against the respective enzyme to estimate their binding 
affinities. 
1.4.  To accurately estimate the binding affinity and enhance docking calculations 
predications by implementing “loop docking”. 
1.5.  To measure the stability of the resulted docked structures over a reasonable time 
scale using molecular dynamic simulations. Furthermore, all docked structures that 
will fail to exhibit stability will be subjected to further docking or rejected. 
1.6.  To compute ligand-enzyme interactions on post-dynamic structures to ensure that 
the proposed leads fit well into the enzyme active site and whether exhibit similar 
interaction trends as reference drugs. 
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1.7.  To quantitatively estimate the contribution of each amino acid residue in the 
enzyme active site towards ligand binding. 
1.8.  To screen a wider set of substituents for further lead optimization and expansion. 
 
 
2. To verify the activity of hydroquinone-based compounds as non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), as proposed by Bruccoleri 5. To accomplish this, the 
following objectives were outlined: 
 
2.1.  To design and investigate the binding affinity and themes for a novel set of 
different     hydroquinone-based structures against RT enzyme at the molecular level.  
2.2.  To identify a wider range of novel hydroquinone-based compounds from the 
commercially available chemical databases. 
2.3.  To perform docking calculations, molecular dynamic stimulations and post-
dynamics analysis and per-residue energy contribution in order to accurately estimate 
the relative binding affinities of the proposed compounds against RT enzyme as well 
as to ensure the stability of the resulted ligand-enzyme complexes. 
2.4.  To validate docking calculations will adopt the same docking approach and apply 
to different FDA-approved NNRTIs and compare results against experimental data. 
 
3. To identify novel CCR5 antagonists as potential HIV-1 entry inhibitors using integrated 
computational tools. To accomplish this, the following objectives were outlined: 
 
3.1.  To identify a wider range of constituents with oxamino-piperidino-piperidine 
amide analogs properties from commercially chemical databases by performing 
hybrid structure-based and ligand-based virtual screening. 
3.2.  To validate docking calculations will adopt the same docking approach and apply 
to different FDA-approved NNRTIs and compare results against experimental data. 
3.3.  To construct a homology model of CCR5 enzyme using CXCR4 has a structural 
template and CCR5 human protein sequence. 
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3.4.  To accurately estimate the binding affinities using docking calculations and 
estimate the stability of systems over a specified time scale using molecular dynamic 
simulations. As well as to investigate the nature of the overall interaction themes 
between the generated leads and target protein and specific amino acid involved in 
ligand binding using post-dynamic analyses.   
3.5.  To build and generate an atom-based 3D-QSAR model using a set of 35 novel 
oxamino-piperidino-piperidine amide analogs with available IC50 (mM) data taken 
from literature. 
 
4. To provide a more comprehensive insight into the precise impact of the M184I mutation 
on RT resistance to lamivudine. To accomplish this, the following objectives were 
outlined: 
4.1.  To provide an deeper understanding into the drug resistance mechanism of the 
RT-M184I mutant to lamivudine using validated models of wild type and M184I 
mutant lamivudine–RT complexes; using multiple molecular dynamic simulations, 
post-dynamic analysis, binding free energy calculations, principle component analysis 
(PCA) and residue interaction network (RIN) analysis, respectively. 
4.2.   To construct validated the 3D X-ray crystal structures of lamivudine-RT 
complexes using a “ligand fitting” strategy. 
 
5. To identify more potent potential HIV-Nef inhibitors by exploiting the structural features 
of B9 using an integrated computational tools framework. To accomplish this, the 
following objectives were outlined: 
 
5.1. To identify a wider range of constituents with diphenylpyrazole analog properties 
to B9 from commercial chemical databases by performing hybrid shape similarity and 
pharmacophore-based virtual screening. 
5.2.  To estimate different binding energy affinities and poses/trends using docking 
calculations.  
5.3.  To validate docking poses and binding energy trends using molecular dynamic 
simulations as well as to provide further verification on the resulted- docked systems. 
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5.4.  To quantify individual amino acid interactions towards total binding free energy 
computed per-residue interactions using MM/GBSA approach. Also, to provide a set 
of chemical structures and detailed binding mode analysis for further optimization 
and expansion.  
 
6. To reveal the dimer packing and unpacking phenomena of HIV-Nef in its apo and 
inhibitor bound conformations.  To accomplish this, the following objectives were 
outlined: 
 
6.1.  To understand the dynamic landscape of HIV-Nef protein structure, dynamics, 
dimerization and inhibitory mechanisms using classical comparative molecular 
dynamic simulations for the apo and bound protein. This was also assisted by a wide 
range of post-dynamic analyses, which includes: dynamic cross correlation (DCC), 
principal component analysis (PCA), radius of gyration (Rg), protein mobility plots 
as well as monitoring other several metrics.  
 
1.3. Novelty and significance of this study 
This incapacitating disease produces high viral titers and in turn causes destruction to the host 
immune system and eventually results in death of infected individuals. The HIV viral core 
encloses three crucial enzymes, reverse transcriptase (RT), integrase (IN) and protease (PR), 
which are imperative targets in viral replication and survival 6-9. Reverse transcriptase (RT) is a 
vital component in the HIV-1 life cycle, where this multifunctional enzyme facilitates the 
conversion of single-stranded viral RNA genome into double-stranded DNA (dsDNA)10, 11. HIV-
1 IN catalyzes two step-wise reactions that are imperative in viral integration: catalysis of virus-
host dsDNA, endonucleolytic processing of the 3’ ends of HIV-1 dsDNA and strand transfer of 
viral and cellular DNA 12, 13. However, HIV-1 PR is responsible for catalytic cleavage of newly 
synthesized polypeptide precursor proteins, gag and gag-pol, which are essential elements for 




The HIV-1 life cycle presents a myriad of factors and enzymes to be targeted for therapeutic 
intervention. Despite the ongoing HIV/AIDS research, to date no cure yet exists for this disease. 
Currently, the most effective treatment comprises of a complex "cocktail” of Food and Drug 
Administration (FDA)-approved and clinical trial drugs that involve multiple drug targets 16-20.  
These drugs target and attack the virus at different stages of its lifecycle, thereby halting viral 
replication and reducing destruction of the immune system. They include: protease inhibitors 
(PIs), reverse transcriptase (RT) inhibitors, integrase (IN) inhibitors and entry inhibitors 21, 22. 
As stated earlier, three main HIV-1 enzymes, protease (PR), integrase (IN) and reverse 
transcriptase (RT), have been exploited as the core of chemotherapy for AIDS treatment 16-20. 
Although, researchers have designed inhibitors that successfully target and inhibit each enzyme, 
however, the therapeutic effects of these drugs are severely compromised by numerous 
implications. For instance, NRTIs have been reported to demonstrate high intrinsic toxicity 4, 
whilst, the less toxic PIs, INIs and NNRTIs are drastically hampered owing to the rapid 
emergence of drug-resistant viral strains 23, 24. Furthermore, persistent therapeutic profiles can 
also result in chronic toxicity.  
At present, due to extensive research, it is known that a single therapy might not always provide 
the desired efficacy vs side effect paradigm. When the high specificity proves insufficient for a 
single target; medicinal chemists and other pharmaceutics have resorted to molecular modelling 
drug design techniques. Also, presently a common tactic employed by clinicians to overcome 
HIV disease resistance to a single drug is the use of multidrug therapy. HAART combines two or 
more antiretroviral drugs that inhibits two HIV targets, thereby blocking viral fusion and which 
in turn effectively reduces viral load and helps improves a patient’s life 25-28. Despite the fact that 
HAART has proved successful in order to ensure the efficacy of such a primary therapeutic 
regimen for AIDS, the benefits of this tactic are more than often compromised by problems, such 
as patient compliance, complicated dosing, intolerable acute and chronic toxicity profiles that 
leads to the failure of complete adherence and which in turn results in multidrug resistance.  
The concept of designing multifunctional inhibitors has been proposed before 29-32, where 
medicinal chemists and other researchers highlight the increasing shift towards multifunctional 
inhibitors as well as the various opportunities and advantages allied with the development of 
such compounds.  
8 
 
Herein, we reported the main concept of designing potential proposed dual acting PR/RT HIV 
inhibitors assisted by an integrated in silico computational approach that exploited the structural 
features of both the inhibitor and enzyme active site. We introduced an in silico “loop-
docking/MD strategy” that relied on the use of docking calculations to predict the preferred 
binding orientation of potential drug candidates within the enzyme active sites, then followed by 
molecular dynamic simulations to accurately estimate the binding affinity, and the stability of 
inhibitor-enzyme complexes and per-residue interaction binding analysis.  
Although, a large number of inhibitors that target RT have been approved for treatment 22, 33, 
there are many complications that hinder the therapeutic effect of these inhibitors. For instance, 
NRTIs demonstrated high levels of cellular toxicity 4, whereas the highly potent and less toxic 
NNRTIs are severely weakened by the rapid emergence of drug-resistant strains 23, 24. Therefore, 
tackling the drug-resistant implications associated with NNRTIs could result in less toxic and 
more potent inhibitors as anti-HIV RT. It is strongly believed that more flexible NNRTIs could 
be more effective against drug-resistant mutants. 
The concept of designing flexible RT inhibitors has been proposed before 34, 35 . Ohtaka and his 
colleagues made a conclusion that a protease inhibitor required to be flexible in nature in order to 
bind to mutant enzymes 34. Soon afterwards, Das et al (2005), concluded that conformational 
flexibility of an NNRTI was crucial in preserving the functionality of an NNRTI being exposed 
to mutations of resist antiviral strains 35. 
The proposal of hydroquinone-based structures as flexible NNRTIs was first introduced by 
Bruccoleri 5, however, this proposal was not supported by either experimental or computational 
evidences. Therefore, the work reported herein is an attempt to verify the activity of 
hydroquinone-based compounds as NNRTIs, as proposed by Bruccoleri 5. In order to accomplish 
this, we have designed and investigated the binding affinity and interaction themes for a novel 
set of different hydroquinone-based structures against the RT enzyme at the molecular level.  
An important fact to consider when predicting the efficacy of a library of ligands is the time 
needed to calculate the affinity of a typical ligand. Screening of large virtual libraries demands a 
high throughput of ligands and requirement for a short period of time in evaluating a single 
compound. Varieties of computational approaches have been developed over the years to predict 
binding constants and this from statistical ones to methodologies based on the evaluation of 
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binding energies and interaction networks. Structure-based virtual screening was performed to 
identify a wider range of novel hydroquinone-based compounds from the commercially available 
chemical databases then followed this de-novo design. Furthermore, we performed docking 
calculations, molecular dynamic stimulations, post-dynamics analysis and per-residue energy 
contribution analysis.   
Even though NRTIs have served as the cornerstones of successful HIV therapy, the largest 
problem in HIV drug therapy is that the virus mutates very quickly, leading not only to drug 
resistance 36, but also drug-resistant variants of the virus that have mutations in the RT target 
protein 37, 38.  For this reason a molecular understanding of the impact of mutations on drug 
resistance will assist in the design of more potent drugs that are active against resistant strains.  
An important constituent of triple-drug anti-AIDS therapy is the NRTI 2', 3'-dideoxy-3'-
thiacytidine (3TC, lamivudine). It has been proven that single mutations at residue 184 of RT in 
HIV cause high-level resistance to 3TC and contribute to the failure of anti-AIDS combination 
therapy 39.  Partially due to the lack of an X-ray crystal structure of the lamivudine-RT complex, 
the precise mechanism by which the M184I mutant develops resistance to lamivudine is not fully 
understood. Based on a previously built model from “unbound” X-ray crystal structures of the 
wild type and M184I mutant, it is thought that steric conflict between the oxathiolane ring of 
lamivudine and the side chain of beta-branched amino acids Ile at position 184 perturbs inhibitor 
binding, leading to a reduction in incorporation of the analog 39. However, this assumption was 
based on approximated “fitted” and “static” models. 
Herewith, we believe this to be a first account study, where multiple molecular dynamics 
simulations, binding free energy calculations, principle component analysis (PCA) and residue 
interaction network (RIN) analysis were employed in order to investigate the atomistic basis of 
the mystery of why the M184I single mutation leaves the HIV-1 reverse transcriptase (RT) 
totally resistant to lamivudine. We believe that, to develop potent and effective anti-HIV NRTIs 
against the viral variants, understanding of the molecular basis of the M184I RT mutation at 
atomic level will be very critical. 
Recently acquired knowledge about the HIV entry process points to new strategies to block viral 
entry. For most HIV strains, the successful infection of their target cells is mainly dependent on 
the presence of CD4 surface molecule, which serves as the primary virus receptor 40, 41. One such 
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example is the chemokine receptor CCR5 has proven to be a crucial pharmaceutical target in the 
contexts of HIV-1 and other inflammatory diseases 42-45. 
 
Only one small molecule, maraviroc, has been currently approved as a potent CCR5 antagonist 
by the FDA 46-48. Despite the fact that no structural information exists about CCR5 precise 
binding site and no reported X-ray 3D crystal structure of CCR5 is yet available; only three other 
previous studies have reported the concept of designing small molecule CCR5 antagonists 42-45. 
For the purpose of our study, we created and validated an actual CCR5 homology model using 
CXCR4 crystal structure and maraviroc as structural templates. For the work described herein, 
we attempted to report more potential small molecule CCR5 antagonists via a validated CCR5 
crystal structure together with an integrated computational design of a hybrid structure-based and 
ligand-based virtual screening, extensive molecular dynamic simulations and post-dynamic 
analyses.  
 
We further also included another highly prominent statistical computational approach to predict 
binding efficacy of constants using QSAR. This method attempts to correlate molecular 
properties to physiochemical properties of a set of structures to predict biological activities of 
other compounds, thereby reducing the time spent on synthesizing numerous compounds. 
Therefore, we incorporated a set of 35 novel oxamino-piperidino-piperidine amide analogs with 
available IC50 (mM) data taken from literature for the development of an atom-based 3D-QSAR 
model.  
 
As an emerging target, HIV-Negative Factor (Nef) protein, an accessory pathogenic factor, plays 
a significant role in HIV replication 49, 50. Reports have indicated that removal of Nef protein 
leads to high viral insensitivity levels. Therefore, targeting Nef is considered a key strategy 
towards HIV/AIDS treatment. 
 
Up-to-date, only one compound has been reported as a potent Nef antagonist, known as B9 109, 
110. This has prompted us to provide this first account of an integrated computational framework 
in order to identify more potential Nef inhibitors. Herein, using a hybrid ligand virtual screening, 
shape similarity- and pharmacophore-based, approach combined with molecular dynamics and 
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post- dynamics analysis were applied to identify potential new leads targeting HIV-Nef with a 
detailed analysis of their binding modes.  
 
Because of its major role in HIV-1 pathogenicity, Nef protein has been proved to be a very 
important target in anti-HIV drug design and discovery process 2, 50. Understanding Nef 
dimerization process and its inhibition mechanism is crucial for the design of more potent 
inhibitors as anti-HIV antagonists.  In recent years, molecular dynamics simulations and post 
dynamics calculations emerged as a close counterpart to experiment and helps in understanding 
complex biological phenomena.  
 
Herein, in order to understand the dynamic landscape HIV-Nef dimerization process and its 
inhibition, comparative molecular dynamics simulations were employed for the apo and bound 
protein. A wide range of post-dynamic analyses were carried out in order to accomplish this task 
– these include; dynamic cross correlation (DCC), principal component analysis (PCA), radius of 
gyration (Rg), protein mobility plots as well as monitoring other several metrics. To our best 
knowledge, this is the first account of such comprehensive computational study on this crucial 
HIV target. Therefore, we believe that this report serves as a cornerstone towards the 
understanding HIV-Nef protein structure and dynamics and its inhibitory mechanism. 
 
To this end, the work presented in this thesis is considered a key cornerstone towards further 
understanding of HIV therapy, in general, and the South African version, in particular. Also, this 
study could serve as a road map for further HIV drug design and development. 
 
1.4. Overview of this work 
This thesis is divided into ten chapters, including this one: 
 
Chapter 1: This chapter addresses the background, aim and objectives, significance as well as 





Chapter 2: It provides a general overview on the HIV/AIDS epidemic and therapy. The chapter 
begins with a historic background on HIV/AIDS epidemic followed by some updated statistics 
on the number of HIV infected individuals worldwide and in Africa, respectively. The chapter 
also highlights numerous aspects such as HIV virus structure, life cycle, and the important 
enzymes required for virus maturation, HIV drug targets, drug resistances, drug inhibitors, 
different mechanisms of action and side effects. The HIV PR, RT and Nef enzymes, which are 
the crucial drug targets and the main focus of the work, are then addressed in details including its 
structures and functions, diverse mechanisms of actions, molecular dynamics of these drug 
targets, inhibitor design strategies and the currently approved FDA drugs.  
 
Chapter 3: This chapter provides a brief introduction to computational chemistry, diverse 
molecular modeling and molecular simulations techniques and their respective applications. 
Some computational approaches have been theoretically explained. This is followed by a 
highlight on the different computational tools used in HIV research with main focus on 
molecular dynamics simulations, molecular docking, principle component analysis, residue 
interaction network analysis, hybrid quantum mechanics and molecular mechanics (QM/MM), 
binding free energy calculations and subsequent dynamics calculations.  
 
Chapter 4: (Published work)  
This chapter demonstrates a unique strategy for developing dual acting inhibitors against HIV-1 
protease and reverse transcriptase via an integrated “tough” in-silico computational protocol that 
exploits the structural features of both the inhibitor and enzyme active sites. The computational 
technique implemented in this study relies on “loop docking” and molecular dynamic 
simulations. 
 
Chapter 5: (Published work)  
The proposal of hydroquinone-based structures as flexible non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) was first introduced by Bruccoleri 5, however, this proposal was not 
supported by either experimental or computational evidences. Therefore, in this chapter, the 
work reported herein is an attempt to verify the activity of hydroquinone-based compounds as 
NNRTIs, as proposed by Bruccoleri 5. In order to accomplish this, we have designed and 
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investigated the binding affinity and themes for a novel set of different hydroquinone-based 
structures against RT enzyme at molecular level.  
 
Chapter 6: (Published work)  
This chapter highlights using integrated computational tools including via a hybrid structure-
based and ligand-based virtual screening approach, to identify novel CCR5 antagonists as 
potential HIV-1 entry inhibitors. Since the X-ray 3D CCR5 crystal structure is not yet available, 
the actual homology model of CCR5 was created using CXCR4 crystal structure as a structural 
template. The structure and dynamics of CCR5 as well as the nature of the overall binding 
affinity themes between the generated leads and target protein were studied using molecular 
dynamics followed by extensive post-dynamic analysis. Also included in this chapter, a set of 35 
novel oxamino-piperidino-piperidine amide analogs with available IC50 (mM) data taken from 
literature for the development of an atom-based 3D-QSAR model. 
 
Chapter 7: (Manuscript submitted)  
This chapter aims to provide more comprehensive insight into revealing the mystery of the 
M184I single mutation that leaves the HIV-1 reverse transcriptase (RT) totally resistant to 
lamivudine. The computational techniques included multiple molecular dynamics simulations, 
binding free energy calculations, principle component analysis (PCA), and residue interaction 
network (RIN) analysis. We believe that, to develop potent and effective anti-HIV NRTIs against 
the viral variants, understanding of molecular basis of M184I RT mutation at atomic level will be 
very critical.  
 
Chapter 8: (Manuscript submitted)  
This first account report of an integrated computational framework used in order to identify more 
potential HIV-Nef inhibitors by exploitation of the only reported potent Nef inhibitor, B9 
structural features. The computational tools include: hybrid shape similarity-and-
pharmacophore-based virtual screening approach, molecular dynamics simulations, post-
dynamics analysis and binding free energy calculations. Also, a set of chemical structural 
features and a detailed analysis of the new leads respective binding modes is provided for further 
lead optimization and expansion. 
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Chapter 9: (Manuscript submitted)  
This is the first effort of such a comprehensive computational reported study on the crucial HIV 
target Nef in order to understand the dynamic landscape of HIV-Nef dimerization process and its 
inhibition using comparative molecular dynamic simulations and a variety of post-dynamic 
analyses (i.e. dynamic cross correlation (DCC), principal component analysis (PCA), radius of 
gyration (Rg), protein mobility plots as well as monitoring other several metrics) for both apo 
and inhibitor bound protein states. We believe that this report serves as a cornerstone towards the 
understanding HIV-Nef protein structure and dynamics and its inhibitory mechanism. 
Chapter 10: This chapter expounds the overall concluding remarks of the entire thesis and 
future plans and recommendations. 
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Heinisch, John W. Mellors, Stuart F. Le Grice and Yves Pommier. (2007) 
Madurahydroxylactone Derivatives as Dual Inhibitors of Human Immunodeficiency 




29. Wang, Z., and Vince, R. (2008) Synthesis of pyrimidine and quinolone conjugates as a 
scaffold for dual D - 9107377 18, 1464-3405. 
30. Wang, Z., and Vince, R. (2008) Design and synthesis of dual inhibitors of HIV reverse 
transcriptase and integrase, D - 9413298 16, 1464-3391. 
31. Espinoza-Fonseca, L. M. (2006)  14, 897. 
32. Blake, L., and Soliman, M. E. S. (2013) Bifunctional Anti-HIV/TB Inhibitors: 
Perspective from In-Silico Design and Molecular Dynamics Simulations, Bentham 10, 
712-716. 
33. Bauman, J. D., Das, K.,  Ho1, W.C., Baweja, M., Himmel, D.M., Clark Jr,A.D., Oren, 
D.A.,  Boyer, P.L., Hughes, S.H., Shatkin, A,J., and  Arnold, E. (2008) Crystal 
engineering of HIV-1 reverse transcriptase for structure-based drug design., Nucleic 
Acids Research 36, 5083–5092. 
34. Ohtaka H, V.-C. A., Xie D, and Freire E. (2002) Overcoming drug resistance in HIV-1 
chemotherapy: The binding thermodynamics of amprenavir and TMC-126 to wild-type 
and drug-resistant mutants of the HIV-1 protease., Protein Sci. 11, 1908–1916. 
35. Das K, L. P., Hughes SH, and Arnold E. (2005) Crystallography and the design of anti-
AIDS drugs: Conformational flexibility and positional adaptability are important in the 
design of non-nucleoside HIV-1 reverse transcriptase inhibitors., Prog Biophys Mol Biol 
88, 209–231. 
36. Hamers, R. L., Kityo, C., Sigaloff, K. C., and de Wit, T. F. R. (2013) Pretreatment HIV-1 
drug resistance in Africa, The Lancet infectious diseases 13, 476-476. 
37. Wainberg, M. A., and Turner, D. (2004) Resistance issues with new 
nucleoside/nucleotide backbone options, Jaids-Journal of Acquired Immune Deficiency 
Syndromes 37, S36-S43. 
38. Gao, H. Q., Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H. (2000) The role 
of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse 
transcriptase, Journal of Molecular Biology 300, 403-418. 
39. Sarafianos, S. G., Das, K., Clark, A. D., Ding, J. P., Boyer, P. L., Hughes, S. H., and 
Arnold, E. (1999) Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves 
steric hindrance with beta-branched amino acids, Proceedings of the National Academy 
of Sciences of the United States of America 96, 10027-10032. 
18 
 
40. Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and Lusso, P. 
(1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major, Science. 
270, 1811-1815. 
41. Fano, A., Ritchie, D. W., and Carrieri, A. (2006) Modeling the structural basis of human 
CCR5 chemokine receptor function: From homology model building and molecular 
dynamics validation to agonist and antagonist docking, Journal of Chemical Information 
and Modeling 46, 1223-1235. 
42. Perez-Nueno, V. I., Ritchie, D. W., Rabal, O., Pascual, R., Borrell, J. I., and Teixido, J. 
(2008) Comparison of ligand-based and receptor-based virtual screening of HIV entry 
inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and 
ligand-receptor docking, Journal of Chemical Information and Modeling 48, 509-533. 
43. Afantitis, A., Melagraki, G., Sarimveis, H., Koutentis, P. A., Markopoulos, J., and 
Igglessi-Markopoulou, O. (2006) Investigation of substituent effect of 1-(3,3-
diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR 
and virtual screening techniques, Journal of Computer-Aided Molecular Design 20, 83-
95. 
44. Aher, Y. D., Agrawal, A., Bharatam, P. V., and Garg, P. (2007) 3D-QSAR studies of 
substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor 
antagonists, Journal of Molecular Modeling 13, 519-529. 
45. Kellenberger, E., Springael, J.-Y., Parmentier, M., Hachet-Haas, M., Galzi, J.-L., and 
Rognan, D. (2007) Identification of nonpeptide CCR5 receptor agonists by structure-
based virtual screening, Journal of Medicinal Chemistry 50, 1294-1303. 
46. Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., 
Neveu, V., Djoumbou, Y., Eisner, R., Guo, A. C., and Wishart, D. S. (2011) DrugBank 
3.0: a comprehensive resource for 'Omics' research on drugs, Nucleic Acids Research 39, 
D1035-D1041. 
47. Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., 
and Hassanali, M. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug 
targets, Nucleic Acids Research 36, D901-D906. 
19 
 
48. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, 
Z., and Woolsey, J. (2006) DrugBank: a comprehensive resource for in silico drug 
discovery and exploration, Nucleic Acids Research 34, D668-D672. 
49. Sarafianos, S. G., Das, K., Hughes, S. H., and Arnold, E. (2004) Taking aim at a moving 
target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases, Current 
Opinion in Structural Biology 14, 716-730. 


























2. Background on HIV/AIDS      
2.1. Introduction 
This chapter briefly explains the background, life cycle and different past and present therapeutic 
regimens for Human Immunodeficiency Virus (HIV), the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS).  
 
2.2. The current status of global HIV/AIDS 
Ever since the first case of illness was reported in 1981, the origin of the Human 
Immunodeficiency Syndrome (HIV), the causative agent of Acquired Immunodeficiency 
Syndrome (AIDS) has been the subject of intense challenges and discussions 1. Since the 
discovery of HIV, an increased amount of efforts has been directed towards providing a deeper 
understanding into the cause of this disease, learning more about its invasive and replicative 
behaviours in host cells.  
 
Since the beginning of this global endemic, over 60 million people have already contracted HIV, 
whereas, an estimated 30 million individuals died because of HIV-related causes 2. According to 
recent statistics, this “global killer” has already infected more than 40 million individuals and 
proclaimed the lives of an estimated 22 million globally 3. During 2012, approximately 9.7 
million individuals were reported to have received antiretroviral therapy (ART) in both 
developed and developing countries 4. The 2013 UNAIDS report 5, reported that an estimated 5.7 
million people were living with HIV/AIDS in South Africa. Of this global estimate, 3.3 million 
infected individuals are under the age of 15, whereas approximately 2.5 million newly infected 
cases and 1.7 million reported deaths 6, 7. Currently, an estimated 34 million are living with 
HIV/AIDS worldwide 6, 7, with an approximated 22.9 million in sub-Saharan Africa that 
constitute this overall global estimate  8.  
 
To date, we still have no precious findings about whom was first infected with HIV and exactly 
how this disease was contracted or became widespread from the initial individual. Nevertheless, 
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conceivably a more demanding concern for researchers today should not be how the AIDS 
epidemic was born, but rather how those it affects can be treated, how the further spread of HIV 
can be prevented and how more effective and safer drugs can be designed and developed to beat 
this vicious virus.  
 
2.3. The quest for a better understanding of the HIV virus 
2.3.1. HIV virus: structure and life cycle 
Amongst the classified infectious diseases, the Human Immunodeficiency Virus (HIV) infection, 
the causative agent of AIDS, remains a challenging epidemic 9. This incapacitating disease 
produces high viral titers and in turn causes destruction to the host immune system and 
eventually results in death of infected individuals. 
 
To date, since the discovery of HIV and its association to AIDS, remarkable efforts have been 
made in order to provide deeper insight into the major physiological and molecular mechanisms 
underlying this infectious disease. A deeper understanding of the HIV structure and life cycle is 
fundamental to scientists in order to design potential retroviral inhibitors as well as explore the 
structural implications of the HIV drug resistance mutations. The HIV virus is highly mutable - 
different variants of the HIV virus can evolve within the body of a single infected individual 10.  
 
Virus strains are classified into different types, groups and subtypes depending on their genetic 
similarities 11, 12. The major issue for effective treatment is attributed to the high genetic diversity 
amongst HIV variants. HIV is classified as a member of the Lentivirus subfamily of retroviruses. 
HIV is further divided into two subtypes, namely HIV-1 and HIV-2. Although both viruses are 
responsible for causing AIDS, HIV-1 is primarily responsible for the global HIV epidemic, 
whereas HIV-2 is located more geographically and has a lower transmission rate and is less 
virulent as compared to HIV-1 and does not necessarily cause AIDS in all infected persons 13, 14.  
Furthermore, HIV-1 can be divided into M (main), O (outlier) and N (non-M or non-O) groups. 
The M group is commonly further subdivided into subtypes (A, B, C, D, F, G, H, J and K), 
unique and circulating recombinant forms 13-16. The genetic material of most organisms are stored 
in long DNA strands, however, in the case of retroviruses the genetic material is encoded in the 
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viral Ribonucleic Acid (RNA).Essentially, a retrovirus uses the reverse transcriptase enzyme to 
reverse transcribe its own RNA into viral DNA within the host cell. Thereafter, the integrase 
enzyme incorporates the newly generated DNA is into the host genome. By now, the host cell 
perceives the viral DNA as its own and hence uses it to produce new viral proteins using the 
protease enzyme that is required for viral replication and infection 17.  
 
2.3.2. Structure of the HIV virus 
The HIV virus genome contains two chains of positive single-stranded RNA, which is imperative 
in the replicative process and to sustain persistent infection (Figure 2.1.). The basic structure of 
HIV consists of three parts: the viral envelope, HIV matrix and the viral core (Figure 2.1.). The 
viral envelope is made up of a lipid bilayer that is derived from the host cell during the bussing 
process and also contains other proteins embedded in it which forms protrusions. These proteins 
include: the glycoprotein (gp) 120 required for host cell attachment and the transmembrane gp41 
is essential for cell fusion 18-20. The HIV matrix consists of different proteins and is positioned 
between the bilayer lipid membrane and the viral core, and also contains the p17 protein, which 
is an important structural protein involved in all stages of the virus life cycle and provides more 
stability to virion particle (Figure 2.1.) 18-20.  The viral core contains the viral capsule protein p24 
(encloses the two ssRNA) and all three vital proteins (reverse transcriptase, protease and 
integrase) required for viral replication (Figure 2.1.). Likewise, the viral core also contains the 
three main viral genes (gag, pol and env), which holds the genetic information that is needed in 




Figure 2.1. Structure of the HIV-1 virus adapted from 21. 
 
 
2.3.3. HIV life cycle 
HIV-1 viral replication is described as a series of steps which begins from host cell attachment, 
then viral genome integration and ending with the generation of nascent viral particles that 
eventually mature and then buds off as infectious virions from the newly infected host cell. To 
date, the armamentarium of antiviral drugs has included a new class of therapeutic regimen drugs 
for HIV-1 called antiretroviral drugs. As explained in the following text, the HIV-1 life cycle 
presents a myriad of factors and targets to be targeted for therapeutic intervention.  
 
A typical HIV life cycle is depicted in Figure 2.2. HIV-1 primarily infects CD4+ T lymphocytes, 
dendritic cells and macrophages found in the immune system 22, 23. In order to have persistently 
effective infection, HIV-1 requires attachment with viral and host cell membranes (Figure 2.2.) 
24, 25.  So HIV-1 enters a CD4+ T-cell or a macrophage when the viral surface HIV-1 glycoprotein 
gp120 binds to a chemokine receptor, either CXCR4 or CCR5 on the host cell surface, thus 
allowing for viral fusion and entrance into the host cell 19, 26-29. The series of receptor binding 
stages triggers conformational changes in the viral envelope, allowing for gp41 hydrophobic 





Figure 2.2. Schematic representation of the HIV-1 life cycle 22. 
 
Once the virus successfully binds to the host cell membrane, thus the fusion of the viral envelope 
with the host cell membrane permits the viral core to become uncoated and all of the viral core 
components (Figure 2.2.), such as viral RNA and different enzymes (reverse transcriptase, 
protease and integrase) are injected into the cell. 
 
Reverse transcriptase (RT) is a multifunctional enzyme that has RNA-dependent DNA 
polymerase, RNase-H and DNA-dependent DNA polymerase activities, all of which are crucial 
for viral replication. RT is responsible for converting ssRNAof HIV-1 into double-stranded DNA 
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(dsDNA) in the host cytoplasm by a process called reverse transcription (Figure 2.2.) 17. Reverse 
transcription is known to produce irreversible errors, thus producing frequent mutations within 
each new virus generation. Also, the end product of reverse transcription is the formation of the 
viral pre-integration complex (PIC). This pre-integration complex contains both viral and cellular 
constituents and is translocated to the nucleus, where integrase incorporates the viral dsDNA into 
the host DNA in a process called integration and this is a step crucial in HIV replication 30.  
 
HIV-1 integrase catalyzes two step-wise reactions that are fundamental in viral integration: 
catalysis of the virus-host dsDNA, endonucleolytic processing of the 3’ ends of HIV-1 dsDNA 
and strand transfer of viral and cellular DNA 31. Integration is a point of no return for a cell that 
fundamentally becomes the “master carrier” of the viral genome, and also known as the provirus 
(Figure 2.2.) 32. Furthermore, integration can be regarded in part responsible for persistent viral 
infections. 
 
After successful integration of the viral DNA, the host cell now becomes latently infected with 
the virus and this provirus anticipates activation. Once the host cell (i.e. the provirus) becomes 
activated, transported to the nucleus, viral DNA is transcribed into messenger RNA (mRNA) 
catalyzed by DNA polymerase in a process called transcription (Figure 2.2.). The mRNA, a 
single-stranded DNA strand complementary to the 3’ end of the viral DNA strand, carries 
genetic material from the nucleus to the host cytoplasm and is translated into viral proteins. The 
end products of translation, cellular enzyme (env) precursor polyproteins and transmembrane 
protein (gag and pol) precursors, are then translocated to the cell membrane and assemble into a 
bud conformation.  
 
When all of the different viral subunits have been generated and processed, they have to be 
cleaved/separated in order for final assembly into a new virus (Figure 2.2.) 33. This separation or 
cleavage is controlled by HIV protease enzyme, which cleaves the newly formed polypeptides, 
and allows for binding to other new functional viral RNA proteins. The final step in HIV-1 life 
cycle is the budding process (Figure 2.2.) 34. In this process, the genetic material (i.e. the viral 
RNA and proteins) enclosed in a nucleocapsid fuses with the deformed cell membrane 
developing a new viral outer membrane 35. Thereafter, the newly formed HIV virions buds off 
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from the host cell membrane and is released into bloodstream ready to scavenge and infect other 
potential host cells (Figure 2.2.) 36-38. 
 
The HIV-1 life cycle has an imperative role in viral reproduction and uptake. Understanding the 
structural dynamics as well as the mechanistic behavior of the HIV-1 life cycle is critical in the 
developmental of anti-HIV drugs. Most of these drugs impedes the early steps of the HIV-1 life 
cycle (i.e. attachment and fusion stages) as well as target and inhibit the vital target proteins, 
reverse transcriptase, integrase and protease and others, critical for viral replication, maturation 
and survival. These HIV targets will further be discussed in the succeeding sections. 
 
2.4. HIV enzymes as potential drug targets 
The viral core encloses three crucial enzymes, reverse transcriptase (RT), integrase (IN) and 
protease (PR), which are fundamental in viral replication and survival. However, other factors 
imperative for viral replication such as entry glycoprotein chemokine receptors (e.g. CCR5) and 
transcription accessory proteins (e.g. Nef) have become targets in drug development in the fight 
against HIV/AIDS. Therefore, in this section the structural as well as the mechanistic features of 
these HIV targets will be explained. 
 
2.4.1. Reverse transcriptase (RT) 
Reverse transcriptase (RT) is a vital component in the HIV-1 life cycle, where this 
multifunctional enzyme facilitates the conversion of single-stranded viral RNA genome into 
double-stranded DNA (Figure 2.3.) 17.  Reverse transcription is accomplished as a result of the 
in-built polymerase-dependent activity in RT, such as the RNA-dependent DNA polymerase, 
RNase-H and DNA-dependent DNA polymerase activities 17. RT was the very first HIV-1 
protein to be used as a target in anti-HIV drug development 17. 
 
As illustrated in Figure 2.3., RT is an asymmetrical heterodimer comprised of a 66-kDa subunit 
and a 51-kDa subunit with 560 and 460 amino acid residues, respectively and is connected to 
each other by a common amino terminus 39, 40. The p66 subunit (Figure 2.3.) is further divided 
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into the polymerase and RNase H domains, which are spatially distinct in nature 40.  The structure 
of the polymerase domain (Figure 2.3.) resembles that of a right hand, however, is comprised of 
three highly conserved regions, and i.e. fingers domain, palm domain and thumb domain, 
respectively 41, 42.  Furthermore, the highly active RNase H domain and connection domain are 
located in this p66 subunit (Figure 2.3.). Although, the p51 subunit consists of the identical 
domains situated in the p66 subunit, however, these are orientated differently 40. These different 
positions are the main reason that the p51 subunit folds differently from the p66 subunit. Even 
though the p51 subunit lacks enzymatic activity, it stills provides a supportive framework for p66 
catalytic activities 43-45. 
 
Figure 2.3. The X-ray crystal structure of reverse transcriptase (RT) (PDB code: 3KLF) with the P51 subunit 
(cyan) and the P66 subunit (green) respectively 40. 
 
Reverse transcriptase is a key role player in several distinct biological functions all of which are 
essential in the retrotranscription procedure. These include: RNase H catalysis, RNA-and-DNA-
dependent DNA synthesis, strand transfer and RNA cleavage 17. The highly dynamic nature of 
RT is primarily responsible for the execution of its array of functions. It is this very high 
dynamic nature that permits the unrestrained gliding of RT over long distances of RNA/DNA 
and DNA/DNA complexes, to effortlessly target the primer terminus for DNA polymerization, 
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and to gain quick access to numerous sites. It was recently reported that RT has an 
interchangeable dual binding mode of action, enabling RT to bind to different nucleic acid 
substrates 39. These two different binding positions are termed RNase H cleavage component 
orientation” and “polymerase component orientation” and co-exist in dynamic equilibrium. 
 
Reverse transcriptase is the target for two distinct classes of antiviral drugs, nucleoside RT 
inhibitors (NRIs) and non-nucleoside RT inhibitors (NNRTIs) 46, which will be discussed in 
detail in the following sections. 
 
2.4.2. Integrase (IN) 
HIV-1 integrase (IN) (Figure 2.4.) was one of the most recent HIV-1 enzymes to be featured in 
antiretroviral drug discovery 47, 48. The highly replicative and infectiveness nature of HIV-1 is 
predominantly dependent upon the insertion of a single DNA copy enclosed in the viral genome 
into the host cell chromosome in a process called integration 49. The HIV-1 IN catalyzes the 
various DNA cleaving and ligating steps that constitute the integration of HIV-1 into the host 
cell genome 50-54.  More specifically, IN catalyzes endonucleolytic processing of the 3’ end of 
dsDNA and DNA strand transfer 53, 54. 
 
The HIV-1 IN enzyme is 31-kDa in size and composed of 288 amino acid residues and three 
distinct domains: an N-terminal domain, the catalytic core and an C-terminal domain, 
respectively (Figure 2.4.) 37, 49, 55. It has been reported that all three domains are indispensable to 
integration, however, it is postulated that the catalytic domain contains principle active site 
amino acids, which are essential for catalyzing both the chemical reactions of integration and 
disintegration processes 56-59.  The N-terminal encloses a His2Cyst2 zinc-binding motif (Figure 
2.4.), which indicates that this domain interacts with nucleic acids; whereas, the C-terminal 
domain houses a DNA binding domain (Figure 2.4.) indicating that this domain can facilitate 





Figure 2.4. Structure of HIV-1 integrase (IN) enzyme (PBD code: 1EX4) with the N-terminal (HH-CC zinc-
binding catalytic core) domain and C-terminal (DNA binding domain) sections. 
 
HIV-1 IN catalyzes 3’ end processing and DNA strand transfer 47, 48, 60. Since integration positions 
in the host genome are non-specific, assimilation can occur at any possible site. Therefore, HIV-
1 IN has become a promising target in anti-HIV drug discovery. Thus, IN inhibitors 
(INIs/InSTIs) to be discussed in the following section are highly specific, as these drugs target 
and inhibit strand transfer and hence block the insertion of viral DNA into cellular DNA 61-64.  As 
the integration of HIV-1 genetic material (i.e. RNA) into the host DNA is crucial for preserving 
the dsDNA found in an infected cell as well as is important for viral protein and RNA 
expression. The mechanism mentioned previously is unique to HIV-1 and is therefore regarded 
as a favorable therapeutic target.  
 
2.4.3. Protease (PR) 
The HIV-1 protease (PR) enzyme has been investigated as a strategic target in anti-HIV drug 
discovery (Figure 2.5.) 65. As stated earlier, HIV-1 PR is responsible for the catalytic cleavage of 
newly synthesized polypeptide precursor proteins, gag and gag-pol, which are essential elements 




Investigation of the X-ray crystal structure of HIV-1 PR revealed that PR is a dimeric protein, 
with each component containing 99 amino acid residues and is 11-kDa in size 70, 71.  As shown in 
Figure 2.5, HIV-1 PR is composed of three canonical domains: N-terminal domain (active site 
cavity), middle domain and C-terminal domain (dimerization cavity). Also, a flexible flap region 
domain encloses the active site and does so more during substrate binding (Figure 2.5.) 34, 72.  It 
was reported that the active site cavity located in the N-terminal domain is fundamental in 
stabilization of the dimer and catalytic sites 1, 34, 70. 
 
Figure 2.5. Structure of the dimer of HIV-1 protease (PR) (PDB code: 3QOZ) with the two-dimerization 
domains (purple and yellow), flaps, a polypeptide substrate (cyan) and active site domain (Asp 25 amino acids 
–cyan) 
 
As mentioned above, HIV-1 PR is an integral enzyme in catalytic splicing of viral polypeptide 
precursor proteins that are required for virion maturation. Therefore, HIV-1 PR presents itself as 
an attractive target in antiretroviral drug development. Protease inhibitors (PIs) bind and inhibit 
PR enzyme, and thus the HIV-1 life cycle is interrupted as the virus is prohibited from maturing 
and therefore cannot transform into its infectious stage. Protease inhibitors will further be 
discussed in the following sections.  
To date, there are currently several FDA-approved drugs in clinical use and commercially 




2.4.4. New avenues for the discovery of potential anti-HIV targets 
Numerous concerns regarding the long-term side effects of antiretroviral drugs and the 
increasing transmission of resistant variants accentuates the requirement to identify new classes 
of drugs, which are able to suppress HIV-1 replication efficiently 9. Thus, there is an on-going 
need for novel therapeutics, which can prevent the entry of HIV-1 into its target cells 73, 74. 
Therefore, the next section provides insight into the structural and functional properties of two 
such new avenue structures, co-receptor chemokine receptor 5 (CCR5) and negative factor (Nef) 
as potential anti-HIV targets.  
 
2.4.4.1. Chemokine Co-receptor receptor 5 (CCR5)  
The entry of the HIV virus into its target cell is mediated by the specific interactions of the target 
cell itself such as the interaction between gp120 viral envelope glycoprotein and the plasmatic 
membrane receptors 75.  
 
Besides CD4, certain chemokine receptors (CCRs) belonging to the G-protein coupled receptor 
superfamily (GPCRs) have recently been identified as co-targets essential for HIV viral entry 
into target cells 73, 76. The chemokine co-receptor 5 (CCR5) (Figure 2.6.) has been reported to be 
a crucial pharmaceutical target in HIV-1 infection and other inflammatory diseases. CCR5 acts 
as an integral co-receptor to gp120 glycoprotein during HIV-1 cell membrane attachment.  
 
 




To date, limited research that has been conducted on this CCR5 co-receptor protein (Figure 2.6.) 
77-80. Despite the fact that no structural information exists about CCR5 precise binding site and 
lack of an X-ray crystal structure, few studies have investigated and reported findings on creating 
homology models and designing small molecule CCR5 antagonists 77-80. Homology modeling of 
CCR5 (Figure 2.6.) has been reported before, where CXCR4 was used as a structural template 73.  
 
2.4.4.2. Negative factor (Nef) 
In addition to the reported structural proteins, HIV-1 is responsible for encoding of four different 
accessory proteins, which are required for immune evasion and optimization for viral replication. 
81, 82. Among these, is HIV-negative factor (Nef) (Figure 2.7.), a small 27-35 kDa myristoylated 
protein, which has an imperative role in HIV-1 pathogenicity and more specifically expressed as 
a virulence factor 81, 82. Nef is produced in large quantities during the early stages of viral gene 
expression 7. 
  
Nef is a myriostoylated protein that is composed of 206 amino acid residues and is located in the 
cytoplasm as well as has association with cellular membranes (Figure 2.7.) 83. The structure of      
HIV-1 Nef  (Figure 2.7.) is characterized by its flexible loop regions that contain several 
sequence motifs as an N-terminal myristoylation site, a central poly-proline PxxP motif for SH3 
domain binding and C-terminal motifs for interaction with clathrin- associated endosomal 
adaptor protein complexes 83.  As illustrated in Figure 2.7, Nef is composed of two dimers, and 
with each dimer been composed of a large sub-domain and small sub-domain and these two 
dimers subunits undergo dimerization in order for Nef protein to become activated, manipulate 





Figure 2.7. Illustration of the HIV-1 Nef dimer protein (PDB code: 1EFN) with two flexible helical loops. 
 
Because of its major role in HIV-1 pathogenicity, Nef protein has been proved to be a very 
important target in anti-HIV drug design and discovery process 
 
2.5. Antiretroviral therapy (HAART) 
In AIDS therapy, the fundamental strategy is to inhibit viral replication and hence, to slow down 
the destruction of the immune system and prolong the lives of infected individuals. Despite the 
ongoing HIV/AIDS research, to date, no cure has yet been found for this disease 84. Currently, 
the most effective treatment comprises a complex "cocktail” FDA-approved and clinical trial 
drugs that involve multiple drug targets 85-88. These drugs target and attack the virus at different 
stages of its lifecycle, thereby halting virus replication and reducing destruction of the immune 
system. These include: protease inhibitors (PIs), reverse transcriptase (RT) inhibitors, integrase 
(IN) inhibitors and entry inhibitors 89. The first antiretroviral drug to be approved by the FDA in 
1987 was a nucleoside reverse transcriptase inhibitor (NRTI) called Zidovudine (AZT) 90. 
Similarly, in 1991, another NRTI, Zalcitibine, was approved for clinical use 91.  Despite the fact 
with the first FDA-approved protease inhibitor, Saquinavir identified in 1995, to date, only nine 
FDA-approved PIs exists 92. Likewise, in 2007, Raltegravir 93, the first integrase inhibitor was 
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approved by the FDA followed by the second INI, Elvitegravir 94 been approved in 2012. The 
latest addition to the class of INIs was Doultegravir, which was approved in 2013 95. 
 
Numerous concerns regarding the long-term side effects of antiretroviral drugs and the 
increasing transmission of resistant variants accentuates the requirement to identify new classes 
of drugs, which are able to suppress HIV-1 replication efficiently 9. Therefore, there is an on-
going need for novel therapeutics, which can target and inhibit the virus at various stages of its 
life cycle 73, 74. 
 
2.5.1. Reverse transcriptase inhibitors 
Since HIV-1 RT is a key role player in viral replication, thus RT has become a significant target 
in drug therapy 96.  These inhibitors mainly interfere with the reverse transcription of viral RNA 
into DNA. In this section, the two distinct classes of approved RT inhibitors (Figure 2.8.): 
nucleoside analog RT inhibitors (NRTIs) 97, 98 and non-nucleoside RT inhibitors (NNRTIs) 97, 99 
are explained in terms of their structural and mechanistic action features. NRTIs are analogs of 
native nucleoside substrates, whereas NNRTIs bind to a non-catalytic allosteric pocket on RT. 
The 12 FDA-approved agents as shown in Figure 2.8 combined from both these classes’ 






Figure 2.8. 2D representation of the 12 FDA-approved RT inhibitors: nucleoside analog RT 
inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs). 
 
2.5.1.1. Nucleoside reverse transcriptase inhibitors (NRTIs) 
As mentioned previously, AZT, an NRTI (Figure 2.8.), was the first reported antiretroviral drug 
to be approved in 1987 for HIV treatment 90. NRTIs are different from other natural 
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deoxynucleotides as these RT inhibitors lack the 3’-hydroxyl group found on the deoxyribose 
moiety 88. NRTIs compete with natural nucleoside substrates for binding to the RT polymerase 
active site, become incorporated into the primer site, covalently bind to DNA and then terminate 
proviral DNA synthesis 97, 99. When NRTIs become incorporated during DNA transcription, 
nucleosides cannot be covalently added and this prevents 5’-3’ phosphordiester bond formation, 
and thus transcription is terminated 100. There are currently eight FDA-approved NRTIs as 
depicted in Figure 2.8., and these include: zidovudine (AZT), lamivudine (3TC), emtricitabine 
(FTC), tenofovir (TDF), didanosine (ddl), stavudine (d4T), zalcitabine (ddC) and abacavir 
(ABC) 92 100. 
 
The next section will discuss the other second type of RT inhibitors, non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), which exhibits less toxicity compared to NRTIs.  
2.5.1.2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) (Figure 2.8.) were first reported in 
1990. This class of RT inhibitors have more site-specific interactions with the allosteric (non-
substrate binding) site on HIV-RT. When RT active site undergoes conformational changes, it 
prevents viral replicative process 101. Currently, there are five approved NNRTIs (Figure 2.8.): 
nevirapine (NVP), etravirine (ETV), efavirenz (EFV) and rilpivirine (RPV) reported during 
1996-2011 101 97, 99. 
 
2.5.2. Integrase inhibitors 
Integrase was one of the most recent HIV-1 enzyme to have been successfully targeted for anti-
HIV therapy 47, 48.  During the past two decades, a variety of small candidate molecule inhibitors 
have been identified from high-throughput screening and other diverse chemical classes as 
potential integrase inhibitors (INIs) 61-64.  Diketo aryl (DKA) and DKA-like inhibitors, or which 
are more commonly known as strand-transfer inhibitors have been identified to date as the most 
promising INIs or INSTIs. These inhibitors either halts HIV transcription by blocking the DNA 
strand transfer reaction or by inhibiting the Tat-TAR interaction 61-64.  Raltegravir, was the first 
integrase inhibitor to be approved by the FDA in 2007 93, followed by elvitegravir approved in 





Figure 2.9. 2D representation of two FDA-approved Integrase inhibitors (INIs): Raltegravir and 
Dolutegravir, respectively. 
 
2.5.3. Protease Inhibitors 
As stated earlier, HIV-1 protease is responsible for the catalytic cleavage of newly formed 
polypeptide protein precursors into smaller particles required for virion maturation 34.  Therefore, 
the timing step of this stage is very critical and thus presents HIV-1 PR as a highly favorable 
target for drug therapy. Protease inhibitors (Figure 2.10.) are the class of antiretroviral drugs that 
target and bind to HIV PR and therefore prevent the virus from maturing and proceeding into its 
infectious stage 1, 71, 103, 104. Protease inhibitors (Figure 2.10.) are considered amongst some of the 
most remarkable achievements in modern medicine. The mechanism of action of PR inhibitors is 
to inhibit the catalytic activity of PR enzyme, which disrupts new virion maturation, and thus 





Figure 2.10. 2D representation of FDA-approved anti-HIV PR drugs. 
 
Since the introduction of HIV PR inhibitors (Figure 2.10.) in 1995 92, these anti-HIV drugs have 
been widely used, more often as the basis in HAART, i.e. the combination of PIs with other anti-
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HIV drugs 103, 104. It has been reported that the introduction of HAART has resulted in decrease 
mortality and prolonged life expectancy of numerous HIV infected individuals. As shown in  
Figure 2.10., there are currently nine PIs approved by the FDA: nelfinavir (NFV), ritonavir 
(RTV), indinavir (IDV), saquinavir (SQV), amprenavir (APV), tipranavir (TPV), atazanavir 
(ATV), lopinavir (LPV) and darunavir (DRV) 105. 
 
2.5.4. Entry inhibitors  
These are competitive type of inhibitors that are specific, because these inhibitors have identical 
chemical and molecular geometrical resemblance to the substrate and competes with the 
substrate for same active site. There are three types of entry inhibitors: fusion inhibitors, 
attachment and co-receptor antagonist inhibitors. However, only the latter type of entry 
inhibitors, co-receptor antagonists’ inhibitors will be described in terms of an example and 
mechanism. 
2.5.4.1. Co-receptor antagonists’ inhibitors 
As mentioned previously in section 2.4.4.1, there are two types of co-receptors namely, CCR5 
and CXCR4 that are expressed on T-cell surface. Co-receptor antagonists were the first class of 
anti-HIV drugs, which did not target the HIV virus directly, however, these drugs bind, fuse and 
block viral attachment to the host cell when they prevent virus/co-receptor interaction. 
Maraviroc, as depicted in Figure 2.11, was the first entry inhibitor approved as a CCR5 co-





Figure 2.11. Maraviroc, the first FDA-approved CCR5 co-receptor antagonist inhibitor. 
 
2.5.5. HIV accessory negative factor (Nef) inhibitors 
Considerate insight into the dimerization and inhibition mechanism of HIV-1 accessory negative 
factor, Nef, is critical in the drug design process of potential Nef antagonists. Thus far, only a 
handful of small molecule inhibitors identified via high throughput screening (HTS) blocks Nef-
dependent viral replicative process. One such molecule identified is a diphenylpyrazolodiazene 
containing small molecule inhibitor, B9 (Figure 2.12.), binds at the dimeric interface of HIV-Nef 
and prevents dimerization of the two Nef subunits 109, 110. 
 









1. Wlodawer, A., and Vondrasek, J. (1998) Inhibitors of HIV-1 protease: A major success 
of structure-assisted drug design, Annual Review of Biophysics and Biomolecular 
Structure 27, 249-284. 
2. Merson, M. H., O'Malley J Fau - Serwadda, D., Serwadda D Fau - Apisuk, C., and 
Apisuk, C. (2008) The history and challenge of HIV prevention, Lancet Infectious 
Diseases 372, 497-500. 
3. UNAIDS. (2011) World AIDS day report 2011,  
http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/
2011/jc2216_worldaidsday_report_2011_en.pdf, 11 Nov. 2013. 
4. UNAIDS. (2012) UNAIDS report on the global AIDS epidemic 2012,  
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012
/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf, 20 Jan. 2014. 
5. UNAIDS. (2012) Global summary of the AIDS epidemic,  
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013
/gr2013/201309_epi_core_en.pdf, 20 Jan 2014. 
6. Soliman, M. E. S. (2013) A Hybrid Structure/Pharmacophore-Based Virtual Screening 
Approach to Design Potential Leads: A Computer-Aided Design of South African HIV-1 
Subtype C Protease Inhibitors, Medicinal Chemistry Research. 
7. Johnson, B. C., Pauly, G.T.,  Rai, G.,  Patel, D.,   Bauman, J.D.,  Baker, H.L.,  Das, K.,  
Schneider, J.P.,  Maloney, D.J., Arnold, E., Thomas, C.J., and  Hughes, S.H. . (2012) A 
comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit 
clinically relevant HIV-1 reverse transcriptase mutants, Retrovirology 1-23. 
8. Ahmed, S. M., Kruger, H. G., Govender, T., Maguire, G. E. M., Sayed, Y., Ibrahim, M. 
A. A., Naicker, P., and Soliman, M. E. S. (2013) Comparison of the molecular dynamics 
and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against 
subtype B and C-SA HIV PR, Chemical Biology & Drug Design 81, 208-218. 
9. Xu, Y., Liu, H., Niu, C. Y., Luo, C., Luo, X. M., Shen, J. H., Chen, K. X., and Jiang, H. 
L. (2004) Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-
42 
 
yl)-butanes based on the structural modeling of human CCR5 receptor, Bioorganic & 
Medicinal Chemistry 12, 6193-6208. 
10. Taylor, J. E., and Korber, B. T. (2005) HIV-1 intra-subtype superinfection rates: 
estimates using a structured coalescent with recombination, Infection, Genetics and 
Evolution 5, 85-95. 
11. Clavel, F., Guetard, D., Brunvezinet, F., Chamaret, S., Rey, M. A., Santosferreira, M. O., 
Laurent, A. G., Dauguet, C., Katlama, C., Rouzioux, C., Klatzmann, D., Champalimaud, 
J. L., and Montagnier, L. (1986) Isolation of a new human retrovirus from west-african 
patients with AIDS, Science 233, 343-346. 
12. Gallo, S. A., Reeves, J. D., Garg, H., Foley, B., Doms, R. W., and Blumenthal, R. (2006) 
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion, 
Retrovirology 3. 
13. McCutchan, F. E. (2006) Global epidemiology of HIV, Journal of Medical Virolgy 78, 
S7-S12. 
14. Sharp, P. M., Bailes, E., Robertson, D. L., Gao, F., and Hahn, B. H. (1999) Origins and 
evolution of AIDS viruses, The Biological Bulletin 196, 338-342. 
15. de Silva, T. I., Cotten, M., and Rowland-Jones, S. L. (2008) HIV-2: the forgotten AIDS 
virus, Trends Microbiol. 16, 588-595. 
16. Reeves, J. D., and Doms, R. W. (2002) Human immunodeficiency virus type 2, Journal 
of  General Virology 83, 1253-1265. 
17. Hu, W.-S., and Hughes, S. H. (2012) HIV-1 reverse transcription, Cold Spring Harbor 
perspectives in medicine 2. 
18. Turner, B. G., and Summers, M. F. (1999) Structural biology of HIV, Journal of 
Molecular Biology 285, 1-32. 
19. Levy, J. A. (2007) HIV and the Pathogenesis of AIDS, 3rd Edition, American Society of 
Microbiology, 1752 N Street Nw, Washington, Dc 20036-2904 USA. 
20. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from 
the HIV envelope glycoprotein, Cell 89, 263-273. 
21. McKeage, K., and Perry, C. M. (2002) Trastuzumab - A review of its use in the treatment 
of metastatic breast cancer overexpressing HER2, Drugs 62, 209-243. 
22. Reinhard Renneberg, A. L. D. (2008) Biotechnology for beginners, Springer, Germany. 
43 
 
23. Cunningham, A. L., Donaghy, H., Harman, A. N., Kim, M., and Turville, S. G. (2010) 
Manipulation of dendritic cell function by viruses, Current Opinion in Microbiology 13, 
524-529. 
24. Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F., 
and Weiss, R. A. (1984) The CD4(T4) antigen is an essential component of the receptor 
for the AIDS retrovirus, Nature 312, 763-767. 
25. Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T., 
Gluckman, J. C., and Montagnier, L. (1984) Lymphocyte-T T4 molecule behaves as the 
receptor for human retrovirus LAV, Nature 312, 767-768. 
26. Berger, E. A., Murphy, P. M., and Farber, J. M. (1999) Chemokine receptors as HIV-1 
coreceptors: Roles in viral entry, tropism, and disease, Annual Review of Immunology 17, 
657-700. 
27. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. 
A. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 
receptor and a neutralizing human antibody, Nature 393, 648-659. 
28. Levy, J. A. (2009) HIV pathogenesis: 25 years of progress and persistent challenges, Aids 
23, 147-160. 
29. Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., 
and Berger, E. A. (1996) CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a 
fusion cofactor for macrophage-tropic HIV-1, Science 272, 1955-1958. 
30. Craigie, R., and Bushman, F. D. (2012) HIV DNA Integration, Cold Spring Harbor 
perspectives in medicine 2, a006890. 
31. Zheng, Y. H., Lovsin, N., and Peterlin, B. M. A. (2005) Newly identified host factors 
modulate HIV replication, Immunology Letters 97, 225-234. 
32. Karn, J., and Stoltzfus, C. M. (2012) Transcriptional and Posttranscriptional Regulation 
of HIV-1 Gene Expression, Cold Spring Harbor perspectives in medicine 2, a006916. 
33. Spearman, P. (2006) Cellular cofactors involved in HIV assembly and budding, Current 
Opinion in HIV and AIDS 1, 200-207. 
34. Brik, A., and Wong, C. H. (2003) HIV-1 protease: mechanism and drug discovery, 
Organic & Biomolecular Chemistry 1, 5-14. 
44 
 
35. Van Lint, C., Bouchat, S., and Marcello, A. (2013) HIV-1 transcription and latency: an 
update, Retrovirology 10. 
36. Esposito, F., Corona, A., and Tramontano, E. (2012) HIV-1 reverse transcriptase still 
remains a new drug target: structure, function, classical inhibitors, and new inhibitors 
with innovative mechanisms of actions, Molecular Biology International 2012, 1-23. 
37. Vangent, D. C., Vink, C., Groeneger, A., and Plasterk, R. H. A. (1993) Complementation 
between HIV integrase proteins mutated in different domains, EMBO Journal 12, 3261-
3267. 
38. Tronchet, J. M. J., and Seman, M. (2003) Nonnucleoside inhibitors of HIV-1 reverse 
transcriptase: From the biology of reverse transcription to molecular design, Current 
Topics in Medicinal Chemistry 3, 1496-1511. 
39. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) Crystal 
structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor, 
Science  256, 1783- 1790. 
40. Rigby, M. (1986) Physical chemistry, 3rd edition - ATKINS,PW, Nature 319, 820-820. 
41. Ilina, T., LaBarge, K., Sarafianos, S.G., Ishima, R., and Parniak, M.A. (2012) Inhibitors 
of HIV-1 Reverse TranscriptaseAssociated Ribonuclease H Activity., Biology 1, 521-
541. 
42. Harpstead, B. (2005) HIV-1 reverse transcriptase structure, activities, and inhibitors., 
Basic Biotechnology MMG 445, 1-7. 
43. Bruccoleri, A. (2013) Positional Adaptability in the Design of Mutation-Resistant 
Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors: A Supramolecular Perspective., 
AIDS Research and Human Retroviruses 29, 1-9. 
44. Esposito, F., Corona, A., and Tramontano, E. (2012) HIV-1 Reverse Transcriptase Still 
Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New 
Inhibitors with InnovativeMechanisms of Actions., Molecular Biology International 
2012, 1-23. 
45. Seckler, J. M., Howard, K.J., Barkley, M.D., and Wintrode, P.L. (2009) Solution 




46. Young, F. E. (1988) The role of the FDA in the effort against AIDS, Public Health 
Reports 103, 242-245. 
47. Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, 
M., Melamed, J. Y., Young, S., Hamill, T., Cole, J. L., and Hazuda, D. J. (2000) HIV-1 
integrase inhibitors that compete with the target DNA substrate define a unique strand 
transfer conformation for integrase, Proceedings of the National Academy of Sciences U. 
S. A. 97, 11244-11249. 
48. Hazuda, D. J., Anthony, N. J., Gomez, R. P., Jolly, S. M., Wai, J. S., Zhuang, L. H., 
Fisher, T. E., Embrey, M., Guare, J. P., Egbertson, M. S., Vacca, J. P., Huff, J. R., 
Felock, P. J., Witmer, M. V., Stillmock, K. A., Danovich, R., Grobler, J., Miller, M. D., 
Espeseth, A. S., Jin, L. X., Chen, I. W., Lin, J. H., Kassahun, K., Ellis, J. D., Wong, B. 
K., Xu, W., Pearson, P. G., Schleif, W. A., Cortese, R., Emini, E., Summa, V., Holloway, 
M. K., and Young, S. D. (2004) A naphthyridine carboxamide provides evidence for 
discordant resistance between mechanistically identical inhibitors of HIV-1 integrase, 
Proceedings of the National Academy of Sciences U. S. A. 101, 11233-11238. 
49. Engelman, A., Bushman, F. D., and Craigie, R. (1993) Identification of discrete 
functional domains of HIV-1 integrase and their organization within an active multimeric 
complex, EMBO Journal 12, 3269-3275. 
50. Chiu, T. K., and Davies, D. R. (2004) Structure and function of HIV-1 integrase, Current 
Topics in Medicinal Chemistry 4, 965-977. 
51. Craigie, R. (2001) HIV integrase, a brief overview from chemistry to therapeutics, 
Journal of Biological Chemistry 276, 23213-23216. 
52. Di Santo, R., Costi, R., Artico, M., Tramontano, E., La Colla, P., and Pani, A. (2003) 
HIV-1 integrase inhibitors that block HIV-1 replication in infected cells. Planning 
synthetic derivatives from natural products, Pure and Applied Chemistry 75, 195-206. 
53. Brin, E., Yi, J., Skalka, A. M., and Leis, J. (2000) Modeling the late steps in HIV-1 
retroviral integrase-catalyzed DNA integration, Journal of Biological Chemistry 275, 
39287-39295. 
54. Yoder, K. E., and Bushman, F. D. (2000) Repair of gaps in retroviral DNA integration 
intermediates, Journal of Virology 74, 11191-11200. 
46 
 
55. Engelman, A., and Craigie, R. (1992) Identification of conserved amino acid residues 
critical for human immunodeficiency virus type 1 integrase function in vitro, Journal of 
Virology 66, 6361-6369. 
56. Barreca, M. L., Ferro, S., Rao, A., De Luca, L., Zappala, M., Monforte, A. M., Debyser, 
Z., Witvrouw, M., and Chimirri, A. (2005) Pharmacophore-based design of HIV-1 
integrase strand-transfer inhibitors, Journal of Medicinal Chemistry 48, 7084-7088. 
57. d'Angelo, J., Mouscadet, J. F., Desmaële, D., Zouhiri, F., and Leh, H. (2001) HIV-1 
integrase: the next target for AIDS therapy?, Pathologie Biologie 49, 237-246. 
58. Grobler, J. A., Stillmock, K., Hu, B. H., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, 
A., Egbertson, M., Bourgeois, M., Melamed, J., Wai, J. S., Young, S., Vacca, J., and 
Hazuda, D. J. (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: Implications 
for metal binding in the active site of phosphotransferase enzymes, Proceedings of the 
National Academy of Sciences of the United States of America 99, 6661-6666. 
59. Zhuang, L. C., Wai, J. S., Embrey, M. W., Fisher, T. E., Egbertson, M. S., Payne, L. S., 
Guare, J. P., Vacca, J. P., Hazuda, D. J., Felock, P. J., Wolfe, A. L., Stillmock, K. A., 
Witmer, M. V., Moyer, G., Schleif, W. A., Gabryelski, L. J., Leonard, Y. M., Lynch, J. J., 
Michelson, S. R., and Young, S. D. (2003) Design and synthesis of 8-hydroxy- 1,6 
naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells, 
Journal of Medicinal Chemistry 46, 453-456. 
60. Carson, M. (1987) Ribbon models of macromolecules, Journal of Molecular Graphics 5, 
103-106. 
61. Hsu, M. C., Schutt, A. D., Holly, M., Slice, L. W., Sherman, M. I., Richman, D. D., 
Potash, M. J., and Volsky, D. J. (1991) Inhibition of HIV replication in acute and chronic 
infections invitro by a tat antagonist, Science 254, 1799-1802. 
62. Hamy, F., Felder, E. R., Heizmann, G., Lazdins, J., AboulEla, F., Varani, G., Karn, J., 
and Klimkait, T. (1997) An inhibitor of the Tat/TAR RNA interaction that effectively 
suppresses HIV-1 replication, Proceedings of the National Academy of Sciences U. S. A. 
94, 3548-3553. 
63. Cupelli, L. A., and Hsu, M. C. (1995) The human-immunodeficiency-virus type-1 tat 
antagonist, RO-5-3335, predominantly inhibits transcription initiation from the viral 
promoter, Journal of Virology 69, 2640-2643. 
47 
 
64. Hwang, S., Tamilarasu, N., Kibler, K., Cao, H., Ali, A., Ping, Y. H., Jeang, K. T., and 
Rana, T. M. (2003) Discovery of a small molecule Tat-trans-activation-responsive RNA 
antagonist that potently inhibits human immunodeficiency virus-1 replication, Journal of 
Biological Chemistry 278, 39092-39103. 
65. Wensing, A. M. J., van Maarseveen, N. M., and Nijhuis, M. (2010) Fifteen years of HIV 
Protease Inhibitors: raising the barrier to resistance, Antiviral Research 85, 59-74. 
66. Darke, P. L., Nutt, R. F., Brady, S. F., Garsky, V. M., Ciccarone, T. M., Leu, C. T., 
Lumma, P. K., Freidinger, R. M., Veber, D. F., and Sigal, I. S. (1988) HIV-1 protease 
specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins, 
Biochemical and  Biophysical Research Commununity 156, 297-303. 
67. Katz, R. A., and Skalka, A. M. (1994) The retroviral enzymes, Annual Review of 
Biochemistry 63, 133-173. 
68. Mager, P. P. (2001) The active site of HIV-1 protease, Medical Research Reviews 21, 
348-353. 
69. Sule, P., and Nagy, A. (1996) Density functional study of strong hydrogen-bonded 
systems: The hydrogen diformiate complex, The Journal of Chemical Physics 104, 8524-
8534. 
70. Castro, H. C., Abreu, P. A., Geraldo, R. B., Martins, R. C. A., dos Santos, R., Loureiro, 
N. I. V., Cabral, L. M., and Rodrigues, C. R. (2011) Looking at the proteases from a 
simple perspective, Journal of Molecular Recognition 24, 165-181. 
71. Martinez-Cajas, J. L., and Wainberg, M. A. (2007) Protease inhibitor resistance in HIV-
infected patients: Molecular and clinical perspectives, Antiviral Research 76, 203-221. 
72. Weber, I. T., and Agniswamy, J. (2009) HIV-1 protease: Structural perspectives on drug 
resistance, Viruses-Basel 1, 1110-1136. 
73. Fano, A., Ritchie, D. W., and Carrieri, A. (2006) Modeling the structural basis of human 
CCR5 chemokine receptor function: From homology model building and molecular 
dynamics validation to agonist and antagonist docking, Journal of Chemical Information 
and Modeling 46, 1223-1235. 
74. Manikandan, S., and Malik, B. K. (2008) Modeling of human CCR5 as target for HIV-I 
and virtual screening with marine therapeutic compounds, Bioinformation 3, 89-94. 
48 
 
75. Cormier, E. G., Persuh, M., Thompson, D. A. D., Lin, S. W., Sakmar, T. P., Olson, W. 
C., and Dragic, T. (2000) Specific interaction of CCR5 amino-terminal domain peptides 
containing sulfotyrosines with HIV-1 envelope glycoprotein gp120, Proceedings of the 
National Academy of Sciences 97, 5762-5767. 
76. F, C., AL, D., A, G.-D., SK, A., RC, G., and P, L. - Identification of RANTES, MIP-1 
alpha, and MIP-1 beta as the major, D - 0404511, T - ppublish. 
77. Perez-Nueno, V. I., Ritchie, D. W., Rabal, O., Pascual, R., Borrell, J. I., and Teixido, J. 
(2008) Comparison of ligand-based and receptor-based virtual screening of HIV entry 
inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and 
ligand-receptor docking, Journal of Chemical Information and Modeling 48, 509-533. 
78. Afantitis, A., Melagraki, G., Sarimveis, H., Koutentis, P. A., Markopoulos, J., and 
Igglessi-Markopoulou, O. (2006) Investigation of substituent effect of 1-(3,3-
diphenylpropyl)-piperidinyl phenylacetamides on CCR5 binding affinity using QSAR 
and virtual screening techniques, Journal of Computer-Aided Molecular Design 20, 83-
95. 
79. Aher, Y. D., Agrawal, A., Bharatam, P. V., and Garg, P. (2007) 3D-QSAR studies of 
substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor 
antagonists, Journal of Molecular Modeling 13, 519-529. 
80. Kellenberger, E., Springael, J.-Y., Parmentier, M., Hachet-Haas, M., Galzi, J.-L., and 
Rognan, D. (2007) Identification of nonpeptide CCR5 receptor agonists by structure-
based virtual screening, Journal of Medicinal Chemistry 50, 1294-1303. 
81. Sarafianos, S. G., Das, K., Hughes, S. H., and Arnold, E. (2004) Taking aim at a moving 
target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases, Current 
Opinion in Structural Biology 14, 716-730. 
82. Das, S. R., and Jameel, S. (2005) Biology of the HIV Nef protein, Indian Journal of 
Medical Research 121, 315-332. 
83. Lee, C. H., Saksela, K., Mirza, U. A., Chait, B. T., and Kuriyan, J. (1996) Crystal 
structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain, 
Cell 85, 931-942. 
49 
 
84. Cohen, M. S., Smith, M. K., Muessig, K. E., Hallett, T. B., Powers, K. A., and Kashuba, 
A. D. (2013) Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do 
we go from here?, The Lancet 382, 1515-1524. 
85. Johnson, B. C., Metifiot, M., Ferris, A., Pommier, Y., and Hughes, S. H. (2013) A 
Homology Model of HIV-1 Integrase and Analysis of Mutations Designed to Test the 
Model, Journal of molecular biology 425, 2133-2146. 
86. Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., and Liu, X. (2013) HIV-1 NNRTIs: 
structural diversity, pharmacophore similarity, and impliations for drug design, Medical 
Reserach Reviews 33, E1-E72. 
87. Patel, J. R., and Prajapati, L. M. (2013) Predictive QSAR modeling on 
tetrahydropyrimidine-2-one derivatives as HIV-1 protease enzyme inhibitors, Medicinal 
Chemistry Research 22, 2795-2801. 
88. Pani, A., Loi, A. G., Mura, M., Marceddu, T., La Colla, P., and Marongiu, M. E. (2002) 
Targeting HIV: Old and new players, Current Drug Targets: Infectious Disorders 2, 17-
32. 
89. Pani, A., Loi, A. G., Mura, M., Marceddu, T., La Colla, P., and Marongiu, M. E. (2002) 
Targeting HIV: Old and new players, Current Drug Targets - Infectious Disorders 2, 17-
32. 
90. Marwick, C. (1987) AZT (zidovudine) just a step away from fda approval for aids 
therapy, JAMA 257, 1281-1282. 
91. Anastasi, J. K., and Rivera, J. L. (1991) AIDS drug update: DDI and DDC, RN 54, 41-43. 
92. James, J. S. (1995) Saquinavir (Invirase): first protease inhibitor approved-
reimbursement, information hotline numbers, AIDS treatment news, 1-2. 
93. Hicks, C., and Gulick, R. M. (2009) Raltegravir: The first HIV type 1 integrase inhibitor, 
Clinical Infectious Diseases 48, 931-939. 
94. FDA. (2012) 
http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/dru
gs/antiviraldrugsadvisorycommittee/ucm305852.pdf, 04 Mar. 2014. 
95. FDA. (2014) Antiretroviral drugs used in the treatment of HIV infection, 
http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivi
ties/ucm118915.htm 02 Feb. 2014. 
50 
 
96. Ilina, T., LaBarge, K., Sarafianos, S. G., Ishima, R., and Parniak, M. A. (2012) Inhibitors 
of HIV-1 reverse transcriptase-associated ribonuclease H activity, Biology 1, 521-541. 
97. Vivet-Boudou, V., Didierjean, J., Isel, C., and Marquet, R. (2006) Nucleoside and 
nucleotide inhibitors of HIV-1 replication, Cellular and Molecular Life Sciences 63, 163-
186. 
98. Bauman, J. D., Das, K., Ho, W. C., Baweja, M., Himmel, D. M., Clark, A. D., Oren, D. 
A., Boyer, P. L., Hughes, S. H., Shatkin, A. J., and Arnold, E. (2008) Crystal engineering 
of HIV-1 reverse transcriptase for structure-based drug design, Nucleic Acids Research 
36, 5083-5092. 
99. Schinazi, R. F., Hernandez-Santiago, B. I., and Hurwitz, S. J. (2006) Pharmacology of 
current and promising nucleosides for the treatment of human immunodeficiency viruses 
Antiviral Reserach 72, 256-256. 
100. Williams, I. G. (2003) Enfuvirtide (Fuzeon (R)): The first fusion inhibitor, International 
Journal of Clinical Practice 57, 890-897. 
101. FDA. (2014) Antiretroviral drugs used in the treatment of HIV infection, 
http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivi
ties/ucm118915.htm, 02 Feb. 2014. 
102. Pommier, Y., Johnson, A. A., and Marchand, C. (2005) Integrase inhibitors to treat 
HIV/AIDS, Nature Reviews: Drug Discovery 4, 236-248. 
103. Krohn, A., Redshaw, S., Ritchie, J. C., Graves, B. J., and Hatada, M. H. (1991) Novel 
binding of highly potent HIV-proteinase inhibitors incorporating the (R)-
hydroxyethylamine isostere, Journal of Medicinal Chemistry 34, 3340-3342. 
104. Kim, E. E., Baker, C. T., Dwyer, M. D., Murcko, M. A., Rao, B. G., Tung, R. D., and 
Navia, M. A. (1995) Crystal structure of HIV-1 protease in complex with VX-478, a 
potent and orally bioavailable inhibitor of the enzyme, Journal of the American Chemical 
Society 117, 1181-1182. 
105. Hughes, P. J., Cretton-Scott, E., Teague, A., and Wensel, T. M. (2011) Protease 
Inhibitors for Patients With HIV-1 Infection: A Comparative Overview, P & T : a peer-
reviewed journal for formulary management 36, 332-345. 
106. Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., 
Neveu, V., Djoumbou, Y., Eisner, R., Guo, A. C., and Wishart, D. S. (2011) DrugBank 
51 
 
3.0: a comprehensive resource for 'Omics' research on drugs, Nucleic Acids Research 39, 
D1035-D1041. 
107. Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., 
and Hassanali, M. (2008) DrugBank: a knowledgebase for drugs, drug actions and drug 
targets, Nucleic Acids Research 36, D901-D906. 
108. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, 
Z., and Woolsey, J. (2006) DrugBank: a comprehensive resource for in silico drug 
discovery and exploration, Nucleic Acids Research 34, D668-D672. 
109. Emert-Sedlak, L. A., Narute, P., Shu, S. T., Poe, J. A., Shi, H., Yanamala, N., Alvarado, 
J. J., Lazo, J. S., Yeh, J. I., Johnston, P. A., and Smithgall, T. E. (2013) Effector Kinase 
Coupling Enables High-Throughput Screens for Direct HIV-1 Nef Antagonists with 
Antiretroviral Activity, Chemistry & Biology 20, 82-91. 
110. Breuer, S., Schievink, S. I., Schulte, A., Blankenfeldt, W., Fackler, O. T., and Geyer, M. 
(2011) Molecular Design, Functional Characterization and Structural Basis of a Protein 





















3. Introduction to computational chemistry 
3.1. Introduction  
Computational chemistry, also known as molecular modeling, may be defined as modeling of 
chemistry at atomic or molecular level using a set of techniques on a computer to investigate 
chemical problems. The term encompasses a wide range of theories and methods which may be 
viewed as offering tools for solving different problems in chemistry. There are three basic 
methods describing computational chemistry, namely quantum mechanics, molecular mechanics 
and molecular dynamics. The former focuses on electronic structure methods and the latter on 
classical laws of physics. In this chapter, mention is made of both computational and theoretical 
tools used in this study.  This chapter begins with a description of the computational chemistry 
concepts that are central to all three delineated computational basic approaches, and these 
include; Schrodinger and Born-Oppenheimer equations and Potential energy surface (PES), 
followed by explanation of the both the computational and theoretical tools used in this our 
studies. 
 
3.2. The Schrodinger equation 
In 1926, an Austrian physicist by the name of Erwin Schrodinger, first proposed the time-
independent Schrodinger equation, which provides a description of quantum system evolution 1. 
The Schrodinger equation in its simplest form is as follows: 
H = T + V                                Eq. 3.1 
Where H is the Hamiltonian operator (sum of the kinetic energy), T is the potential energy, V is 
the operator 2, 3. 
 
If particles are measured in terms of point masses based upon the assumption of assumed 
neglecting relativistic effects, then the Hamiltonian for a particular molecule will be composed of 
all kinetic and potential energy operators for all its electrons and nuclei. The Hamiltonian 
equation is as follows: 
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      Eq. 3.2  
 
As the Schrodinger equation is composed of several sets of equations, the disadvantage is that it 
cannot be applied to solve molecular system problems instead the Born-Oppenheimer 
approximation 1, 3, 4 serves the purpose.  
 
3.3. Born-Oppenheimer approximation 
An approximation, conducted by Born and Oppenheimer in 1927, explained that nuclear 
coordinates are the parameters that define molecular geometry 5 as well as highlighted the ratio 
between energy and nuclear coordinates, as described in PES. The Born-Oppenheimer 
approximation expounds that the Schrodinger equation for a specific molecular system may be 
split into two individual equations namely, electronic and nuclear equations. As nuclei are fixed, 
so the nuclear kinetic energy operator is deleted, and thus statically distributed electron 
contributions with a molecule can be solved. 
        Eq. 3.3. 
 
Below is the Schrodinger equation for fixed nuclei electrons, which can be presented as: 
                                        Eq. 3.4 
3.4. Potential energy surface 
The potential energy surface (PES) is a mathematical function that relates the energy of a 
molecular system in terms of its geometry 6. This PES ratio provides a deeper visual insight into 
understanding the relationship between potential energy and its geometry of a molecule. It also 
affords researchers a chance to understand the workings of computational chemistry programs in 





Figure 3.1. A model representation of a two-dimensional potential energy surface 9 
 
PES is represented as a graphical plot expressed as the ratio between molecular energy verses 
molecular geometry (Figure 3.1.). Molecular potential energy is directly proportional to its 
molecular geometric conformations. High energy regions depicts high-energy molecular 
conformational changes with unfavorable electronic interactions, whereas, regions of low 
potential energy expounds low energy molecular conformations with favorable electronic 
interactions 7, 8 10.  
 
3.5. Quantum mechanics 
Quantum is derived from the Latin word quantus which means “how much” and the first 
reported account in 1990, is believed to have been by Max Planck, who used quantum to 
demonstrate the absorption and emission spectra of energy as a measure of constrained particle 
quantities 1, 2, 6, 11.  However, the word mechanics denotes how an object would behave when a 
force (i.e. gravitational force) is applied. Molecules are composed of neutrons, electrons and 
nuclei, and therefore quantum chemistry studies electron motion when nuclear charges exert 
different electromagnetic forces in molecules 1, 2, 6, 11. Thorough knowledge of quantum 
chemistry and in particular understanding of the Schrodinger equation is needed in order to gain 
a deeper insight into molecular electron behavior and as well as molecular structures and 
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reaction. Because in quantum chemistry, system properties are expressed as a wave function, 
which is solved by the Schrodinger equation1, 2, 6, 11.  
 
3.6. Molecular mechanics 
Molecular mechanics (MM) is based on classical physics and the fundamental basis of modern 
physics is quantum mechanics. MM is commonly employed for large systems in order to predict 
relative potential energies of molecules in terms of molecular conformational changes or atom 
rearrangements 3, 4, 6. MM may also be used to predict the equilibrated geometrical and transition 
states of molecules and relative energies of various conformers 12. Although many of the details 
of mechanical, chemical and biological interactions in cells are currently unclear, MM can 
provide understanding of the mechanical deformation of proteins and nucleic acids and provide 
key insights for understanding the changes in cellular structure, response and function under 
force 13. This may serve as a useful tool for diagnostic and therapeutic interventions in many 
diseases. MM may be simply described as a ball-and-spring model of atoms and molecules that 
have classical forces exerted between each other. MM calculations, often referred to as force 
field calculations, reveals the qualitative nature of how molecules interacts with one another 14.  
 
3.6.1. Force field 
A force field is a mathematical function with a delineated set parameters, which describes the 
relationship of molecular energy systems to specific particle coordinates. Some of the commonly 
used biomolecular force fields include: AMBER 15, CHARM 16, NAMD 17, GROMOS 18, and 
OPLS-AA 19. All force field parameters are obtained from either experimental data sources, ab 
initio or semi-empirical QM 20. There is an assumption that force field functions are solely 
dependent on atomic orientations and have been used as representatives for providing description 
of PES for different types of molecular systems with varying degrees of freedom. This force field 
function must provide a deeper understanding into the particular forces acting within the 
molecular system. Among these, is the valence force field function, applied for organic 
molecules, and may be used to calculate the energy of these molecules governed by the 
following set of parameters: internal coordinates, bond lengths, bond angels, dihedral angels and 




                                     Eq. 3.5 
 
In these studies, the AMBER Force Field 21 was used, the standard AMBER Force Field was 
utilized for proteins, and however, the General AMBER Force Field (GAFF) was used to 
parameterize ligands.  
 
3.7. Molecular dynamics 
Molecular dynamics (MD) is a computational chemistry method used for molecular simulations 
of atoms in a modeled system with a given mass and charge. It also integrates energy equations 
of motion which are numerically solved to trace the time progression of a particular system 
under the assessment of kinetic and thermodynamic properties 22, 23. The stimulating system has 
MM or QM methods applied. MD simply applies Newton’s equations of motion to atoms on an 
energy surface for generating atomic trajectories of a complex molecular system; 
                                                                                                   Eq. 3.6 
Where  – is the particle position vector (i), t – time, mi – mass of 
particle, therefore Fi - force acting on (i) particle at t and mi. 
For assimilation of the above-mentioned second order linear differential equations, specification 
of instant particle forces, positions and velocities are required 20. The Verlet algorithm is applied 
to solve the equations of motion 24. The time progression of a molecular system and MD 
trajectories are outlined by position and velocity vectors, which are propagated using numerical 
integrators at specific time frames. This  describes a particle orientation space that alternates 
with time as compared to  which explains a system’s thermodynamics (i.e. kinetic energy 
and temperature). The functional properties of a stimulating system that may be affected by a 
dynamic cascade of events may be directly identified at the atomic level 25.    
          
3.7.1. Binding free energy 
Binding free energy calculations are important in ligand-protein systems interactions and 
formation, and also in other aspects of computational drug design discovery including protein-
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protein system behaviors and determining protein structures 26, 27 28 29-31. Computer-based free 
binding energies of macromolecules and other varying molecular systems are calculated using 
either the Molecular Mechanics/Poisson-Boltzmann Surface Area (MMPB-SA) or Molecular 
Mechanics/Generalized Born Surface Area (MMGB-SA) techniques 25, 32, 33, which combines 
MM with the continuum solvation of a molecular system at low computational cost 33. In the 
current studies, MM-PBSA free energy calculations were applied for the diverse molecular 
systems encountered 34. A detailed explanation on free binding energy calculations has been 
described herein (see Chapters 7-9). 
 
3.8. Hybrid QM/MM method 
To reduce negative implications associated with using QM and MM approaches, therefore 
computational chemists have established combinational QM/MM algorithms, which merge QM 
descriptors with the low cost computing rate of MM 35.  As shown in Figure 3.2,  is a model 
representation of an hybrid QM/MM approach, which is separated into two domains namely, the 
reactive domain defined by QM, whereas, the non-reactive domain treated with MM 36-39. While 
QM calculations are very accurate at describing the electronic structure of molecular systems, it 
is highly computationally expensive and time consuming 40. Combined QM/MM procedures 
intend to accurately describe quantum mechanics with the low cost applied to molecular 
mechanics computationally (33).                
         MD on entire molecule 
          MM region 




Figure 3.2. A schematic representation of a hybrid QM/MM/MD model 
 
Fluctuating electronic rates in molecular systems and ligand-receptor interactions in metal-
containing systems cannot be explained by classical MM approaches. Hybrid QM/MM may not 
relevant in all structure-based drug design processes, however, other crucial molecular systems 
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may not be well described by other computational methods, thus hybrid QM/MM is an 
imperative computational tool in drug design.  
 
3.9. Principle component analysis 
Classical MD analysis can only provide limited insight into the dynamic landscape frameworks 
of highly large and complex biomolecular systems. Therefore, other diverse computational 
methods have been established that can deal with the large number of explicit degrees of 
freedom 41-44.   One such widely used approach is principle component analysis (PCA), which 
explores the structural fluctuations experienced within biological systems.  
 
PCA is a mathematical statistical technique based on covariance analysis that can transform the 
original space of correlated variables into reduced space of independent variables and is often 
used to highlight the large correlated motions in biological systems 45, 46. PCA reduces the 
dimensionality of data from an MD simulation trajectory in order to extract dominant nodes 
accountable for pronounced molecule or protein motions that corresponds to correlated 
vibrational nodes 47-52. A particular protein movement is denoted by an eigenvector with a 
specific corresponding energy contribution eigenvalue component. If a specific MD trajectory is 
projected onto a particular eigenvector, it describes the time-dependent movements that 
components undergo during a specific vibrational mode 48. 
 
Herein, PCA was implemented for detection of the overall motion of the enzyme backbone to 
elucidate the difference between wild type protein states compared to mutant/resistant variant 
states (see Chapter 7) 53. It was also used to reduce the dimensionality of data from an MD 
simulation to extract dominant modes in Nef bound and apo protein systems (see Chapters 8 
and 9). 
 
3.10. Residue Interaction Network  
It has been reported that either resistant mutant forms or substitution in a target protein may 
affect the binding affinity of drugs to specific targets through modification of their residue 
interaction networks (RINs) 54-57. Few studies have demonstrated that analyzing and visualizing 
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the RIN of proteins provided deeper insight on vital biological interactions in highly complex 
molecular systems 58, 59.   
 
The RINalyzer software, a Java plugin for Cytoscape, is used for analysis and visualization of 
RINs in different proteins and biological systems. It also provides comprehensive insight into 
analyzing structural and functional properties or connections in different systems. In general, a 
RIN is created from a 3D protein structure as located in Protein Data Bank (PDB) files. 
RINalyzer permits one to concurrently visualize and explore the interactive 2D RIN in 
Cytoscape with a corresponding 3D representation in the molecular viewer UCSF Chimera 
program. The basic layout of an interaction network displays network nodes that represents 
various amino acid residues, whereas edges denotes respective molecular interactions between 
these amino acids.  
 
3.11. Molecular modelling tools used in this study 
3.11.1. Homology modeling  
The availability of an actual X-ray crystal structure of a particular target of interest is critical in 
drug design discovery. Most targets can be readily downloaded from numerous protein websites, 
for example, the PDB and Drug Bank etc. However, previously if a specific target was not 
available, then scientists resorted to alternative powerful biophysical techniques namely, X-ray 
crystallography, NMR spectroscopy and electron microscopy for protein structure determination 
60. Despite the fact that using X-ray crystallography was the best approach to determine nearly 
accurate and high-resolution protein structures, but over the years, numerous implications have 
drastically affected the implementation of this methodology; such as increased trial-and-error 
and experimental time rates needed, as well as the lack of X-ray crystal structures of some 
biological important targets.  
 
Therefore, homology modeling has been implemented, which predicts three dimensional (3D) 
protein structures that have little or no high resolution structural information by using closely 
related X-ray protein crystal structures with known structural information as homologues and 
protein sequencing data 61. Protein resolution is defined as an insight into the degree of 
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diffraction patterns and electron density calculations. So protein structures of lower resolution   
(i.e. >3 Å) only display basic atomic framework details as compared to higher resolution 
structures (i.e. ~1 Å), where one can probe deeper into the atomic electron density map and are 
well-arranged. Thus, it is suggested that proteins with well-defined crystallographic structures 
(i.e. 1-3 Å) should be selected as homologues.  
 
Herein, we introduced the concept of homology modeling in one of our studies (Chapter 6). As 
illustrated in Figure 3.3 below, the actual human CCR5 enzyme was homology modeled using 
crystal structure CXCR4 (PDB: 3ODU) as a structural homologue and the human CCR5 protein 
sequence retrieved from the UniProt database (Uniprot ID: P51681).  
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In-silico pharmacophore and structure-based drug design guided by binding mode analysis and 
molecular dynamics simulations is an effective approach for identifying novel potent and 
selective inhibitors.  Herein, we demonstrated a unique strategy for developing dual acting 
inhibitors against HIV-1 protease (PR) and reverse transcriptase (RT).  Via an integrated 
computational protocol relies on “loop docking” and molecular dynamics simulations, the 
designed targets exhibited binding affinities comparable to, and in some cases better than, known 
active reference drugs. 
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Three main HIV-1 enzymes have been exploited as the core of chemotherapy for AIDS 
treatment. These enzymes are HIV-1 protease (PR), reverse transcriptase (RT) and integrase (IN) 
1, 2.  However, designing inhibitors to target each single enzyme has proved a successful strategy 
for treatment, the therapeutic effect of these inhibitors is drastically hampered by many 
implications. Nucleoside RT inhibitors (NRTIs) exhibited high intrinsic toxicity 3, whereas the 
less toxic protease inhibitors (PIs), non-nucleoside RT inhibitors (NNRTIs) and integrase 
inhibitors (INIs) are severely compromised by the rapid emergence of resistant viral strains 4-6.  
 
A common tactic to overcome HIV disease resistant to a single therapy is the use of multidrug 
therapy. Highly Active Antiretroviral Therapy (HAART) 7 combines NRTIs with NNRTIs or PIs 
and effectively reduces HIV viral load which in turn considerably improves the life quality of 
AIDS patients 8.  Even though, HARRT proved successful, to ensure the efficacy of this primary 
treatment for AIDS, complete adherence - which is very difficult to attain because of 
complicated dosing and intolerable acute and chronic toxicities - is essential. Failure to achieve 
adherence typically results in viral rebound and, even worse, multidrug resistance. 
 
To this end, we envisage a dual acting anti-HIV therapy using a single drug that concomitantly 
inhibit two viral enzymes could result in lower toxicity, simplified dosing, and improved patient 
adherence, therefore reducing the possibility of drug resistance. 
 
The concept of designing of multifunctional ligands has been proposed before 9. Multifunctional 
ligands were classified into three categories on the basis of how the scaffolds were combined 9: 
(a) conjugate, if scaffold are linked by a linker, (b) fused, if they directly coupled with no linker, 
and (c) merged, if the scaffolds are integrated into a single structure sharing common feature.  
Another classification based on the targeted protein binding sites was also introduced. Targeted 
protein binding sites could be: (a’) adjacent within a single protein structure 10, 11, (b’) located in 
different proteins but recognize similar endogenous ligands 12, 13, and (c’) located in different 
proteins but recognize unrelated ligands 14-16.  In this report, we propose potential inhibitors 




In this study, we aimed to design novel inhibitors with potential dual activity against HIV PR 
and RT enzymes. Our design is initially based on the pharmacophoric features conserved in most 
potent FDA-approved PR and NRT inhibitors (Figure 4.1.).  Then, the pharmacophore-based 
created scaffolds were subjected to structure-based screening against the respective enzyme to 




Figure 4.1. The design of dual acting inhibitors is based on the pharmacophoric features of known inhibitors 
for each enzyme target and the binding theme of these pharmacophoric groups with the respective enzyme 
active site.  Darunavir-PR complex (PDB code: 3QOZ) and Zidovudine-RT complex (PDB code: 3KLF) were 




In the current work, the strategy to design potential dual acting inhibitors is assisted by an 
integrated in-silico approach that exploits the structural features of both the inhibitor and the 
enzyme active site.  With no doubt that the most appropriate way to verify the activity of in-
silico designed target is the experimental in-vitro and/or in-vivo testing, however, the time and 
cost factors should be considered carefully before testing anticipated inhibitors. Validated 
computational tools could serve as useful tools to save time and effort in the drug design process. 
In this report, we introduce a “tough” in-silico approach that relies on the use of docking 
calculations followed by molecular dynamics simulations to accurately estimate the binding 
affinity as well as the stability of the inhibitor-enzyme complexes.  As a matter of fact, we 
believe that docking calculations could be entirely misleading and even using the same software, 
in many case, may result in different predictions.  In order to ensure reliable docking results we 
embarked on a novel approach which we name “loop-docking” to enhance the docking 
calculations predications (see Methods sections). Furthermore, the docked structures were then 
subjected to molecular dynamics simulations to ensure that these docked structure are stable 
enough over a reasonable time scale.  Docked structures that fail to exhibit stability during MD 
simulations are subjected to further docking or rejected. The “loop docking”/MD strategy have 
been tested and proved successful on 30 X-ray crystal structures of various ligand-protein 
complexes (A manuscript that fully describe this approach has been submitted and under 
review).  Herewith, we report the main concept and structural scaffolds of proposed dual acting 
PR/RT HIV inhibitors.  Screening of a wider set of substituents for further lead optimization is 
still running.  Synthesis of these compounds is quite feasible and most starting structures are 
commercially available.  Since the synthesis and testing of the proposed inhibitors is still on-
going, detailed information about the synthetic procedure, structural analysis and biological 
testing will be revealed in a forthcoming publication.  Previously, we have released the X-ray 
crystal structure of the HIV PR subtype C 17 as well as several reports on the synthesis, NMR 
and biological testing of a series of anti-HIV PR inhibitors 18-22.  Also, we demonstrated an 
extensive study on the relative binding affinities of nine anti-HIV FDA-approved drugs against 
different PRs subtypes 17.   
 
The unique strategy adopted in this report could serve as a powerful tool in the process of drug 
design and development, not only against HIV, but for a wide range of biological targets as well. 
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4.3. Methods: in-silico design and validation 
4.3.1. Constructing of the proposed structures and conformational ensembles 
Proposed structures were constructed and energy minimized using Avogadros software 23.  To 
ensure through conformational sampling of the ligand candidates, low-energy conformations 
were generated for each molecule using Omega v1.8b 24.  For each compound, conformers 
generated within a range of 3.0 kcal/mol from the lowest energy conformer were investigated. 
 
4.3.2. Protein systems 
Protein structures were obtained from the protein data bank (http://www.rcsb.org/).  The PDB 
codes 3QOZ and 3KLF were used for PR and RT, respectively.  Procedure for enzyme model 
preparation for docking and MD simulations is explained in details elsewhere 18-20.   
 
4.3.3. Docking calculations: “loop docking” 
The idea behind our in-house “loop docking” approach is based on the fact that consecutive 
docking runs could remarkably improve the docking energy and orientation.  From our 
experience with docking, we realized that in many cases the best-docked structure could be a 
docking artifact and does not represent the best docking orientation. Therefore, we always opt to 
re-run the docking calculation using the best-docked structure from initial docking as a starting 
structure for a second docking run and so on. We used a few scripts to allow this process to be 
automated. This automated “loop docking” will continue until a threshold value is reached. The 
threshold value is the difference between the docking binding energy of the last run and the 
preceding one.  A threshold value of 0.05 was found to be appropriate. When this imposed value 
reached, the docking stops and the best-docked structure is selected. Autodock software 25 was 
used for docking calculations.  Details on docking set up and parameters can be found in our 
previous reports 18-20.  
4.3.4. Molecular dynamics (MD) simulations 
As before 17, MD simulations were performed for all inhibitor-enzyme complexes (8 systems in 





4.4. Results and Discussion 
4.4.1. Design plan: pharmacophore and structure-based design 
Our design began with the chemical knowledge of the structural features of PR and RT inhibitors 
as well as the anatomy of the binding sites of both enzymes.  First, we carefully studied the 
binding mode for all up-to-date resolved HIV PR and RT X-ray crystal structures of ligand-
enzyme complexes in order to determine the common and most conserved pharmacophoric 
groups that critically involved in the ligand binding. However, finding a specific feasible way to 
help us easily analyze these ligand-enzyme binding themes was not an easy task to accomplish.  
After many trials, we came up with an efficient and viable procedure.  For each enzyme class, 
PR and RT, all X-ray crystal structures were aligned using Chimera software 27.  This enabled us 
to easily focus only on the bound ligands to determine the common structural and binding 
components.  Then, Ligplot software 28 was used to create a visual map of the most critical 
binding interactions between the ligands and enzyme active site.  Information gained from this 
extensive structural and binding analysis allowed us to define the most important fragments for 
each class of inhibitors, PRIs and NRTIs (see Figure 4.1).  For PRIs, a characteristic structural 
feature is that hydrogen bond donors in the core of the ligand is important to form a hydrogen 
bond with the active site Asp25/Asp25’ residues. It has been shown that the interaction between 
the two catalytic aspartates and the hydroxyl group is worth more than 4 kcal/mol 29.  Another 
feature is that the PR enzyme S1/S1’subsites are mostly hydrophobic and ligand with 
hydrophobic groups that can fill in theses subsites have showed significant enzyme inhibitory 
activity 30.  Some studies have also reported that inhibitors that interact with the flap residues 
could be potential inhibitors 31.  
The same previous procedure has been repeated for the X-crystal structures of RT-NRTIs 
complexes in order to understand the binding theme of these inhibitors and obtain information on 
the most critical pharmacophoric moieties. Unlike PR inhibitors, it turned out that the binding 
behavior of NRTIs slightly varies from one crystal structure to another, however, seven amino 
acid residues seemed to be mainly involved in the binding with the inhibitors. These amino acids 
are Arg72, Gln151, Met184, Ala114, Asp113, Tyr115 and Phe116. 
 
Based on all the above-mentioned compiled information, we proposed main four structural 
scaffolds (see Table 4.1) that we believe it could exhibit dual acting HIV PR/RT inhibitory 
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activity.  Lead optimization and expansion phases, in which a larger set of compounds will be 
evaluated, are on-going.  As mentioned above, synthesis of these proposed targets is quite 
feasible and almost all starting structures are commercially available. 
 
4.4.2. Docking and MD simulations 
The docking binding free energies for the proposed structures (1-4) against PR and RT are 
shown in Table 4.1.  Docking of reference drugs, Darunavir and Ziduvidine, was also performed 
for comparison (Table 4.1). 
 
The docked complexes were then subjected to MD simulation for 5 ns to ensure the stability of 
the ligands in the enzyme active sites.  Form our previous experience with docking, in many 
cases, we found that, even the best docked structure flies away from the enzyme active site 
within a few picoseconds of MD simulations.  Therefore, we believe that docking calculations 
that are not validated by relatively a long MD run to ensure the stability of the system is not 
reliable.  Interestingly, for all the proposed compounds-enzyme complexes, the average RMSD 
values were below 2.3 Å and the variation of the potential energies falls within 1000 kcal/mol 
and this is a good indication of the system stability. The PDB coordinates for all docked 
complexes (8 in total) are provided with the supplementary material.  
  
Table 4.1. 2D structures, the calculated binding energy and chemical properties based on 
Lipinski’s rule of five.  























































































MWt (539.5), LogP(0.50), Ha (9), Hd(6) 
-8.4 -6.5 
* Calculated binding energy for DRV and AZT against PR and RT enzymes, respectively.  
** Calculated using MarvinSketch (http://www.chemaxon.com) 
 
As evident from Table 4.1., interestingly, structure 2 shows the best binding affinity towards PR 
and RT. This might due to the inclusion the bis-tetrahydrofuranyl moiety. The bis-
tetrahydrofuranyl moiety is found in Darunavir structure and as we anticipated, inclusion of this 
moiety resulted in a structure (compound 2) with high binding affinity comparable to Darunavir.  
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As also seen from Table 4.1, all the proposed structures show better binding affinity towards RT 
than Ziduvidine.  This observation might be explained that inclusion of hydrophobic fragments 
in the structures increases hydrophobic interactions with the enzyme pocket residues and hence, 
improved the overall inhibitor binding.   
4.4.3. Ligand-enzyme interactions 
Post-dynamic complex structures were analyzed to ensure that the proposed structures fit well in 
the enzyme active pocket and, to some extent, exhibit similar interaction trends as the reference 
drugs with their respective enzyme targets.  As evident from the hydrogen bonding and 
electrostatic interactions plots (Figure 4.2.), all proposed compounds showed, to a great extent, 
comparable interactions as in the crystal structures of the prototypes, DRV and AZT (all PDB 





Figure 4.2. Compound 2 in complex with PR and RT, A and B, respectively, showing the hydrogen bonding 
and electrostatic interactions with the enzymes active site. 
 
4.4.4. Per-residue interaction 
For further lead optimization and expansion, it is useful to have a quantitative estimation of the 
contribution of each amino acid residues in the enzyme active site towards ligand binding.  To 
accomplish this, we computed the per-residue interaction MolDock scoring function 32.  Insight 
obtained from per-residue interactions will allow us to tailor inhibitors that can strongly interact 
with those residues showed the most contribution towards the binding. Per-residue interactions 





Figure 4.3. Per-residue interactions of compound 2 with PR and RT, A and B, respectively. 
 
From the hydrogen bonding interaction plots and per-residue interaction calculations, inhibitors 
clearly exhibited strong interaction with PR enzyme via hydrogen bond with the active site 
residues Asp25/Asp25’, a conserved interaction seen in all X-ray crystal structures of PIs-
enzyme complexes. Interestingly, compound 2 showed a strong interaction with the flap 
residues, Ile50/Ile50’.  Inhibitors that can interact with flap residues are believed to interfere with 
the flap opening and closure process, hence enzyme normal function 31.  With respect to RT, 
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proposed structures showed hydrogen bonding as well as hydrophobic interactions with active 
site pocket residues, most importantly with Tyr115, Asp110, Arg72 and Ly219 (Figure 4.2. and 
4.3.). These interactions were also seen in the X-ray crystal structure of the AZT-RT complex. 
 
As evident from the docking, MD simulations and per-residue calculations, the four proposed 
lead compounds are expected to be potential dual acting inhibitors and good starting point for 
further optimization and expansion.  
 
The design strategy presented here could be implemented in the drug design and development 
process not only against HIV targets but also a wide range of biological systems   
 
4.5. Conclusion  
Based on the structural information of known HIV PR and RT inhibitors and the understanding 
of their binding mechanisms to the targets, novel leads were proposed as potential dual acting 
PR/RT inhibitors. Using hybrid computational approaches involving “loop docking” and 
molecular dynamics simulations and per-residue interactions calculations, the proposed 
structures were found to exhibit better binding affinities when compared to the prototype drugs. 
Compound 2 with bis-tetrahydrofuranyl moiety was found to be the most active compound 
against both PR and RT.  The structures presented in this work are proposed as promising leads 
for developing potential drugs against HIV/AIDS therapy. Moreover, the in-silico strategy 





1. Wlodawer, A., and Vondrasek, J. (1998) Inhibitors of HIV-1 protease: A major success 
of structure-assisted drug design, Annual Review of Biophysics and Biomolecular 
Structure 27, 249-284. 
2. Pani, A., Loi, A. G., Mura, M., Marceddu, T., La Colla, P., and Marongiu, M. E. (2002) 




3. Schinazi, R. F., Hernandez-Santiago, B. I., and Hurwitz, S. J. (2006) Pharmacology of 
current and promising nucleosides for the treatment of human immunodeficiency viruses 
(vol 71, pg 322, 2006), Antiviral Research 72, 256-256. 
4. Young, B., and Kuritzkes, D. R. (2002) Resistance to HIV-1 protease inhibitors., 
Infectious Diseases and Therapy 25, 257-282. 
5. Bacheler, L. T. (1999) Resistance to non-nucleoside inhibitors of HIV-I reverse 
transcriptase, Drug Resistance Update 2, 56-67. 
6. Mbisa, J. L., Martin, S. A., and Cane, P. A. (2011) Patterns of resistance development 
with integrase inhibitors in HIV, Infection and drug resistance 4, 65-76. 
7. Yeni, P. (2006) Update on HAART in HIV, Journal of Hepatology 44, S100-S103. 
8. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., 
Aschman, D. J., and Holmberg, S. D. (1998) Declining morbidity and mortality among 
patients with advanced human immunodeficiency virus infection, The New England 
Journal of Medicine 338, 853-860. 
9. Morphy, R., and Rankovic, Z. (2009) Designing Multiple Ligands - Medicinal Chemistry 
Strategies and Challenges, Current Pharmaceutical Design 15, 587-600. 
10. Lewis, W. G., Green, L. G., Grynszpan, F., Radic, Z., Carlier, P. R., Taylor, P., Finn, M. 
G., and Sharpless, K. B. (2002) Click chemistry in situ: Acetylcholinesterase as a reaction 
vessel for the selective assembly of a femtomolar inhibitor from an array of building 
blocks, Angewandte Chemie International Edition 41, 1053-+. 
11. Munoz-Torrero, D., and Camps, P. (2006) Dimeric and hybrid anti-Alzheimer drug 
candidates, Current Medicinal Chemistry 13, 399-422. 
12. Gemma, S., Gabellieri, E., Huleatt, P., Fattorusso, C., Borriello, M., Catalanotti, B., 
Butini, S., De Angelis, M., Novellino, E., Nacci, V., Belinskaya, T., Saxena, A., and 
Campiani, G. (2006) Discovery of huperzine A-tacrine hybrids as potent inhibitors of 
human cholinesterases targeting their midgorge recognition sites, Journal of Medicinal 
Chemistry 49, 3421-3425. 
13. Yamamoto, M., Ikeda, S., Kondo, H., and Inoue, S. (2002) Design and synthesis of dual 
inhibitors for matrix metalloproteinase and cathepsin, Bioorganic and Medicinal 
Chemistry Letters 12, 375-378. 
80 
 
14. Kawanishi, Y., Ishihara, S., Tsushima, T., Seno, K., Miyagoshi, M., Hagishita, S., 
Ishikawa, M., Shima, N., Shimamura, M., and Ishihara, Y. (1996) Synthesis and 
pharmacological evaluation of highly potent dual histamine H-2 and gastrin receptor 
antagonists, Bioorganic and Medicinal Chemistry Letters 6, 1427-1430. 
15. Ryckmans, T., Balancon, L., Berton, O., Genicot, C., Lamberty, Y., Lallemand, B., 
Pasau, P., Pirlot, N., Quere, L., and Talaga, P. (2002) First dual NK1 antagonists-
serotonin reuptake inhibitors: Synthesis and SAR of a new class of potential 
antidepressants, Bioorganic and Medicinal Chemistry Letters 12, 261-264. 
16. Groneberg, R. D., Burns, C. J., Morrissette, M. M., Ullrich, J. W., Morris, R. L., 
Darnbrough, S., Djuric, S. W., Condon, S. M., McGeehan, G. M., Labaudiniere, R., 
Neuenschwander, K., Scotese, A. C., and Kline, J. A. (1999) Dual inhibition of 
phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid 
template, Journal of Medicinal Chemistry 42, 541-544. 
17. S.M., A., Kruger, H. G., Govender, T., Maguire, G. E., Sayed, Y., Ibrahim, M. A., 
Naicker, P., and Soliman, M. E. (2013) Comparison of the Molecular Dynamics and 
Calculated Binding Free Energies for Nine FDA-Approved HIV-1 PR Drugs Against 
Subtype B and C-SA HIV PR, D - 101262549 81, 208-218. 
18. Honarparvar, B., Makatini, M. M., Pawar, S. A., Petzold, K., Soliman, M. E., Arvidsson, 
P. I., Sayed, Y., Govender, T., Maguire, G. E., and Kruger, H. G. (2012) 
Pentacycloundecane-diol-Based HIV-1 Protease Inhibitors: Biological Screening, 2D 
NMR, and Molecular Simulation Studies, ChemMedChem 7, 1009-1019. 
19. Karpoormath, R., Sayed, Y., Govender, P., Govender, T., Kruger, H. G., Soliman, M. E., 
and Maguire, G. E. (2012) Pentacycloundecane derived hydroxy acid peptides: a new 
class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type 
C-SA protease inhibitors, Bioorganic Chemistry 40, 19-29. 
20. Makatini, M., Petzold, K., Sriharsha, N. S., Ndlovu, N., Soliman, M. E. S., Honarparvar, 
B., Parboosing, R., Naidoo, A., Arvidsson, P. I., Sayed, Y., Govender, P., Maguire, G. E. 
M., Kruger, H. G., and Govender, T. (2011) Synthesis and Structural Studies of 
Pentacycloundecane-based HIV-1 PR Inhibitors: A Hybrid 2D-NMR and 




21. Makatini, M., Petzold, K., Sriharsha, S., Soliman, M. E. S., Honarparvar, B., Arvidson, P. 
I., Sayed, Y., Govender, P., Maguire, G. E. M., Kruger, H., and Govender, T. (2011) 
Pentacycloundecane-based Inhibitors of Wild-type C-South African HIV Protease 
Bioorganic and Medicinal Chemistry Letters 15 2274-2277. 
22. Makatini, M. M., Petzold, K., Alves, C. N., Arvidsson, P. I., Honarparvar, B., Govender, 
P., Govender, T., Kruger, H. G., Sayed, Y., Jeronimolameira, Maguire, G. E., and 
Soliman, M. E. S. (2013) Synthesis, 2D-NMR and molecular modelling studies of 
pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA 
protease inhibitors, Journal of Enzyme Inhibition and Medicinal Chemistry 28, 78-88. 
23. Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., and 
Hutchison, G. R. (2012) Avogadro: An advanced semantic chemical editor, visualization, 
and analysis platform", Journal of Cheminformatics 4, 1-17. 
24. Hawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A., and Stahl, M. T. 
(2010) Conformer Generation with OMEGA: Algorithm and Validation Using High 
Quality Structures from the Protein Databank and Cambridge Structural Database, ournal 
of Chemical Information and Modeling 50, 572-584. 
25. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., and 
Olson, A. J. (1998) Automated docking using a Lamarckian genetic algorithm and an 
empirical binding free energy function, Journal of Computational Chemistry 19, 1639-
1662. 
26. Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, 
A., Simmerling, C., Wang, B., and Woods, R. J. (2005) The Amber biomolecular 
simulation programs, Journal of Computational Chemistry 26, 1668-1688. 
27. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. 
C., and Ferrin, T. E. (2004) UCSF Chimera--a visualization system for exploratory 
research and analysis, Journal of Computational Chemistry 25, 1605-1612. 
28. Wallace, A. C., Laskowski, R. A., and Thornton, J. M. (1995) Ligplot - A program to 
generate schematic diagrams of protein ligand interactions, Protein Engineering 8, 127-
134. 
29. Appelt, K. (1993) Crystal structures of HIV-1 protease-inhibitor complexes, Perspectives 
in Drug Discovery and Design 1, 23-48. 
82 
 
30. Brik, A., and Wong, C. (2003) HIV-1 protease: mechanism and drug discovery, Organic 
and Biomolecular Chemistry 1, 5-14. 
31. Damm, K. L., Ung, P. M., Quintero, J. J., Gestwicki, J. E., and Carlson, H. A. (2008) A 
poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket, 89, 643-
652. 
32. Thomsen, R., and Christensen, M. (2006) MolDock: a new technique for high-accuracy 





























Computer-aided perspective for the design of flexible HIV non-nucleoside 
reverse transcriptase inhibitors (NNRTIs): de-novo design, virtual screening 
and molecular dynamics simulations 
Suri Moonsamya and Mahmoud E. S. Solimana* 
aSchool of Health Sciences, University of KwaZulu-Natal, Westville, Durban 4001, South Africa 
* Corresponding author: Mahmoud E. Soliman, email: soliman@ukzn.ac.za 
Telephone: +27 031 260 7413, Fax: +27 031 260 779 
 
5.1. Abstract 
Flexible hydroquinone-based compounds were previously proposed as potential mutant-resistant 
NNRTIs inhibitors, however, experimental or computational evidences did not support this 
proposal. Herewith, using an integrated in-silico computational approach involving de-novo 
design, structure-based virtual screening (SBVS), molecular dynamics simulations and post-
dynamic per-residue binding energy decomposition analysis, the binding affinity as well as the 
interaction landscape of novel flexible hydroquinone-based compounds were investigated to 
explore their activity as potential NNRTIs. The proposed leads were found to exhibit improved 
binding affinity when compared to FDA-approved NNRTIs, rilpvirine, nevirapine and efavirenz, 
however, the bioavailability profile of these compounds could hamper their uses as effective 
drugs.  Results obtained from this extensive study could assist medicinal and biochemistry 





As the human immunodeficiency virus type 1 (HIV-1) has been proven to be the cause of the 
acquired immunodeficiency syndrome (AIDS) 1, this disease poses detrimental effects for world 
health as it is estimated that 34 million people live with HIV/AIDS worldwide 2, 3.  
 
The reverse transcription (RT) enzyme is important for HIV-1 replication 4. HIV-1 RT is a vital 
component in the virus life cycle, where this enzyme facilitates converting single-stranded RNA 
viral genome into double-stranded DNA 4-6. As RT is considered as a critical component in the 
virus life cycle, this HIV protein has become a major target for antiviral therapy 7, 8. In particular, 
the two classes of antiviral drugs that target RT are nucleoside RT inhibitors (NRIs) and non-
nucleoside RT inhibitors (NNRTIs) 4, 9, 10. Both classes inhibit the RT-associated polymerase 
activity: the NRTIs compete with the natural dNTP substrate and act as chain terminators; 
whereas the NNRTIs bind to an allosteric pocket and inhibit polymerization non-competitively 4. 
Although, a large number of inhibitors that target RT have been approved for treatment 9, 10, 
there are many complications that hinder the therapeutic effect of these inhibitors. For instance, 
NRTIs demonstrated high levels of cellular toxicity 11, whereas the highly potent and less toxic 
NNRTIs are severely weakened by the rapid emergence of drug-resistant strains 1, 12. Therefore, 
tackling the drug-resistant implications associated with NNRTIs could result in less toxic and 
more potent inhibitors as anti-HIV RT. It is strongly believed that more flexible NNRTIs could 
be more effective against drug-resistant mutants (4, 12, 13). 
 
The concept of designing flexible RT inhibitors has been proposed before (4, 12, 13). Ohtaka and 
his colleagues made a conclusion that a protease inhibitor required to be flexible in nature in 
order to bind to mutant enzymes 13. Soon afterwards, Das et al (2005), concluded that 
conformational flexibility of an NNRTI was crucial in preserving the functionality of an NNRTI 
being exposed to mutations of resist antiviral strains 14. Furthermore, it was suggested that the 
L100 mutant of HIV-1 RT was proficiently inhibited by diarylpyrimidine (DAPY)-based 
inhibitors 14, as these inhibitors are torsionally flexible and so are capable of binding to any 




To this end, in this report, via using integrated in-silico approaches, including de-novo design, 
structure-based virtual screening (SBVS) and molecular dynamics simulations, we propose novel 
flexible hydroquinone-based structures as potential leads to inhibit HIV-1 RT. Specifically, our 
main purpose is to design and identify flexible ligands with enhanced conformational freedom to 
allow positional adaptability within RT enzyme active site and as a result could become mutant-
resistant inhibitors.  
 
The proposal of hydroquinone-based structures as flexible NNRTIs was first introduced by 
Bruccoleri 5, however, this proposal was not supported by either experimental or computational 
evidences. Therefore, the work reported herein is an attempt to verify the activity of 
hydroquinone-based compounds as NNRTIs, as proposed by Bruccoleri 5. In order to accomplish 
this, we have designed and investigated the binding affinity and themes for a novel set of 
different hydroquinone-based structures against RT enzyme at molecular level. Structure-based 
virtual screening in order to identify a wider range of novel hydroquinone-based compounds 
from the commercially available chemical databases then followed this de-novo design. Docking 
calculations, molecular dynamic stimulations and post-dynamics analysis and per-residue energy 
contribution were performed in order to accurately estimate the relative binding affinities of the 
proposed compounds against RT enzyme as well as to ensure the stability of the resulted ligand-
enzyme complexes. To validate our calculations, the same docking approach adopted for the 
proposed compounds was performed for different FDA-approved NNRTIs and results were 
compared against experimental data.  
 
Information gained from this study could shed light on the activity of a new series of lead 
compounds as potential anti-HIV RT.  Also, the study could be of much interest to medicinal 
chemistry and biochemistry researchers for further investigation and development.  
 
5.3. Computational Methods 
5.3.1. De-novo design of the proposed structures and conformational ensembles  
Seven proposed structures were modeled, geometry optimized and energy minimized using 
MMFF94 force field implemented in Avogadros software 16. Via conformational sampling, low-
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energy conformations were produced for each proposed ligand using Omega v1.8b 17. 
Conformational isomers developed for each molecule were only examined, if these isomers were 
within a range of 3.0 kcal/mol from the lowest energy conformer. 
5.3.2. Protein systems 
The coordinates of the RT enzyme bound to rilpvirine, a new generation NNRTI and commonly 
abbreviated as TMC 278, were acquired from the protein data bank (http://www.rcsb.org/) (PDB 
code: 2ZD1). Other NRRTIs used in this study were also obtained from the protein data bank 
and identified by the following PDB codes: nevirapine (NVP) (PDB code: 4B3Q) and efavirenz 
(EFZ) (PDB code: 1IKW) (Figure 5.1.). 
The full computational scenario describing the preparation of enzyme systems for subsequent 
docking and MD simulations can be found in our earlier reports 18-22. 
5.3.3. Docking calculations: Structure-based virtual screening (SBVS). 
Docking calculations were conducted using Autodock Vina 23 screening software. The Screening 
procedure was run using the software default settings; however, the exhaustiveness of the 
screening was set to the value of 8. The grid box used to define the screening site was elucidated 
using the Autodock Vina functionality built into Chimera 24. The box was defined around Asp55, 
Glu56, Asp79, Arg82, Ile84, Pro85, Val99, Lys108, Val123, Arg141 and Ser169. The X, Y and 
Z centers were defined as 49.7, -27.3 and 38.11, respectively. The X, Y and Z size dimensions 
were defined as 42, 38 and 48, respectively. Autodock Vina generated screening results in the 
pdbqt format. Ten compounds with the best binding energies were selected from each of the two 
libraries. The docking results of these compounds were visualized the Viewdock feature in 
Chimera software. 
To validate the accuracy of docking method in this work, three FDA-approved drugs with known 
experimental data (IC50) were seeded in the docking runs and results were compared against 
experimental data. 
5.3.4. 2D shape similarity-based compounds library generation 
The best-docked structure resulted from the de-novo design (section 5.3.1.) was used as template 
for the generation of a 2D shape similarity-based compounds library retrieved from the 
Chemicalize database (http://www.chemicalize.org/). The structure of the template compound 
was drawn using the MarvinSketch Software (Chemaxon, http://wwwchemaxon.com). This was 
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then used to generate a SMILES code, which was used to query the Chemicalize database. The 
database was queried for all structures that had greater than 70% shape similarity to the reference 
template. This results in a total number of 1007 compounds. As explained in our previous report, 
physicochemical filters were imposed to enhance structures mining process 25.  However, in this 
study, only compounds with molecular weight between 300 and 550 mg/mol will be selected – 
this resulted in 303 hits. No other criteria were imposed to ensure the inclusion of the maximum 
number of compounds. These compounds were downloaded as a single file in the mol2 format. 
Molegro Molecular Viewer (MMV) software suite 26 was then used to create the individual mol2 
files. These files were then converted into the pdbqt format required for Autodock Vina using 
Raccoon software 27. Conformational sampling (see section 5.3.1.) was also performed for all 
retrieved compounds before docking into the RT enzyme. 
5.3.5. Molecular dynamics (MD) and post-dynamic analysis 
The two best docked ligand-enzyme complexes resulted from the SBVS for the de-novo 
designed structures and 2D shape similarity-based compounds library were subjected to MD 
simulations using Amber software following the procedure explained in earlier report 28.  For 
analyzing the interactions of post-dynamic protein-ligand complexes, the Ligplot programme 
(27) was used to plot the hydrogen bond and hydrophobic interactions between receptor and 
ligand atoms within a range of 5 Å. Chimera software 24 was used to visualize and prepare 
figures for the top ranked molecules. Per-residue energy decomposition was computed using 
Moldock scoring functions (25). 
 
 
5.4. Results and Discussion 
5.4.1. De-novo design plan  
First, the enzyme target, RT enzyme, active site was carefully examined in order to explore the 
nature of the binding site pocket. It was observed that the binding themes differ amongst the 
crystal structures of various NNRTIs to RT. Specifically, NNRTIs bind to the hydrophobic 
pocket situated in the p66 subunit of HIV-1 RT 5. In our study, we determined the active site 
residues of RT to include: Lys-103, Leu-236, Val-108 and Tyr-190. The NNRTI-binding site 
also has a high degree of flexibility and as a result can bind NNRTIS of diverse shapes and sizes, 
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which only opens in the presence of an inhibitor 5, 14. Some NNRTIs display “butterfly-like” 
conformations whereas others show “horseshoe” conformations 5, 14.  
 
Based on the study reported by Bruccoleri 5 we proposed seven de-novo ligands (Table 5.1.) that 
we anticipate to have potent flexible non-nucleoside inhibitory activity against HIV-1 RT. 
 
Our design initially began with a covalently linked hydroquinone trimer, structure 1 (Table 5.1.). 
Then, in order to provide more flexibility to the structure, we introduced O atom and CH2 
spacers between the hydroquinone rings. After docking, we noticed that these compounds do not 
optimally fill the enzyme active site pocket as evident from the poor binding affinity (structures 
1, 2 and 3 - Table 5.1.). Then we opted to design larger structures by adding phenyl rings on the 
spacer atoms, CH2, in order to maximize the hydrophobic interactions between the inhibitors and 
the active site residues (structure 4, Table 5.1.). As expected, this approach has improved the 
binding affinity by 1.2 kcal/mol (Table 5.1.). We tried a parallel approach to the former one, 
however, this time by linearly expanding the hydroquinone moieties to create tetramers with and 
without spacers, compounds 5, 6, respectively (Table 5.1.). However, these compounds showed 
modest activity when compared to the prototype, rilpivirine. Adding one more hydroquinone 
moiety to structure 7 has remarkably improved the binding affinity (Table 5.1.).  
The reason for this observation is perhaps due to the fact that compound 7 is fully occupying the 
active site, therefore showed more enhanced binding affinity towards RT.  
 
As evident from Table 5.1, all the de-novo set 1 designed compounds (Table 5.1.), following the 
design plan proposed by Bruccoleri 5, exhibited lower binding affinity towards RT when 
compared to rilpivirine (-11.4 kcal/mol) – excluding compound 7 which shows a slightly better 
binding affinity, however, this is very subtle difference if experimental errors are considered.  
 
From these results, it seems to us that the designed compounds exhibit humble activity as 
NNRTIs. Many factors might contribute to these findings: (1) the docking method applied might 
not be accurate enough to provide accurate estimates of the binding energies, (2) our chemical 
intuition might have drifted away and led to the design in the wrong direction (3) our design 
have not covered a wider range of structural scaffolds which might have higher binding affinities 
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towards RT. In order to eliminate the first factor, we opted to validate the docking protocol 
applied in this work. One of the most commonly used approaches to validate docking results is 
“cross-validation” where other docking programs are used to validate the data obtained from the 
original docking software. From our experience, we found that using different software, with 
different scoring functions, could generate different results and be misleading, therefore, we did 
not opt to use this validation method.  We always believe that the most rational way to validate 
docking calculations, or even any other computational tool, is to run the calculations on a set of 
compounds with available experimental data. Results from calculations, are then compared 
against experimental data for validation. Another reliable approach to validate docking results is 
to perform docking for the bound inhibitors in the X-ray crystal structure of the inhibitor-enzyme 
complex, then the RMSD of the docked complex is then compared against the native X-ray 
structure.  
 
To this end, in this work, we performed docking analyses on three FDA approved NNRTI drugs 
using our docking methodology (Figure 5.1.). The PDB coded structures were obtained from the 
Protein Data Bank (http://www.rcsb.org/) and experimental IC50 values were obtained from the 
Binding database (http:// www.bindingdb.org/). It is worth mentioning that, we have previously 
used the same docking approach in several experimental reports and it proved reliable to a great 
extent 18-22. As evident from the docking results (Figure 5.1.), the docked energies are in great 
accordance with the experimental IC50.  This implies that the docking methods used in this work 
could be reliable enough to estimate the binding affinities for the proposed compounds.   
Figure 5.1. should be here 
As mentioned above, and as evident from the humble binding affinities of the de-novo designed 
compounds, our chemical intuition for the design of potential leads might have failed to build up 
the right structural scaffolds or at least have not covered a wider range of compounds to probably 
include those with better binding affinities. To this end, we opted to search for similar 
compounds in the commercially available chemical database (www.chemicalize.org).  Our query 
of the database was based on 2D shape similarity-based identity to our best-docked structure 
(compound 7- Table 1) from the de-novo design as a reference template.  All compounds in the 
generated library (see Methods sections for details) were then docked into the active site of the 
RT enzyme. As shown in Table 5.1, the top 10 compounds from the SVBS session exhibited 
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remarkably higher binding energies as compared to Rilpvirine (-11.4 kcal/mol), with binding 
energies ranging from -12.8 to -11.8 kcal/mol. 
Table 5.1 should be here 
By looking at the structures retrieved from the database, we found that, however, architecturally 
similar, none of the compounds retained a hydroquinone fragment.  Also, in all structures, a 
carbon spacer exists between all phenyl rings. Another conclusion can be drawn by looking at 
Table 5.1, the de-novo designed library vs. virtually screened library, is that inclusion of methyl 
groups at different positions on the main structure skeleton has a significant positive impact on 
the binding affinity. This could be explained based on the fact that the NNRT active site is 
mostly hydrophobic in nature. Based on the conclusions drawn from Table 5.1, we opted to 
optimize the initially de-novo designed leads by inclusion of methyl groups on the skeleton of 
the structures having a spacer between aromatic rings, structure 2, 4 and 6, in order to see 
whether or not this will enhance the binding affinities. Inclusion of methyl groups on the 
hydroquinone skeleton, structure 18, 19 and 20, has improved the binding affinity by 0.5 - 0.9 
kcal/mol (Table 5.1.). We assume that inclusion of methyl group has increased the chances of 
hydrophobic interactions with the hydrophobic residues in the enzyme active site. To verify this 
assumption, we performed interaction and per-residue binding energy decomposition analysis on 
the post-dynamic ligand enzyme complexes resulted from the docking calculations (see section 
5.4.1.).   
5.4.2. Molecular Dynamics simulations and post-dynamic analysis 
In order to obtain more insight on the stability of the resulted docked complexes, the nature of 
overall interaction theme between the proposed ligands and the target protein and the specific 
amino acids involved in the ligand binding, we performed a 2 ns MD simulations followed by 
extensive post-dynamic analyses on the docked ligand-enzyme complexes from the de-novo 
design and chemical database.   
 
From our previous experience with molecular docking, in many occasions, we experienced that 
even best docked structures may fly away from the enzyme active site within a few picoseconds 
of MD simulations. Therefore, we believe that docking calculations that are not validated by 
relatively a long MD run to ensure the stability of the system might not be reliable. Interestingly, 
for all the compounds-enzyme complexes, the average RMSD values were below 2.2 Å and the 
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variation of the potential energies falls within 900 kcal/mol and this is a good indication of the 
system stability. The PDBs for all docked complexes are provided with the supplementary 
material.  
 
In order to perform additional lead optimization and expansion phases, it is highly beneficial to 
have a quantitative estimation of the contribution of individual amino acid residues in the 
enzyme active site towards ligand binding and we achieved this by the computation of the per-
residue interaction MolDock scoring function (25). Per-residue interactions for the reference 
compound (TMC 278) and compounds showed improved affinities with RT, compounds 8, 7, 
and 20 are shown in Figure 5.2.  
Figure 5.2. should be here 
From the per-residue interaction calculations, compounds 7, 8 and 20 demonstrated remarkable 
interactions with the active site residues Tyr183, Pro97, Leu102, Leu236, Phe229 and Tyr190 
(Figure 5.2.). However, to further gain better depiction of these interactions, hydrogen bond and 
electrostatic interactions maps for the 2n MD averaged complex structures of 8 and 20 with RT 
(Figure 5.3.). These plots were created using Ligplot software (27). 
Figure 5.3. should be here 
As evident from the post-dynamic hydrogen bond and electrostatic interactions (Figure 3A) as 
well as per-residue analysis (Figure 5.2.), the de-novo design-based compound 20 showed a 
strong hydrophobic interaction with Tyr183 and hydrogen bond interactions with His237, 
Lys103, Gly95 and Gln93 (Figure 5.4A). Table 5.1 and Figure 5.4. also showed that compound 
8 exhibited its favorable affinity than compound 20 due to the increased hydrophobic 
interactions with the RT active site residues.  
 
The integrated computational tools adopted in this work has explored the inhibitory landscape of 
a number of hydroquinone-based polymeric compounds as suggested by Bruccoleri 5 and proved 
that these compounds, to a reasonable extent, could be potential leads as anti HIV RT. However, 
the bioavailability profile of these compounds could be problematic since most of them violates 
Lipinski’s rule of five (especially, logP values and the number of hydrogen bond donors and 
acceptors). Also the toxicity profiles of these compounds need to be experimentally evaluated. 
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We believe that the computational workflow presented in this study could be a useful tool in the 
process of design and development of novel leads against biological targets  
 
5.5. Conclusion 
In the present study, and guided by the study presented by Bruccoleri 5, we proposed seven de-
novo hydroquinone -based ligands that we anticipated to have potent flexible non-nucleoside 
inhibitory activity against HIV-1 RT. However, these de-novo proposed compounds exhibited 
moderate binding affinities when compared to a rilpivirine. To optimize our de-novo design, we 
opted to mine for a wider range of similar compounds from the chemical database. However, the 
chemical database did not retrieve any hydroquinone-based structures, it guided us to optimize 
our leads. Inclusion of hydrophobic moieties on the hydroquinone skeleton has improved the 
binding interaction with the RT active site. Despite that fact that proposed compounds exhibited 
comparable binding affinities as rilpivirine, most of these compounds violate Lipinski’s rule of 
five and expected to have low bioavailability profile. Along with the computational insight 
provided from this report, further experimental investigations are needed to evaluate the 
bioavailability as well as the toxicity profiles of these compounds. 
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Table 5.1. The 2D structure, calculated binding energy and physicochemical properties of the de-novo 













































































































































































































































































Figure 5.1. 2D structures of FDA-approved HIV NNRTIs used as reference compounds for 




































Figure 5.2. Per-residue interactions of the reference compound (TMC 278) and the proposed 


































Figure 5.3. Hydrogen bonding and electrostatic interactions for the de-novo design-based 
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Exploiting an integrated in-silico computational technique encompassing homology modeling, 
structure-based and pharmacophore-based virtual screening, molecular dynamic simulations, per-
residue energy decomposition analysis and atom-based 3D-QSAR analysis, we proposed ten 
compounds as novel CCR5 antagonists as potential HIV-1 entry inhibitors. Via validated 
docking calculations, binding free energies revealed that the novel leads demonstrated better 
binding affinities with CCR5 compared to Maraviroc, an FDA-approved HIV-1 entry inhibitor 
and in clinical use. Per-residue interaction energy decomposition analysis on the averaged MD 
structure showed that hydrophobic active residues Trp86, Tyr89 and Tyr108 contributed the 
most to inhibitor binding. 
 
The validated 3D-QSAR model showed a high cross-validated rcv2 value of 0.84 using three 
principal components and non-cross-validated r2 value of 0.941. Also it was found that almost all 
compounds in the test set and training set yielded a good predicted value.  
Information gained from this study could shed light on the activity of a new series of lead 
compounds as potential HIV entry inhibitors and serve as a powerful tool in the drug design and 
development machinery. 
Keywords: CCR5 antagonists, HIV-1 entry inhibitors, homology modeling, virtual screening, 
molecular dynamic simulations, 3D QSAR analysis, computer-aided drug design. 
 













The human immunodeficiency virus type 1 (HIV-1) infection, which eventually leads to the 
acquired immunodeficiency syndrome (AIDS) 1, remains to be a fatal disease threatening 
human health 2. An estimated 34 million people live with HIV/AIDS worldwide 3, 4. 
Approximately 22.9 million individuals in sub-Saharan Africa constitute the overall global 
estimate 3-5. 
 
In AIDS therapy, the main treatment strategy is to inhibit HIV-1 replication and slow the 
destruction of the immune system. Currently, a number of viral targets are being used to 
develop anti-HIV drugs. These targets are mainly viral proteins which are essential for viral 
replication and survival, for example, protease enzyme (PR) 6, reverse transcriptase (RT) 7 
and integrase (IN) 8. Several drugs which are currently in clinical use have been developed to 
inhibit these potential viral targets 9.  
 
Numerous concerns regarding the long-term side effects of antiretroviral drugs and the 
increasing transmission of resistant variants accentuates the requirement to identify new 
classes of drugs, which are able to suppress HIV-1 replication efficiently 2. Therefore, there 
is an on-going need for novel therapeutics, which can prevent the entry of HIV-1 into its 
target cells 10, 11.  
 
The entry of the HIV virus into its target cell is mediated by the specific interactions of the 
target cell itself such as the interaction between gp120 viral envelope glycoprotein and the 
plasmatic membrane receptors 12. In turn these specific interactions produce conformational 
alterations in both the glycoprotein and in the membrane receptors that facilitates fusion of 
the HIV virus and the target cell.  Numerous studies have evaluated the role of CD4 and its 
interaction with gp120 and concluded that the CD4-gp120 interaction is a crucial component, 
but is not adequate for the disease to become established 13, 14. 
 
Besides CD4, certain chemokine receptors (CCRs) belonging to the G-protein coupled 
receptor superfamily (GPCRs) have recently been identified as co-targets essential for HIV 
viral entry into target cells 10, 15. The different CCRs and their natural chemokine ligands 
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such as RANTES, MIP-1alpha and MCP2, which are responsible for signaling regulation 
amidst immune cells and thus signify potential target systems for preventing virus-cell 
fusion. Several studies have reported on the identification and characterization of diverse 
CCRs 16.  Besides a CCR that is viral strain dependent, the majority of CCR strains, which 
are the R5 isolates, transmitted during sexual intercourse and act on CCR5 throughout the 
disease 16.  
 
The chemokine co-receptor CCR5 has proven to be a critical pharmaceutical target in the 
contexts of HIV-1 and inflammatory diseases. CCR5 functions as an integral protein in the 
HIV-1 entry into host cells by acting as a crucial co-receptor for the gp120 viral envelope 
glycoprotein 1. Furthermore, the impact of CCR5 in HIV-1 transmission can moreover be 
demonstrated from experimental data, whereby individuals that are homozygous for the 32-
base pair deletion for the CCR5 allele produce a defective CCR5 co-receptor and are resistant 
to R5-tropic HIV-1 infection, however are otherwise generally healthy 17. This fact has 
prompted an enormous research impact in the past decade for identifying anti-HIV agents 
that specifically target the CCR5-mediated entry mechanism. Furthermore, this implies that 
functional inhibition of CCR5 may help protect against infection without provoking damage 
to patients and, therefore, that blocking viral entry using small-molecule antagonists selective 
for this receptor might provide a new and more effective type of anti-HIV drug. 
 
The concept of designing small molecule CCR5 antagonists has been investigated before 1, 11, 
18. Although no structural information exists about the precise binding site of CCR5 with any 
FDA approved inhibitor is available. Numerous studies have demonstrated CCR5 modeling 
of possible inhibitors using computational approaches including virtual screening, molecular 
docking, molecular dynamic stimulations and pharmacophore modeling. Perez-Nueno et al 
(2008), reported a detailed comparative report of ligand-based and receptor-based virtual 
screening methods to discover potential HIV entry inhibitors for CXCR4 and CCR5 
receptors 19. In theory, virtual screening of structure-based approaches yields better results 
than ligand-based methods. Afantitis et al (2006) and Aher et al. (2007), revealed CCR5 
antagonists derived from 1-(3, 3-diphenylpropyl)-piperidinyl amides using virtual screening 
and quantitative structure-activity relationships (QSAR) studies 20, 21. In a previous report by 
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Kellenberger et al (2007), structure –based techniques were used to model the physics of 
protein-ligand interactions in conjugation with combined 2D and 3D structure-based 
methodologies, which were utilized to find 10 CCR5 binders from a library of 1.6 million 
compounds 22. Researchers have developed new approaches of combining computational 
molecular modeling methodologies, for example molecular docking, 3D-QSAR, comparative 
receptor modeling and virtual screening to discover potential CCR5 HIV-1 entry inhibitor 
drugs 1. Xu et al (2004), studied the detailed interactive relationship between CCR5 and its 
inhibitors using a docking-based 3D-QSAR approach along with protein modeling and MD 
stimulation 2. However, in other mechanistic studies of protein-ligand entry inhibitor 
interactions, investigators have used homology modeling, molecular docking and molecular 
dynamic stimulation techniques 1.  
 
 
Figure 6.1. 2D Structure of the known FDA-approved CCR5 antagonist, Maraviroc. 
 
To this end, in this report, via a hybrid structure-based and ligand-based virtual screening, we 
aim to identify novel CCR5 antagonists as potential HIV-1 entry inhibitors based on a human 
CCR5 homology model template and a known FDA-approved CCR5 antagonist (Figure 
6.1.), maraviroc, as prototypes. Virtual screening of ligand-based compounds libraries were 
generated via two distinct yet complimentary approaches: (a) structural similarity-based 
compound generated library – this library generated compounds that bear a 2D structural 
similarity to maraviroc, whereas the (b) Pharmacophore-based generated library – this library 
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generated compounds that contained the pharmacophoric groups of the maraviroc structure. 
Merging this integrated technique allows us to ensure that our generated compounds library 
encompasses structural units with diversity, yet with mutual pharmacophoric and structural 
features. Thereafter, the ligand-based compounds libraries were subjected to virtual screening 
against the CCR5 enzyme using docking calculations. 
 
To validate our docking calculations, the same docking approach adopted for the ligand-
based libraries was performed on a group of compounds with known experimental data 
attained from inhibition assays against HIV-1 CCR5 and the results were compared against 
experimental data. Furthermore, from our previous experience with molecular docking, and 
in numerous insistences, the reliability of a stable protein-ligand complex might not be a true 
reflection. Therefore, in order to obtain more insight on the stability of the resulted docked 
complexes, the nature of the overall interaction themes between the generated ligands and the 
target protein, and the specific amino acids involved in the ligand binding, we performed 1 ns 
MD simulations followed by extensive post-dynamic analyses on the ligand-enzyme 
complexes resulted from our docking simulations.  
 
We took our study a step further by obtaining a set of 35 novel oxamino-piperidino-
piperidine amide analogs with available IC50 (mM) data taken from literature for the 
development of our atom-based 3D-QSAR model 1. 
 
It is worth mentioning that the three dimensional (3D) CCR5 structure is not yet available. 
However, homology-modeling of CCR5 has been performed before 10.  Therefore, in this 
study, the actual human CCR5 homology model was developed using the crystal structure of 
CXCR4 as a structural template. Information gained from this study could shed light on the 
activity of a new series of lead compounds as potential HIV entry inhibitors. This study 





     6.3. Computational methods  
 
      6.3.1. Homology modeling of CCR5  
In order for our molecular docking study to be executed, the crystal structure of human 
CCR5 was homology modeled using the human CCR5 protein sequence retrieved from the 
UniProt database 23 (Uniprot ID: P51681). The actual homology model of CCR5 was created 
using the CXCR4 crystal structure (PDB ID: 3ODU) as a structural template using the 
Modeler software 24 add-on in Chimera 25. Our enzyme model was established with 
hydrogens, whilst all the important active site amino acid residues numbers were identified 
using Chimera Multi-align Viewer 25.  
      6.3.2. Maraviroc structure acquisition and preparation 
The structure of maraviroc, an FDA-approved known CCR5 antagonist, in a mol2 file format 
was acquired from the DrugBank 26-28. This antagonist had its geometry optimized and 
energy minimized using MMFF94 force field executed in Avogardros software 29. 
Thereafter, for succeeding analyses, the CCR5 antagonist was kept in a mol2 file format. 
      6.3.3. Ligand library generation 
      6.3.3.1. Structural similarity-based compound library generation 
Maraviroc was used as a template for the generation of a 2D shape similarity-based 
compounds library generated from the Zinc database. The maraviroc structure was drawn 
using the MarvinSketch software (Chemaxon, http://www.chemaxon.com). This was then 
utilized to create a SMILES code, which was employed to query the Zinc Database. This 
database was queried for all structures that had greater than 60% shape similarity to 
maraviroc. The query search generated a total of 1002 compound hits. As explained in our 
earlier report, certain physiochemical filters were implemented to enhance the structure query 
process 3. In this study, the pre-defined subset physiochemical filter was set at drug-like 
qualities. Only compounds with molecular weight between 150 and 500 were selected – this 
resulted in 480 hits. Other criteria were imposed to ensure the inclusion of the maximum 
number of compounds, such as the compounds had to have an xlog P between -4 and 5, a net 
charge between -5 and 5, rotatable bonds between 0 and 8, a polar surface area of between 0 
and 150, have hydrogen bond donors/acceptors between 0 and 10, and polar desolvation 
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between 0 and 1kcal/mol whereas compounds must have an apolar desolvation between -100 
and 40kcal/mol. Thereafter, these compounds were downloaded as a single mol2 file format 
and were individually separated into mol2 files using Molegro Molecular Viewer (MMV) 
software suite 30. These files were then converted into pdbqt format needed for Autodock 
Vina using Raccoon software 31.  
      6.3.3.2. Pharmacophore-based library generation 
The Zinc Pharmer database 32 was used to generate the pharmacophore screening compound 
libraries. We imported our maraviroc inhibitor structure into Zinc Pharmer with our chosen 
pharmacophoric regions as illustrated in Figure 6.2. These were chosen based on their 
probability of forming good interactions with the receptor. Furthermore, the Lipinski Rule of 
Five was imposed as the set criterion for screening compounds. Also, it was imposed for 
constriction of conformational variations of the same ligand. The purpose of doing this was 
to reduce any duplication, since the virtual screening software executed diverse 
conformational variations of the same ligand. The query search generated a total of 602 
compounds. All these compounds were downloaded as a single sdf file format and then 
separated and processed as explained above in section 6.3.3.1.  
 
Figure 6.2. (A) Maraviroc structure used as a template for pharmacophore-based and 
structural similarity-based compound library generation. Pharmacophore selection criteria. 
Green depicts hydrophobicity, purple depicts aromatic and white depicts hydrogen donor. 






       6.3.4. Virtual screening and validation of docking protocol 
In our study, the known CCR5 antagonist (Maraviroc) and the two respective ligand-based 
compound libraries were subjected to virtual screening against the crystal structure of the 
human HIV-1 CCR5 enzyme. The Autodock Vina 33 screening software was used to conduct 
docking calculations. Although the Screening procedure was run using the software default 
settings; the exhaustiveness of the screening was fixed to the value of 8. The grid box used to 
define the screening site was clarified by using the functionality property of Autodock Vina, 
which is constructed in Chimera 25. The grid box was defined around the following amino 
acid residues, namely Phe85, Trp86, Trp 89, Leu104, Tyr108, Ile 198, Try251 and Glu283, 
which resembled the active site residues found in the crystal structure of CXCR4 enzyme 
following the sequence alignment done in Chimera. The X, Y and Z centres were defined as 
11.01, -2.08 and 45, 69, respectively. The X, Y and Z size dimensions were defined as 58, 82 
and 74, respectively. Autodock Vinas produced screening results in the pdbqt format. From 
each of the two compound libraries, we selected ten compounds that displayed the best 
binding energies. Afterwards, the obtained docking results for each of the ten compounds 
from each library were visualized using the Viewdock feature in the Chimera software.  
 
     6.3.5. Molecular dynamics simulations and post-dynamic analysis 
The best-docked ligand-enzyme complexes resulted from the structure-similarity and 
pharmacophore-based compounds library were exposed to MD stimulations using the Amber 
software 34 following the procedure explained in our previous report 33. In order to examine 
the post-dynamic ligand-protein interactions, in terms of plots representing the hydrogen 
bond and hydrophobic interactions between the protein and ligand atoms within a range of 
5Å were performed using the Molecular Viewing Operator (MOE) program 
(http://www.chemcomp.com/). The top-ranked were visualized and their figures prepared 
using the Chimera software 25. Moldock scoring functions 30 was employed for computing 
the per-residue energy decomposition calculations.  
       6.3.6. Three-dimensional (3D) QSAR analysis  
A set of 35 novel oxamino-piperidino-piperidine amide analogs (Figure 6.4.) with available 
IC50 (mM) data was taken from literature for the development of the atom-based 3D-QSAR 
model  (Table 6.1.) 1. This 3D-QSAR study has been carried out in Discovery studio 3.5 
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(http://www.accelrys.org). The 1/logIC50 value of CCR5 was used in this study. Of the 35 
compounds reported, 26 compounds were used as a training set and the remaining 9 
compounds were used as a test set, based on a random selection. The compounds in the test 
set have a range of biological activity values similar to that of the training set. The ligands 
were pre-aligned using a molecular overlay method and placed in a 3D grid space        
(Figure 6.3.). The grid spacing was 1 Å. The energy potentials on every grid point were then 
calculated using a CHARM force field which used the electrostatic potential and the Van der 
Waals potential and treated as separate terms. A +1e point charge is used as the electrostatic 
potential probe and distance-dependent dielectric constant is used to mimic the solvation 
effect. For the Van der Waals potential a carbon atom with a 1.73 Å radius is used as a probe. 
The energy grid potentials can be used as independent variables to create partial least-squares 
(PLS). Further the best 3D-QSAR model was validated by predicting activities of the 9 test 
set compounds. The 3D-QSAR was evaluated by cross-validated R2, Q2. The predicted 1/ 
logIC50 at 6th PLS factor are tabulated in Table 6.1. 
 
 





Figure 6.4.  The 2D structures for the oxamino-piperidino-piperidine amide analogs used in the 3D 
QSAR of this work. 
 
 
Table 6.1. Dataset analyzed for 3D QSAR with experimental 1/logIC50, predicted 1/logIC50 and 
residual value.  
 










































































































































































































































































































































































     t = test set. The conformation of compound denoted in ( ). 
 
    6.4. Results and Discussion 
     6.4.1. Homology modeling of CCR5 
The actual homology model of human CCR5 was modeled using the 3ODU crystal structure 
as a structural modeling template. As outlined in Figure 6.5, both these proteins 
demonstrated good structural similarity in and around the active site residues, with most of 
the residues having relatively identical locations to each other. The Multi-align Viewer tool 
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located in Chimera recorded a 42.11% shared similarity between the two proteins’ 
sequences; after modeling, the enzyme model had a zDOPE score of 0.91 with an RMSD of 
1.1771 Å. Four differences were observed between the active site sequences of our modeled 
CCR5 and the 3ODU model template, which included Leu204 (3ODU) corresponding to 
Leu104 (CCR5), Trp85 corresponding to Trp86, and two residue gaps namely corresponding 
to Leu213 and Phe113 from 3ODU (Table 6.2.). We assumed that these noted differences 
had very minimal effects in the docking study as result of shared structural similarity 
between the Leu and Trp residues, respectively. Further investigation is required to verify 
this assumption. All non-modeled regions were removed from the active site to allow 





Figure 6.5. (A) Superimposed structures of 3ODU 17 and modeled CCR5 enzyme (blue) with CCR5 
antagonist, maraviroc 35. (B) The 2D sequence alignment of 3ODU and the homology model 
generated for our study. Yellow highlighting represents α-helices and green highlighting represents 




Table 6.2. Comparison of the active site residues between the modeling template (3ODU) and 
modeled structure. 
 


































                           #                -              Differing Residue 
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6.4.2. Virtual Screening 
Results obtained from virtual screening for the pharmacophore and structure-based libraries are 












Table 6.3. List of the top 10 screened compounds based on their docked binding energy. 































































































































































































































































































































*Similarity-based library, **Pharmacophore-based library 
 
Our query of the ZINC database for compounds sharing 2D shape similarity-based identity to our 
maraviroc structure used as a reference template generated 220 compound hits. In addition, our 
query of ZINCPharmer for pharmacologically related compounds generated 120 compound hits. 
All compounds in the two generated compounds libraries (see Methods sections for details) were 
then docked into the active site of the CCR5 enzyme using Autodock Vina and thereafter, the top 
10 compounds were chosen from each library. As shown in Table 6.3 and Figure 6.6, the entire 
top 10 ranked compounds from each library exhibited remarkably higher binding energies 
compared to Maraviroc (-10.2 kcal/mol), with binding energies ranging from -12.2 to -11.6 
kcal/mol for the 2D shape similarity-based identity library, whereas the pharmacophore-based 
library had binding energies ranging from -12.0 to -11.4 kcal/mol.  
 
As outlined in Figure 6.6, an unforeseen observation revealed that compounds that were 
architecturally similar had higher binding energies on average compared to those that were 
pharmacophorically-based. Although, there was not a huge variance amongst both libraries, 
however, it raised the inquiry about the particular importance of each pharmacophoric area 
needed for CCR5 antagonist behavior. Perhaps the reason for this apparent difference is that the 
chosen pharmacophorically-based vicinities executed significant effects as we originally 
predicted. A further investigation is required to inquest more intensely into the site specific 
interactions performed by individual pharmacophoric regions and how does these interactions 
affect inhibitor binding affinities and functioning. It was also worth noting that compounds 3, 5, 
7 and 8 from both the structure-based and pharmacophore-based generated libraries displayed the 
same binding energies (Figure 6.6.). A possible explanation for this observation is that the 
docking parameters utilized did lead to relatively accurate results. Another interesting 
observation was that there was not a large difference amongst the top 10 binding energies for 
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compounds from both the structure-based and pharmacophore-based generated libraries with a 
difference of -0.60 kcal/mol between the highest and lowest ranked compounds (Figure 6.6.). 
Possibly this observation may be attributed to the conservancy of the crucial pharmacophoric and 
architecturally shared properties “amidst these compounds allowing for “alleged stability”, and 




1 ZINC71849459 ZINC00634884 
2 ZINC32760563 ZINC00825224 
3 ZINC25010434 ZINC00851466 
4 ZINC32760533 ZINC00877991 
5 ZINC71818945 ZINC00895634 
6 ZINC11546940 ZINC00895646 
7 ZINC19698213 ZINC00895774 
8 ZINC25010439 ZINC01038388 
9 ZINC71849397 ZINC01080881 
10 ZINC76956688 ZINC01247854 
 






With the intention of finding the best compounds of this study, the top 10 best-docked 
compounds from an integration of both compound libraries were revealed (Figure 6.7. and 
Table 6.3.). We instantly noticed that these compounds were remarkably larger in size compared 
to Maraviroc (Figure 6.7.). Furthermore, majority of the compounds occupied the spaces 
between Tyr89, Trp94, Glu283, Leu104, Thr195, Tyr251, Phe109, Ile198 and Trp248, 
something that was not achieved by Maraviroc as a result of its smaller size (Figure 6.7.). It may 
be deduced that an integration of these factors may be responsible for the higher binding energies 
demonstrated in this study, as the total number of interactions with the active site seems to be 
remarkably higher compared to those felt by Maraviroc.  
 
 
Figure 6.7. Docking conformations of the known CCR5 antagonist (Maraviroc) and the top 10 
ranked docked compounds from both the pharmacophore-based and structure-based libraries 
determined in this study, all complexed with CCR5 enzyme. 
 
 
From our docking results, it appears that the virtual screening compound hits elucidated exhibit 
humble activity as CCR5 antagonists. Numerous factors might contribute to these findings, but 
one of importance to us is that the docking protocol applied might not be accurate enough to 
provide precise estimates of the different binding energies. In an effort to eradicate this factor, 
we opted to validate the docking method applied in this study. “Cross validation” was employed 
to validate our docking results. It is where other docking programs are used to validate the data 
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attained from the original docking software. Due to previous experience of using different 
docking software with various scoring functions would generate results that could be different 
and be misleading, we opted to disregard this docking validation approach. We strongly believe 
that the utmost rational mannerism for validation of docking calculations, or even any other 
computational tool, is to perform the calculations on a set of compounds with available 
experimental data and these results are then compared against known experimental data for 
validation.  
 
To this end, in this work, we performed docking analyses on a set of compounds assayed using 
our docking method. The structures and experimental IC50 values were obtained from Binding 
database (http://www.bindingdb.org/). The binding energy of each compound was then plotted 
against its corresponding experimental IC50 value (Figure 6.8.). As evident from the docking 
results (Figure 6.8.), the docked energies are in great accordance with the experimental IC50. We 
observed that as the binding affinity increased (lower binding energy), the IC50 increased (Figure 
6.8.). We postulate that the larger the binding affinity, the more concentration is needed for 
complete enzyme inhibition. To us, this proves to be an interesting trend, since the top 10 ranked 
compounds which were obtained from both libraries (Table 6.3.) had higher binding energies 
compared to any of those used in the assay. This implies that the docking approaches used in this 
work could be reliable enough to estimate the binding affinities for the top 10 ranked compounds 




Figure 6.8. The binding energies determined in our study and were compared against IC50 values 
for the compounds assayed. The higher the binding affinity, the higher the IC50 . 
  
6.4.3. Molecular dynamics simulations and post-dynamic analysis 
In order to obtain more insight on the stability of the resulted docked highest ranked virtual 
screening hit complexes, the nature of overall interaction theme between the proposed ligands 
and the target protein and the specific amino acids involved in ligand binding, we performed 1 ns 
MD stimulations followed by extensive post-dynamic analyses on the ligand-enzyme complexes 






Figure 6.9. The highest ranked virtual screening hit lead complexes with CCR5 subjected to MD 
simulations. Structure-based compound (ZINC71849459) in complex with CCR5 (Black). 
Pharmacophore-based compound (ZINC00634884) with CCR5 (Blue). 
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MD stimulations of 1 ns were performed for the highest ranked virtual screening hit complexes 
(Figure 6.9.), to ensure the stability of the ligand within the CCR5 active site. From our previous 
experience with molecular docking, in many occasions, we experienced that even best docked 
structures may fly away from the enzyme active site within a few picoseconds of MD 
stimulations. Therefore, we believe that docking calculations that are not validated by relatively 
a long MD run to ensure stability of the system might not be reliable. Interestingly, for all the 
compound-enzyme complexes, the average RMSD values were below 2.5 Å. In addition, the 
variability of the potential energies fell with 1000 kcal/mol and this suggested being a good 
indicator of the system stability.  
 
In an effort to investigate the contribution of a single amino acid towards ligand (and/or 
antagonist) binding, we computed per-residue interactions using Moldock software 30        
(Figure 6.10.). The top ranked antagonist with the highest binding energy within each compound 
library was assessed, which included ZINC71849459 from the structure-based identity library 
and ZINC00634884 from the pharmacophore-based library. We noticed that Lys197, Phe109, 
Trp86, Tyr89 and Try108 exhibited remarkably interactions with both of those docked ligands. 
However, Trp86, Tyr89, Thr105, and Tyr108 demonstrated especially better interactions with 
ZINC00634884 (pharmacophore-based library), whereas Lys197, Leu196 and Glu283 showed 
good interactions with ZINC71849459 (structure-based identity library). As shown in Figure 
6.11, in order to gain a better understanding of the ligand-amino acid interactions occurring 
within CCR5’s active site, we generated a plot of the specific amino acid residues-ligand 





Figure 6.10. Per-residue interactions for the highest ranked compounds with the best binding 
energy from the structure-based and pharmacophore-based libraries. 
 
 
The MOE plot analysis of ZINC71849459 bound to CCR5 enzyme’s active site revealed that the 
ligand was especially well surrounded electrostatically by several amino acid residues within the 
active site (Figure 6.11a). However, it could be noted that the ligand ZINC00634884 bound to 
the active site was not well cradled electrostatically by the amino acid residues compared to the 
former (Figure 6.11b). An interesting observation was that not a single amino acid formed any 
hydrogen bonds between the protein and ligand for anyone of the two ligands investigated. As 
shown in Figure 6.11, on average the hydrophobic amino acid residues played crucial roles in 
protein-ligand interactions than the hydrophilic amino acid residues. Another important 
observation was that the stronger ligand-amino acid residue interactions exhibited here in Figure 















Figure 6.11. Pharmacophore-based compound (ZINC00634884) with CCR5 (A) and Structure-
based compound (ZINC71849459) in complex with CCR5 (B), respectively, showing the hydrogen 
bonding and electrostatic interactions with the enzyme’s active site using MOE. 
 
The atom-based 3D-QSAR model developed from the training set of 26 inhibitors (Table 6.1.) 
and the test set of 9 inhibitors using molecular overlay alignments (Figure 6.4.). The 3D-QSAR 
model was built after model development and validation based on the internal predictions of the 
training set and the external predictions of the test set. PLS analyses of the CCR5 inhibitor 
training sets showed a high cross-validated rcv2 value of 0.84 using three principal components 
and non-cross-validated r2 value of 0.941. All of the parameters of these QSAR model showed 
certain reliability and feasible predictability to help us design new and high selectivity CCR5 
inhibitors. From Figure 6.12, we can see that almost all compounds in the test set and training 
set yielded a good predicted value. The graphical plot of observed vs. calculated TPH1 inhibitory 
activity for both the training set as well as the test set is shown in Figure 6.12. 
 





In the present work, the structure of human CCR5 was homology modeled using the crystal 
structure of CXCR4 as a structural modeling template. The protein appeared to be modeled with 
a remarkably degree of accuracy, specifically at the active site where docking studies were 
performed. Our query of the ZINC database for drug-like compounds that shared 2D shape 
similarity-based identity and query of ZINCPharmer for pharmacologically related drug-like 
compounds to a known FDA-approved CCR5 antagonist called Maraviroc. The entire top 10 
ranked compounds from each library exhibited remarkably higher binding energies compared to 
the best-docked structure of Maraviroc. Moreover, an unforeseen observation revealed that 
compounds that were architecturally similar had higher binding energies on average compared to 
those that were pharmacophorically-based. To validate our docking calculations, the same 
docking approach adopted for the ligand-based libraries was performed on a set of compounds 
with known experimental data attained from inhibition assays against HIV-1 CCR5 and the 
results were compared against experimental data. The docked energies are in great accordance 
with the experimental IC50. We observed that as the binding affinity increased (lower binding 
energy), the IC50 increased. We postulated that the larger the binding affinity, the more 
concentration is needed for complete enzyme inhibition. To us, this proves to be an interesting 
trend, since the top 10 ranked compounds which were obtained from both libraries had higher 
binding energies compared to any of those used in the biological assay, therefore it stands to 
reason compound hits elucidated in this study exhibit humble activity as CCR5 antagonists. 
Also, this implies that the docking approaches used in this work could be reliable enough to 
estimate the binding affinities for other compounds to be studied. Furthermore, from our 
previous experience with molecular docking, and in numerous insistences, the reliability of a 
stable protein-ligand complex might not be a true reflection. Therefore, in order to obtain more 
insight on the stability of the resulted docked complexes, the nature of the overall interaction 
themes between the generated ligands and the target protein, and the specific amino acids 
involved in the ligand binding, we performed 5 ns MD simulations followed by extensive post-
dynamic analyses on the ligand-enzyme complexes resulted from our docking simulations. We 
took our study a step further by obtaining a set of 35 novel oxamino-piperidino-piperidine amide 
analogs with available IC50 (mM) data taken from literature for the development of our atom-
based 3D-QSAR model. All of the parameters of the QSAR model showed certain reliability and 
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feasible predictability to help us design new and high selectivity CCR5 inhibitors. Our novel 
identified leads have the propensity to be considered as potential CCR5 antagonists and 
moreover as potential HIV-1 entry inhibitors. Information gained from this study could shed 
light on the activity of a new series of lead compounds as potential HIV entry inhibitors and 
should serve as a powerful tool in the drug design and development machinery. 
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Molecular dynamics simulations, binding free energy calculations, principle component analysis 
(PCA) and residue interaction network (RIN) analysis were employed in order to investigate the 
atomistic basis of the mystery of why the M184I single mutation leaves the HIV-1 reverse 
transcriptase (RT) totally resistant to lamivudine. Results showed that single mutations at residue 
184 of RT caused; (1) distortion of the orientation of lamivudine in the active site due to the 
steric conflict between the oxathiolane ring of lamivudine and the side chain of beta-branched 
amino acids Ile at position 184 which, in turn, perturbs inhibitor binding, (2) decrease in the 
binding affinity by (~8 kcal/mol) when compared to the wild type, (3) variation in the overall 
enzyme motion as evident from the PCA for both systems and (4) distortion of the hydrogen 
bonding network and atomic interactions with the inhibitor.  
The comprehensive analysis presented in this report can provide useful information for 
understanding the drug resistance mechanism against lamivudine. The results can also provide 
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Since Acquired Immunodeficiency Syndrome (AIDS) was first reported in the early 1980s, this 
global killer has claimed the lives of an estimated 22 million individuals 1. Amongst the 
classified infectious diseases, the Human Immunodeficiency Virus type 1 (HIV-1) infection, the 
causative agent of AIDS, remains a challenging epidemic 2. It has been reported that 34 million 
people live with HIV/AIDS globally and in sub-Saharan Africa, approximately 22.9 million 
individuals contribute to the overall global estimate 3.  
 
Despite extensive ongoing HIV/AIDS research, to date, no cure has been found for this disease. 
Currently, the most effective treatment comprises a complex "cocktail” of Food and Drug 
Administration (FDA)-approved and clinical trial drugs that involve multiple drug targets 4. 
These drugs target and attack the virus at different stages of its lifecycle, thereby halting virus 
replication and reducing destruction of the immune system. They include: protease inhibitors 
(PIs), reverse transcriptase (RT) inhibitors, integrase (IN) inhibitors and entry inhibitors 5. 
 
HIV-1 is a retrovirus that replicates within a host cell. The RT enzyme is an essential component 
for HIV-1 replication 6. RT is responsible for converting single-stranded RNA viral genome into 
double-stranded DNA 6, 7. Because of its integral role in the virus lifecycle, HIV-1 RT is a major 
target for drug therapy 8.  
 
Currently, approved HIV-1 RT inhibitors used in antiretroviral therapy can be divided into two 
classes: (a) nucleoside analog RT inhibitors (NRTIs) 9, 10, which compete with natural nucleoside 
substrates for binding to the RT polymerase active site and after their incorporation into the 
primer site, they act as terminators of proviral DNA synthesis; (b) non-nucleoside RT inhibitors 
(NNRTIs), which bind to a hydrophobic pocket close to the RT active site 7, 9. More specifically 
when NRTIs are phosphorylated intracellularly, these drugs become activated and hence inhibit 
reverse transcription by triggering chain termination once incorporated into viral DNA 7, 10. 
The initial introduction of NRTIs for treatment of HIV and later presented as the favored central 
core drugs of highly active antiretroviral therapy (HAART), has substantially reduced HIV-
related morbidity and mortality rates 11. Following zidovudine (AZT) as the first NRTI drug 
approved by the FDA for HIV therapy 11, numerous other FDA-approved NRTIs have been 
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discovered including: lamivudine (3TC), stavudine (D4T), tenofovir (TFV) and emtricitabine 
(FTC) amongst others 11, 12. However, even though NRTIs have served as the cornerstones of 
successful HIV therapy, the largest problem in HIV drug therapy is that the virus mutates very 
quickly, leading not only to drug resistance 13, but also drug-resistant variants of the virus that 
have mutations in the RT target protein 14, 15. For this reason a molecular understanding of the 
impact of mutations on drug resistance will assist in the design of more potent drugs that are 
active against resistant strains. 
 
An important constituent of triple-drug anti-AIDS therapy is the NRTI 2', 3'-dideoxy-3'-
thiacytidine (3TC, lamivudine). It has been proven that single mutations at residue 184 of RT in 
HIV cause high-level resistance to 3TC and contribute to the failure of anti-AIDS combination 
therapy 16.  
 
Partially due to the lack of an X-ray crystal structure of the lamivudine-RT complex, the precise 
mechanism by which the M184I mutant develops resistance to lamivudine is not fully 
understood. Based on a previously built model from “unbound” X-ray crystal structures of the 
wild type and M184I mutant, it is thought that steric conflict between the oxathiolane ring of 
lamivudine and the side chain of beta-branched amino acids Ile at position 184 perturbs inhibitor 
binding, leading to a reduction in incorporation of the analog 16. However, this assumption was 
based on approximated “fitted” and “static” models.  
 
In this work we aim to provide more comprehensive insight into the precise impact of the M184I 
mutation on resistance to lamivudine. We believe that, to develop potent and effective anti-HIV 
NRTIs against the viral variants, understanding of molecular basis of the M184I RT mutation at 
atomic level will be very critical.  
 
In recent years molecular modeling tools have become close counterparts of experiments. In one 
of our recent papers, the interface between computation and experiment within the biological 
context was comprehensively highlighted 17. Various molecular modeling approaches such as 
molecular docking, molecular dynamics (MD) simulation and binding free energy calculations 
have proven useful in understanding the molecular basis of drug resistance to different biological 
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systems. This includes, but is not limited to, the drug resistance mechanisms against HIV 
protease 18-20, HIV reverse transcriptase (RT) 21, HIV integrase (IN) 22, influenza neuraminidase 
(NA) 23, 24, and HCV protease 22, 25, 26.  
 
Standard MD analysis for large biomolecular systems can only provide limited information about 
the dynamic landscape of these systems. During the last few years, multiple approaches have 
been devised to deal with the large number of explicit degrees of freedom 27-30.  Principal 
Component Analysis (PCA) or essential dynamics analysis is one of widely used approaches to 
explore the structural fluctuations of biological systems. PCA is a statistical procedure based on 
covariance analysis that can transform the original space of correlated variables into a reduced 
space of independent variables and is often used to highlight large correlated motions in 
macromolecules 31, 32. It takes the trajectory of an MD simulation into account and reduces the 
dimensionality of the data to extract dominant modes in the motion of a molecule 33-36. In normal 
mode analysis these pronounced motions resulting from the protein movement correspond to 
correlated vibrational nodes or collective group motion of atoms 37, 38. The eigenvector for a 
given motion has a corresponding eigenvalue, which signifies the energetic contribution of a 
particular component to the motion. Projection of a trajectory onto a specific eigenvector 
highlights the time dependent motions that the components perform during a particular 
vibrational mode 34. 
 
PCA has been used to identify the overall motion of the enzyme backbone to check the 
difference from one state to another with high utility in the comparison of wild type proteins with 
those of mutant/resistant strains 39. Via PCA, it is possible to identify the dominant motions 
observed during a simulation through visual inspection. A large portion of overall fluctuation of 
macromolecules can often be accounted for by a few low frequency eigenvectors with high 
eigenvalues 40. If motion between two different macromolecules is similar then the eigenvectors 
coming from individual trajectories should be similar to each other. For this reason, PCA has 
proved an efficient tool that can be used to compare motions of different macromolecules 41. 
 
It has also been observed that the resistant mutation or substitution in the target protein often 
impacts the binding ability of drugs through modification of the residue interaction network 
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(RIN) communication of the targets 42-45. Recently, some reports have shown that the analysis 
and interactive visualization of RIN of proteins can reveal important information on biological 
interactions in complex systems 46, 47.  
 
In this work, using validated models of lamivudine-RT complexes, wild type and the M184I 
mutant, MD simulations, post-dynamics analysis, binding free energy calculations, PCA and 
RIN analysis were employed to provide an insight into the drug resistance mechanism of the RT-
M184I mutant to lamivudine. To our knowledge, this report is the first account of such 
comprehensive computational analysis being used to reveal the precise impact of the M184I 
mutation on RT resistance to lamivudine.  
The compilation of the computational and molecular informatics tools presented in this study 
could serve as powerful tools to understand protein structures and dynamics, drug resistance and 
could also be incorporated in the drug discovery and development workflows. 
 
7.3. Computational Methods  
7.3.1. System Preparation 
With the lack of a Lamivudine-RT complex crystal structure, the construction of a reasonable 
initial set of 3D coordinates for the complex presented a challenge. Since molecular docking can, 
in many instances, produce unrealistic ligand orientations in the active site, we opted not to 
perform docking calculations but instead to use a “ligand fitting” strategy based on known X-ray 
crystal structures of similar inhibitors in complex with RT. This approach has proven successful 
in the past, as reported previously 48, 49. The X-ray crystal structure of RT in complex with 
zidovudine, AZT, (PDB code: 1RTD) was used as the starting coordinates (Figure 7.1.). This 
choice was based on the fact that since AZT and 3TC are structurally analogous, similar binding 
modes would be anticipated (Figure 7.1.). This protein is crystalized in a polymeric form, but 
only one chain (chain A) was used for simulations to reduce the computational cost. Despite 
being distal from the active site, the X-ray crystal structure mutations, P1K, Q258C, and E478Q 
mutations were modified to retain the native wild type structure. Co-crystalized solvent 
molecules were also deleted. Lamivudine was then superimposed against zidovudine (Figure 
7.2.); the latter was then removed, leaving lamivudine sitting in the RT active site. Methionine 
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(Met) at position 184 was then manually mutated into isoleucine (Ile). The Chimera software 
package (https://www.cgl.ucsf.edu/chimera/) was used for ligand superimposition as well as 
amino acid residue mutation.  
 
 
Figure 7.1. 2D structures of zidovudine and lamivudine (3TC), A and B, respectively (AZT). 
 
 
Figure 7.2. Lamivudine (3CT, cyan-colored carbon backbone) is superimposed against the 




7.3.2. Molecular Dynamics Simulation 
A multiple MD-trajectory approach was adapted to understand the impact of M184I mutation on 
lamivudine binding with HIV-RT. A long MD run might lead to high statistical errors with 
denatured protein configuration during simulation period. In view of aforesaid, a multiple MD 
simulation acts as a high reliable alternative approach which lowers down force-field induces 
artifacts, statistical bias and computational time 50. In this case a multiple MD approach was 
adapted for both the systems from an initial starting configuration generated from a 2ns MD run, 
followed by 4 different individual MD runs for a timescale of 5 ns with different initial velocities 




Initial 2 ns MD simulation 
4 different starting configurations were 









Analysis of the individual trajectories as well as the 
average 
4 X 5 ns MD simulations starting from each configuration 
with different velocities  
 








7.3.2.1. MD simulations set up and parameters 
The MD simulations for the Lamivudine-RT complexes (i.e. wild-type and mutant) were 
performed using the GPU version of the PMEMD engine provided with the Amber 12 package 
51-53. Two protonation states ionized and unionized; of the triphosphate moieties attached to the 
ligand were considered (See Results and Discussion and Supplementary Material 2). The 
FF99SB variant of the AMBER force field 54 was used to describe the protein. The restrained 
electrostatic potential (RESP) procedure 55 was used to calculate the partial atomic charges for 
the ligands at the HF/6-31G* level using the Gaussian 03 package 56. The LEAP module in 
Amber 12 was used for addition of hydrogen atoms to the protein and the addition of counter 
ions for neutralization. The systems were embedded within an orthorhombic box of TIP3P 57 
water molecules such that no protein atom was within 8 Å of any box edge. Periodic boundary 
conditions were enforced and the long-range electrostatic interactions were treated with the 
particle-mesh Ewald method 58 incorporated in Amber12 with a direct space and vdW cut-off of 
12 Å. The following MD procedure was applied to the initial 2 ns MD as well as the individual 5 
ns MD runs (see Figure 3). Initial energy minimization of each system, with a restraint potential 
of 500 kcal/mol Å2 applied to the solute, was performed for 1000 steps of steepest descent 
followed by 1000 steps of conjugate gradient minimization.  A further 1000 steps of unrestrained 
conjugate gradient minimization of the entire system were then carried out. Canonical ensemble 
(NVT) MD simulations were then carried out for 50 ps, with gradual heating from 0 to 300K 
with harmonic restraints of 5 kcal/mol Å2 applied to all solute atoms and a Langevin thermostat 
with a random collision frequency of 1/ps. The systems were subsequently equilibrated at 300 K 
in the NPT ensemble for 500 ps, during which no restrains were imposed and a Berendsen 
barostat was used to maintain the pressure at 1 bar. The SHAKE algorithm 59 was used to 
constrain the bonds of all hydrogen atoms , a time step of 2 fs and the SPFP precision model60, 
61was used for all MD runs. A short production run for 2ns was performed followed by a 
multiple MD production run of 4*5ns from the last restart file (configuration generated from 2ns 
MD run) in an isothermal isobaric (NPT) ensemble using a Berendsen barostat for each case62 
with a target pressure of 1 bar and a pressure coupling constant of 2 ps. Coordinates were saved 
every 1 ps and the trajectories were analyzed every 1 ps using the PTRAJ module implemented 





7.3.3. Thermodynamic Calculations  
The binding free energies of Lamivudine and RTs, wild type and mutant, were computed using 
the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) approach 63-66. For each 
5 ns trajectory, the binding free energy was averaged over 1000 snapshots at 5 ps intervals. 
Average values over the 4 trajectories were also computed (see Table 1). The following set of 
equations describes the calculation of the binding free energy: 
ΔGbind = Gcomplex – Greceptor – Gligand                                      (1) 
ΔGbind = Egas + Gsol – TS                                                 (2) 
Egas = Eint + Evdw +Eele                 (3) 
Gsol = GGB + GSA              (4) 
GSA = γSASA             (5) 
Where Egas is the gas-phase energy; Eint is the internal energy; and Eele and EvdW are the Coulomb 
and Van der Waals energies, respectively. Egas is evaluated directly from the ff03 force field 
terms. The solvation free energy, denoted by Gsol, can be decomposed into polar and nonpolar 
contribution states. The polar solvation contribution, GGB, is determined by solving the GB 
equation, whereas, GSA, the nonpolar solvation contribution is estimated from the solvent 
accessible surface area (SASA) determined using a water probe radius of 1.4 Å. T and S 
correspond to temperature and total solute entropy, respectively.  
In order to determine the individual amino acid contribution towards total binding free energy 
between the Lamivudine inhibitor and wild-type/mutant HIV-RT types, a decomposition analysis 
of the interaction energy for each residue was computed by using the MM/GBSA binding free 
energy decomposition protocol in Amber 12.  
 
7.3.4. Principle Component Analysis (PCA) 
Before processing the MD trajectories for PCA, each 5 ns MD trajectories of the wild type and 
mutant complexes were stripped of solvent and ions using the PTRAJ module in AMBER 12.0. 
The stripped trajectories were then aligned against the fully minimized structure. PCA was 
performed for C- atoms on 1000 snapshots each at 5 ps intervals. Using in-house scripts, the 
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first two principal components were calculated and the covariance matrices were generated. The 
first two principal components (PC1 and PC2) generated from each of the 4 individual 5 ns 
trajectories were averaged for both wild and M184I mutant. The first two principal components 
correspond to the first two Eigen vectors of the covariance matrix. The PCA scatter plots were 
then generated using the Xmgrace program (http://plasma-gate.weizmann.ac.il/Grace/). All 
structural diagrams were created using VMD 67. The porcupine plots were generated using the 
ProDy interface of normal mode wizard (NMW) of VMD 68.  
7.3.5. Residue Interaction Networks (RIN) analysis 
The fully minimized structure of each system, wild and M184I mutant was used for constructing 
the RIN interactively in 2D graphs. The PROBE 36 software was used to identify the contacts 
(i.e. non-covalent interactions) between amino acids in the proteins by evaluating their atomic 
packing using small-probe contact dot surfaces. PROBE uses a small virtual probe (typically 
0.25 Å) that is rolled around the van der Waals surface of each atom and an interaction (contact 
dot) is detected if the probe touches another non-covalently bonded atom 36.  
7.3.5.1. Interactive visual analysis of residue networks 
The RIN generated from the MD averaged structures were used to visualize the network using 
Cytoscape 69 and the plugin RINalyzer 46. In a RIN, the nodes represent the protein amino acid 
residues and the edges between them represent the non-covalent interactions. The edges are 




7.4. Results and Discussion 
7.4.1. MD simulations and systems stability 
RMSD and potential energy fluctuations were monitored to ensure that the systems were well 
equilibrated before any further MD analysis. RMSD and potential energy plots are provided as 
Supplementary Material (Supplementary Materials 1). 
All corresponding PDB coordinates of the simulated systems (wild and mutant for unionized and 




7.4.2. Post-dynamic analysis: wild type versus M184I mutant 
7.4.2.1. Root of mean square fluctuation (RMSF) 
Figure 7.4 shows the residue based root mean square fluctuations (RMSF) of the wild type and 
M184I mutant simulations. The most interesting observation is that the amino acid residues in 
the region 170-220 (which contains the mutation site at position 184) show higher fluctuation in 
the mutant than compared with the wild type. One possible explanation is that the Ile184 residue 
in the mutant interacts less with the surrounding than methionine.  
Interestingly, the M184I mutation was also found to impact the overall dynamics of some distal 
amino acid regions (Figure 7.4.). For instances, residues 2-50 exhibit larger fluctuations while 







Figure 7.4. RMSF for the wild type and M184I mutant Lamivudine-RT complex systems: T1, T2, 
T3, T4 and T-Avg denote for the 4 individual 5 ns MD trajectories and the overall average, 





7.4.2.2. Steric conflict between Ile184 and oxathiolane ring of lamivudine 
Steric conflict between the oxathiolane ring of lamivudine and the side chain of beta-branched 
amino acids Ile at position 184 has traditionally been assumed to be responsible for the perturbed 
inhibitor binding. However, this assumption was based on static models 16. In this study to test 
this assumption we monitored the distance between the (O) atom of oxathiolane ring and the C of 
the amino acid residue at position 184 (Met in wild type and Ile in mutant) during the MD 
trajectory. Figure 7.5 suggests that substitution of Met with Ile results in increased steric conflict 
with the ligand that continues to exist during the duration of the MD simulation as evident from 
the increased separation between the (O) atom of oxathiolane ring and the C of the amino acid 





residue at position 184 (Met or Ile). T1, T2, T3, T4 and T-Avg denote for the 4 individual 5 ns MD 
trajectories and the overall average, respectively. 
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7.4.3. MM/PBSA binding free energy calculations 
All the components of molecular mechanics and solvation energy were averaged over a 4*5ns 
multiple MD simulation in each case using the MM/GBSA technique are listed in Table 7.1. The 
calculated binding free energy (∆Gbind) between lamivudine and wild-type RT is -45.6597 
kcal/mol compared to -38.5251 kcal/mol in the case of M184I mutant. Such a large reduction in 
binding affinity (~8 kcal/mol) as a result of mutation could significantly impair ligand binding 
and thus the effectiveness of lamivudine against the mutant – this is in a great accordance with 
experimental data (the EC50 value in case of M184I mutant is ~1000 times lower than the wild 
type) 70. The calculated van der Waals contributions (∆EvdW) to the binding free energy in the 
lamivudine wild-type bound RT complex (-48.2095 kcal/mol) are higher than that for the 
lamivudine bound M184I mutant RT complex (-42.5814 kcal/mol). On the other hand, the 
calculated electrostatic contributions (∆Eele) to the binding free energy for lamivudine bound 
M184I mutant RT complex (-16.9961 kcal/mol) are lower compared to that for the lamivudine 
wild-type bound RT complex (-24.6420 kcal/mol). In the lamivudine wild-type bound RT 
complex, the calculated solvation contributions (∆Gsol. ∆Gsol = ∆GSA + ∆GGB) to the binding free 
energy (26.4379 kcal/mol) are higher than that for the lamivudine bound M184I mutant RT 
complex (21.0511 kcal/mol). The free energy components shown in Table 7.1 suggests that the 
majority of the favorable contributions observed for lamivudine binding arise from ∆EvdW and 
∆Eele. The remarkable difference (~13 kcal/mol) in the ∆Ggas as a result of mutation also 
confirmed that M184I mutation could lead to loss of efficacy of lamivudine. 
 
 
Table 7.1. The calculated binding free energies based on MM/GBSA method. T1, T2, T3, T4 and T-
























































































































































For the un-protonated triphosphate moiety, interestingly, however, the same trend was observed 
in the overall binding affinity, the electrostatic contribution was higher when compared to the 
protonated state – this might be due to higher electrostatic interactions between the active site 
residues with the charged triphosphate moiety (see Supplementary Material 2). 
 
7.4.3. Validation of the binding energy calculations 
To validate the binding free energy results, another RT mutation, M184V, with available 
experimental data71 was considered. Encouragingly, the calculated binding free energy was 
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found to be in a good agreement with experimental data (see Supplementary Material). Such 
findings imply that the simulation protocol of this work is appropriate and reliable. 
7.4.4. Per-residue interaction energy decomposition analysis 
The binding free energy was further decomposed into contributions from each HIV-RT amino 
acid residue. In Table 7.2, the comparison of protein-ligand interaction spectra between wild-
type and M184I mutant are shown. It can be observed from the energy decomposition analysis 
that in the lamivudine bound wild-type HIV-RT system, the major contributions were -3.21, -
2.16 and -1.14 kcal/mol from amino acid residues Arg72, Tyr115, and Met184, respectively 
(Table 7.2.). On the other hand, there were some minor contributions towards the interaction 
energy from residues Asp110 (-0.13 kcal/mol), Ala114 (-0.79 kcal/mol) and Phe116 (-0.83 
kcal/mol).  
 
As shown in Table 7.2 below, the decomposed van der Waals and electrostatic energies for 
residues 72, 115 and 184 in the lamivudine bound M184I mutant complex implies that the 
change in the van der Waals contribution is what is mostly responsible for the decrease in the 
interaction energy. Furthermore, when Met is mutated to Ile at position 184, the prominent van 
der Waals contributions towards the total binding free energy from this residue increased by two-
fold with a slight decrease in electrostatic contribution but it ultimately lowers the total van der 
Waals contributions of other prominet residues which ultimately affects the total binding free 
energy. This finding stands consistent with decreased van der Waals contributions from Arg72 (-
3.21 to -2.07 kcal/mol) and Tyr115 (-2.16 to -2.10 kcal/mol) and an overall loss of van der Waals 












Table 7.2. The decomposed van der Waals and electrostatic energies (kcal/mol) for residues 72, 113, 
115 and 184 in Lamivudine bound wild-type and M184I mutant complexes (values were averaged 
over the 4 individual trajectories). 
 






























Interestingly, as evident from Table 7.2, mutation of Met to Ile at position 184 has improved the 
binding at the site of mutation - this might be due to better hydrophobic interactions with the Ile 
side chain – the overall drug binding affinity is reduced due to the negative impact of the 
mutation on the binding affinity of the nearby active residues. Different binding forces between 








Figure 7.6. Representative structures for the lamivudine-RT complexes: wild type, A and M184I, B, 
respectively with graphical representation of the different binding forces.  
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7.4.5. Principle component analysis (PCA) 
Figure 7.7, shows a PCA scatter plot generated for the wild type and M184I mutant showing a 
significant difference between both systems as evident from the characteristic structures plotted 
along the direction of two principal components. From the scatter plot, it is clear that 
eigenvectors computed from the MD trajectory for both systems are quite varied which clearly 
indicates difference in protein motion between wild and M184I mutant. 
 
 
Figure 7.7. PCA scatter plot of 1000 snapshots along the pair of first two principal components, 
PC1 and PC2 for wild type and M184I mutant showing difference in eigenvectors. Eigen values 






In most cases a few low frequency normal modes are enough to capture major protein motions 
along specific directions, which are represented by eigenvectors. In this case we generate 
porcupine plots with three low frequency modes (Mode=1, 2 & 3) to visualize the comparative 
motion difference between wild type and mutant (Figure 7.8.). The eigenvectors show a clear 
difference in direction of motion, which is consistent with the PCA, scatter plot. 
              
 
Figure 7.8. Porcupine plots showing atomic components for wild, A and M184I mutant, B, in 
different active modes. The green, red, grey arrows represent eigenvectors showing direction of 
motions across Mode 1; Mode 2 & Mode 3, respectively. 
 
7.4.6. Residue interaction network (RIN) 
The network analysis of the protein backbone is a new strategy to identify key residue 
interactions and can be used to explore the difference in residue interaction networks between 
different proteins including wild type and mutants. In this work we investigated the relationship 
between key residues of the wild type and M184I mutant by generating residue interaction 
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networks using the representative structures from the 5ns of MD. As evident from the RIN plots 
(Figures 7.9. and 7.10.), it is clear that the M184I mutation has distorted the overall residue 
interaction network when compared to wild type. For instance, as shown in Figures 7 and 8, 
there is a hydrogen bond interaction between Tyr115 and Met184 whereas in the case of the 
mutant where Met184 has been mutated to Ile184 the hydrogen bond interaction with Tyr115 
changes to just a close atom interaction. It is interesting to observe that in the case of the wild 
type, Pro157 builds a close atom interaction with Met184 whereas in the case of the mutant there 
is a close atom interaction instead between Gln161 and Ile184. Again, the M184I mutation 
affects the interaction network, which ultimately affects the protein backbone and consequently 
the drug binding landscape. 
 
 
Figure 7.9. Residue Interaction Network showing close atom interactions between Ile184 and 
Tyr115 in case of M184I mutant, A, and hydrogen bond interaction between Met184 and Tyr115 in 






Figure 7.10. Residue Interaction Network showing close atom interactions between Gln161 & 
Ile184 in case of M184I mutant, C and close atom interaction between Pro157 & Met184 in case of 







The precise molecular understanding of the serious impact of a single M184I on the RT 
resistance to lamivudine is lacking in literature. In this report, we embarked on a wide range of 
computational approaches in order to provide a multi-dimensional view on M184I resistance to 
lamivudine. Multiple molecular dynamics simulations, binding free energy calculations, 
principle component analysis (PCA) and residue interaction network (RIN) analysis led us to 
several findings that can explain the serious impact of M184I mutation on drug resistance. These 
findings verified that mutation decreased drug binding affinity by ~8 kcal/mol, distorted the 
ligand optimum orientation in the RT active site, affected the overall enzyme conformational 
landscape and distorted the atomic interaction network with the ligand.  
The findings of this report can provide potential markers for further design of novel inhibitors 
that are less susceptible to drug resistance. 
 
7.6. Supplementary Materials 
RMSD vs. time and Potential Energy (kcal/mol) vs. time data for ionized and unionized form of 
wild and M184I variant of HIV-RT complexed with lamivudine as well as of M184V variant is 
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As an emerging target, HIV-Nef protein, an accessory pathogenic factor, plays a significant role 
in HIV replication. Reports indicated that removal of Nef protein leads to high level of viral 
insensitivity. Therefore, targeting Nef is considered a key strategy towards HIV/AIDS treatment. 
Up-to-date, only one compound has been reported as a potent Nef inhibitor, known as B9. This 
has prompted us to provide this first account of an integrated computational framework in order 
to identify more potential Nef inhibitors. Herein, using a hybrid ligand virtual screening, shape 
similarity- and pharmacophore-based, approach combined with molecular dynamics and post 
dynamics analysis were applied to identify potential new leads targeting HIV-Nef with a detailed 
analysis of their binding modes. The top ranked compounds from the shape similarity-based 
library (ZINC04177596, ∆Gbind= -28.7482 kcal/mol) and pharmacophore-based library 
(ZINC36617540, ∆Gbind= -20.2271 kcal/mol) possess comparatively better binding affinities 
than the reference molecule, B9 (∆Gbind= -18.0694 kcal/mol). Both top identified hits, 
ZINC04177596 and ZINC36617540 showed similar binding mode at the active site as the 
prototype, B9. Hydrophobic and electrostatic interactions seemed to be the prominent binding 
forces that hold these ligands at the dimer interface of Nef protein. A set of chemical structural 
features that can be used as a guide in the design of potential Nef inhibitors is also highlighted 
herein.  
We believe that information gained from this study would be of great importance in the 
discovery and design of potential small molecules targeting HIV-Nef. 
 
Key words: Hybrid ligand-based virtual screening; HIV-Nef; HIV/AIDS; molecular dynamics 
(MD); binding free energy 
 








Ever since the Acquired Immunodeficiency Syndrome (AIDS) was first reported in 1983, this 
global endemic has already proclaimed the lives of estimated 22 million individuals worldwide 1. 
The Human Immunodeficiency Virus type 1 (HIV-1) responsible for causing AIDS still remains 
one of the most challenging classified infectious diseases 1, 2. Globally, it has been reported that 
an estimated 34 million people live with HIV/AIDS 3, 4, and this includes approximately 22.9 
million people that characterize this overall global estimate 3, 4. 
 
Despite the substantial effort made in HIV/AIDS research, no cure still exists for this global 
endemic. At present, the only effective therapeutic regimen comprises of multiple drug 
combinations that target different HIV enzymes at various stages of its life cycle 5. These include 
reverse transcriptase (RT) inhibitors, protease inhibitors (PIs), integrase (IN) inhibitors, entry 
inhibitors and progression inhibitors 5, 6. 
 
Nef (Negative Factor) is an accessory gene product of HIV, which has an imperative role in viral 
replication 7, 8. It was shown that a large deletion in the Nef gene greatly reduces the severity of 
HIV 9. The Nef is a small protein (~ 27-35 kDa) and myristoylated in nature 8. Its primary mode 
of transport is localization from the cytosol into the host plasma membrane 8, 9. Nef plays a 
crucial role by down regulating the surface expression of CD4, MHC-I, MHC-II, and CD28, 
which are critical in the formation of immune synapses 10, 11. 
 
Recent drug discovery attempted to report the Nef protein as a crucial target in designing novel 
antiretroviral drugs. To date, only two previous studies have reported the concept of designing 
potential Nef inhibitors against HIV/AIDS 12, 13. These were carried out mainly using high-
throughput screening (HTS) as well as some small-scale structure-based drug design approaches. 
One such example is the compound B9, which has been discovered from HTS appeared very 
effective at inhibiting the dimerization of the two Nef dimers and hence blocking Nef 
functionality. The binding pocket of B9 with Nef dimer has been identified as potential hot spot 
to design novel small molecule inhibitors 14, 15. Guanidine alkaloid-p53 interactions and other 
compounds interactions with HIV-Nef and SH3 domains have been classified as potential drug 




In recent years, molecular modeling techniques have become close counterparts between 
computation and experimental in biological contexts 16-21. Numerous computational tools are 
now accessible for searching chemical databases for novel compounds with desired features. 
Among these tools is virtual screening, which has become an imperative tool in current drug 
discovery scenarios 22-25. Virtual screening can be divided into ligand-based and structure-based 
approaches 25-27 (19-22). Ligand-based virtual screening methods use the knowledge of a known 
ligand and an unknown receptor site to estimate the binding affinities of potential hit leads for a 
given target 25-27. However, structure-based virtual screening (SBVS) techniques use the 
knowledge of the 3D structure of a target protein in order to provide estimation of the binding 
affinities of small compounds towards the target of interest 28-31. Even though, both techniques 
implement the use of different molecular knowledge, these approaches are complimentary in 
nature. 
 
As indicated above, only one compound, known as B9, was reported to inhibit Nef dimerization 
and identified as a potential starting point for further optimization. To this end, the aim of this 
work is to identify more potential Nef inhibitors by exploiting the structural features of B9 using 
a framework of computational tools. These tools include a hybrid shape similarity and 
pharmacophore-based virtual screening approach, molecular dynamics simulations, post-
dynamics analysis and binding free energy calculations.  
 
It is worth mentioning that most virtual screening engines rely primarily on docking calculations. 
It is also widely known that results based solely on docking calculations, in many cases, could be 
artifacts and/or questionable32. Therefore, in this work, in order to verify the stability of the 
docked complexes over a reasonable time scale as well as to obtain more reliable binding free 
energy estimates, the docked complexes of the top hits and the reference inhibitor were subjected 
to 30 ns MD simulations and binding free energy calculations. The detailed binding mode of the 
top-ranked hits is presented using per-residue interaction energy decomposition as well as 




To our knowledge, this report is the first account of an integrated computational approach 
applied in order to identify potential novel leads against HIV-Nef protein. The integrated in-
silico computational and molecular bioinformatics tactics presented in this study could serve as a 
powerful tool for the identification of novel small molecules targeting HIV-Nef and many other 




8.4. Computational Methods 









8.4.1. B9 structure acquisition and preparation 
The structure of newly discovered diphenylpyrazole moiety, B9 (Figure 8.2.), which proved as 
an effective antagonist of Nef-dependent HIV replication, was obtained from the DrugBank 33-35 
36 in the mol file format. Energy minimization and geometry optimization was carried out using 
MMFF94s force field integrated with Avogadro 36. The optimized structure was saved in mol2 
format for subsequent analysis. 
 
Figure 8.2. The 2D chemical structure of reference inhibitor as a prototype B9. 
8.4.2. Protein systems 
The crystal structure of conserved core of HIV-1 Nef dimer with SH3 domain (Figure 8.3.) was 
retrieved from protein data bank (PDB: 1EFN). An entire comprehensive description of protein 
system preparation for docking and MD simulation is explained else in our previous reports 37-40. 
 
Figure 8.3. Crystal structure of HIV-Nef conserved region in complex with the SH3 domain (PDB: 
1EFN). The residues at the SH3 domain ranging from 85-141 are highlighted in orange. 
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8.4.3. Ligand library Generation 
8.4.3.1. Shape similarity based ligand library generation 
The ZINC database 41, which contains over 21 million ready to dock compounds, was screened 
for the generation of the shape similarity-based compound library generated from the structural 
template of B9 (Figure 8.2.). The general chemical structure of B9 was drawn using Chemdraw 
(http://www.chemdraw.com/) and following this the structure was uploaded and the Zinc 
Database was queried for all scaffolds that having a >70% similarity. As explained in our 
previous reports 3, Lipinski rule of five 42 was implemented to increase drug-like properties 
amongst generated hits. The shape similarity search ultimately resulted in 560 drug-like hit 
molecules for further screening. Structure of all the query generated molecules were downloaded 
in a single mol2 file and were separated using Molegro Molecular Viewer (MMV) 43 and 
converted to the required pdbqt format using Raccoon for subsequent virtual screening using 
Autodock Vina 44. 
 
8.4.3.2. Pharmacophore-based ligand library generation 
The pharmacophore-based ligand library was generated using ZINC Pharmer 45. The B9 
structural template was uploaded into ZINC Pharmer in order to generate pharmacophoric 
regions, which contains fundamental points necessary for protein-ligand interactions as depicted 
in Figure 8.4. To produce a concise library with drug-like compounds and exclude duplication, 
Lipinski’s Rule of Five42 was set as a criterion. This extensive pharmacophore-based query led to 
the generation of 650 hits. Subsequently, structure of all generated were downloaded and 






Figure 8.4. Pharmacophoric features used to search for new leads (yellow, green depicts hydrogen 
bond acceptor and hydrophobicity respectively, whereas pink depicts the aromatic moieties; arrows 
indicate the constraint direction). 
 
 
8.4.4. Docking calculation: Hybrid virtual screening approach 
 
In this study, the drug-like libraries generated using shape similarity and pharmacophore based 
approach were subjected to structure-based virtual screening using an enhanced loop docking 
protocol46, 47 against the HIV-Nef target protein using Autodock Vina 48, using compound B9 as 
a proto type 49. 
 
Virtual screening was carried out using Autodock Vina’s default settings with an exhaustiveness 
set at 8.0. The grid box was defined around the following key residues Arg72, Gln151, Lys219, 
Met184, Ala114, Asp110, Asp113, Tyr115 and Phe116, which covered the conserved core 
region14, 15, 50 of HIV-Nef protein. The X, Yand Z centre values of the grid box were defined as -
106.28, -125.77 and -57.61, respectively, whereas, the X, Y and Z size dimensions were defined 
as 16, 13 and 20.4, respectively. All generated screening results are saved in the pdbqt format by 
Autodock Vina. Ten top-docked compounds on the basis of their binding affinities (kcal/mol) 
were selected from each of the two compound libraries. The different docked poses of the 





8.4.5. Molecular Dynamics (MD) simulations and post-dynamic analysis 
 
In recent year’s molecular dynamics study have been extensively used to validate results 
generated from virtual screening as well as to gain insight into protein ligand interaction and 
stability of docked complexes. The top two best-docked compounds selected from the 
pharmacophore-based and shape similarity-based libraries were subjected to  an all atom 
unrestrained MD simulations using GPU version of PMEMD engine provided with the Amber 
12 software package 51. The protein structure was represented and parameterized using the ff99sb 
variant of the AMBER force field implemented with Amber12 52. The geometry and the charges 
of the ligands were optimized at HF/6-31G* level using Gaussian 09 53. Finally 
ANTECHAMBER module was used to add partial atomic charges using restrained electrostatic 
potential procedure (RESP). The Leap module integrated with Amber12 was used to add missing 
hydrogen atoms and counter ions for neutralisation. Finally both systems were immersed within 
an orthorhombic box of TIP3P 54 water molecules such that no protein atom was within 8 Å of 
any box edge. Long-range electrostatic interactions were treated using particle mesh Ewald 
(PME) method with a direct space and vdW cut-off of 12 Å. Each system was initially 
minimized with an applied restraint potential of 500 kcal/mol Å2 to the solute, followed by 1000 
step of steepest descent followed by another 1000 steps of conjugate gradients. A further 1000 
steps of minimization were carried out using conjugate gradients algorithm. All minimizations 
were carried out using CPU version of PMEMED engine provided with Amber12. Prior to 
minimization, a gradual heating from 0 to 300K was performed for both the systems with a 
harmonic restraint of 5kcal/mol Å2 and a langevin thermostat with collision frequency of 1/ps 
using NVT ensemble. Both systems were subsequently equilibrated at 300K in a non-restrained 
NPT ensemble with pressure maintained at 1bar. The SHAKE algorithm 55 was used to constrain 
the bonds of all hydrogen atoms, a 2 fs time step and SPFP precision model was used for both 
MD runs. Finally, an isothermal isobaric (NPT) ensemble and Berendsen barostat 56 with a target 
pressure of 1 bar and a pressure coupling constant of 2 ps was used to perform 30 ns MD runs for 
both systems. The trajectories were saved in every 1ps and further analysis e.g. RMSD, RMSF, 
potential energy kcal/mol) were carried out using the PTRAJ module implemented with 
Amber12. 
All system preparation, visualization and plots were carried out using Chimera molecular 
modelling tool and Origin data analysis software respectively. 
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8.6. Thermodynamic Calculations  
The binding free energy profiles of the best-docked compounds from each compound library in 
complex with the HIV-Nef dimer were calculated using the Molecular Mechanics/Generalized 
Born Surface Area (MM/GBSA) approach 41, 57-59. We applied a single trajectory tactic and the 
binding free energy calculations were averaged over a timescale of 1000 snapshots at 30 ps 
intervals for the 5ns MD trajectory. The following set of equations describes the calculations of 
the binding free energy: 
ΔGbind = Gcomplex – Greceptor – Gligand                                      (1) 
ΔGbind = Egas + Gsol – TS                                                 (2) 
Egas = Eint + Evdw +Eele                 (3) 
Gsol = GGB + GSA              (4) 















Electrostatic and Van der Waals energies 
Gaseous energy from the ff03 force field 
terms 
Solvation free energy 
Polar solvation contribution 




In order to determine the individual amino acid contribution towards total binding free energy 
between the top two hits from virtual screening with HIV-Nef, a per-residue energy 
decomposition analysis of the interaction energy for each residue was computed by using the 
MM/GBSA binding free energy decomposition protocol implemented in Amber 12. 
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8.5. Results and Discussion 
8.5.1. Validation of Computational Approach 
 
Molecular docking study can often led to identification of false positives 60, 61. To ensure the 
robustness of our docking protocol we compared the docking score (binding energy) of two 
previously reported Nef inhibitors with their respective biological activity. These datas were 
compared against the docking score and inhibitory activity of compound B9. To ensure the 
correct trend in binding free energies among the ligands used as a test set, MM/GBSA based 
binding free energy was calculated taking in account compound B9 as a standard. Recent 
findings suggest that the binding free energy profile from MM/GBSA protocol often highly 
correlates with the experimental activity61-65. Table 8.1 highlights molecular docking and 
MM/GBSA based binding free energy profile of two Nef inhibitors (Figure 8.5.) used a test set 
in comparison with B9. Both of these compounds bind at dimeric active site of HIV-Nef  
(Figure 8.6.) with the binding free energies highly correlate with their respective biological 
activity. Outcome from this validation confirmed the robustness of our approach and its accuracy 
in identifying novel in-silico molecules targeting HIV-Nef. 
 





Figure 8.6. The binding orientation of B9 (red), compound 1 (violet) and compound 2 (blue) inside 
the dimeric interafce of HIV-Nef. 
 
 
Table 8.1. Comparison of biological activity, docking score and ∆Gbind among two test set 
compounds, compound 1 14 and compound 2 14 in comparison with B9. 
Inhibitors IC50 (μM)14 Docking Score (kcal/mol) ∆Gbind (kcal/mol)* 
Compound 1 4.8 -6.4 -16.0583±0.3032 
Compound 2 5.4 -5.6 -12.3062±0.2042 
B9 2.8 -6.8 -18.0694±0.4378 
* Binding free energy profile using MM/GBSA approach 
 
8.5.2. Hybrid Virtual screening 
To date, only a single known molecule (compound B9) that inhibits the interaction of Nef exists. 
Therefore, the main objective of this study was to identify potential drug-like molecules targeting 
HIV-Nef, taking in account the structural and pharmacophoric features of compound B9 as 
reference template.  
 
As a result of the extensive computational cost incurred, virtual screening has become quite 
feasible for the mining of large compound libraries. The ZINC database query for compounds 
sharing shape similarity to our diphenylpyrazole scaffold-containing template (B9) yielded 560 
compound hits. Likewise, our query of the ZINCPharmer for pharmacophoric similarity yielded 
a total of 650 hits. In an effort to unveil potential new drug-like leads against the HIV-Nef target 
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protein, we merged both the generated structure-based and pharmacophore-based compound 
libraries obtained from virtual screening and elucidated the top 10 best-docked compounds based 
on binding energy (Table 8.2.).  
 
 






































































































































































































































































































































































*top docked compound from shape similarity-based library, **top docked compound from Pharmacophore-based library, R= 
reference inhibitor 
 
It was observed that all of the top 10 compounds possessed better binding affinities compared to 
the prototype, B9, with binding free energy ranging from -7.3 kcal/mol to -8.8 kcal/mol for shape 
similarity based library and -7.0 kcal/mol to -8.6 kcal/mol for pharmacophore based library. A 
surprising observation was that, compounds shared shape similarity had lower binding free 
energies (kcal/mol) on average compared to pharmacophore based library (Table 8.3.). Though 
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these differences were very subtle but it raises question on the importance of inclusion of 
specific pharmacophoric features that could be important for binding to target. 
 
Table 8.3. The top 10 ranked ZINC compounds from shape based and pharmacophore based 
library 








1 ZINC04177596 -8.8 ZINC36617540 -8.6 
2 ZINC18055982 -8.4 ZINC04565301 -8.4 
3 ZINC18057425 -7.9 ZINC36617540 -8.1 
4 ZINC18129984 -7.8 ZINC04557245 -8 
5 ZINC17129824 -7.6 ZINC18009096 -7.8 
6 ZINC17129910 -7.6 ZINC17140000 -7.3 
7 ZINC17141898 -7.6 ZINC17140008 -7.2 
8 ZINC17140002 -7.5 ZINC17140010 -7.1 
9 ZINC17140006 -7.4 ZINC17140012 -7.0 
10 ZINC04323473 -7.3 ZINC17140014 -7.0 
 
Interestingly, the top 10 compounds from both libraries as well as compound B9 bind at the 
dimeric interface of HIV-Nef (Figure 8.7.).  
 
 
Figure 8.7. Outlined docking orientations of the top-ranked 10 compounds and prototype inhibitor, 






It was perceived that all of the compounds, including B9, occupied the spaces between residues 
Arg72, Gln151, Lys219, Met184, Ala114, Asp110, Asp113, Trp113, Tyr115 and Phe116, 
respectively14. This was in great accordance to the fact that inhibition of Nef dimerization is 
crucial for inhibitory activity of potential inhibitors.  
 
The top-docked compound from the pharmacophore-based library, ZINC36617540, was found 
to bind at the conserved core region of HIV-Nef dimer, interacting with the amino acid residues 
at SH3 domain (residues 85-141) (Figure 8.13.). Similar interactions with SH3 domain were 
observed in case of the top-docked compound from the shape similarity-based library, 
ZINC04177596, however, one hydrogen bond with Gln273 was observed (Figure 8.13.). Such 
interactions with the Nef-SH3 domain were anticipated to play a key role in inhibiting Nef 




Figure 8.8. 2D structural comparison between reference structure of B9 with ZINC04177596 (top-
docked compound from shape similarity-based library) and ZINC36617540 (top-docked compound 
from pharmacophore-based library), respectively. 
8.5.3. MD simulations and Binding free energy calculations 
 
Ligand orientation and/or binding energy results from docking calculations could be artifacts32. 
Therefore, it is necessary to supplement docking results with molecular dynamics simulations in 
order to validate the docking poses as well as binding energy values/trends. To this end, the two 
top-ranked screened compounds from each library, ZINC36617540 and ZINC04177596, as well 
as diphenpyrazole containing reference drug (B9) complexed with the Nef protein were 
subjected to a 30 ns MD simulations. RMSD and potential energy fluctuations were monitored 
along the MD trajectories for all systems (Figure 8.9.). These findings provide further 
verification on the stability of our docked systems. 
 
Figure 8.9. The RMSD and potential energy map of two top-ranked virtual screening hits 




Figure 8.10 depicted the residue-based root mean square fluctuations (RMSF) of the two top-
ranked system simulations. An interesting observation was that amino acid residues between 50-
225 showed higher fluctuations in the pharmacophore-based (ZINC36677840) regions as 
compared to those residues within the shape similarity-based (ZINC04177896) regions. This 
might be due to the fact that these amino acids in the pharmacophore-based structure interacts 
less with the surrounding regions within the active site compared to the amino acids found in the 
shape similarity-based compound. 
 
 
             Figure 8.10. The per-residue fluctuations for the two top-ranked hits (ZINC36617540 and 
ZINC04177596) complexed with Nef dimer during the process of molecular dynamics. 
 
                   All the free energy components are representative of averaged quantities over the 30 ns MD 
simulations calculated using the MM/GBSA approach are shown below in Table 8.2. 
Interestingly, the calculated binding free energy (∆Gbind) of B9 against Nef target protein is -
18.06 kcal/mol compared to -20.28 kcal/mol and -28.75 kcal/mol in the case of ZINC36617540 
and ZINC04177596, respectively. As evident from the binding energy decomposition analysis 
(Table 8.4.), it was observed that ∆EvdW and ∆Eele are contributing the most towards ligand 
binding. It was also found that, the van der Waals contributions (∆EvdW) to the binding energy in 
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the pharmacophore-based (ZINC36617540) and shape similarity-based bound (ZINC04177596) 
Nef systems (-33.50 kcal/mol and -38.03 kcal/mol) are higher than that for the B9 bound Nef 
system (-26.90 kcal/mol). However, the calculated electrostatic contributions (∆Eele) to the 
binding free energy in case of pharmacophore-based (ZINC36617540) and shape similarity-
based (ZINC04177596) bound with Nef systems were 0.18 kcal/mol and -2.40 kcal/mol lower 
respectively compared to -0.75 kcal/mol of the B9 bound Nef system (Table 8.4.). 
 
Table 8.4. The binding free energies of the best-docked compounds from each compound library in 
complex with the Nef protein calculated using the MM/GBSA approach. 
 
 
8.5.4. Per-residue interaction energy decomposition analysis 
 
To quantify individual amino acid interactions towards total binding free energy, we also 
computed per-residue interactions using MM/GBSA approach 66 (Figure 8.11. and 8.1.2) over 
1000 snapshots from simulation. We noted from the per-residue interaction profile (Figure 8.11. 
and 8.12.) that Pro270, Asp259, Asp256, Gln273, Gln255 and Gln252 were found to be 
conserved interacting amino acid residues in with both the pharmacophore-based 
(ZINC36617540) and shape similarity-based bound (ZINC04177596) hits. However, major 
contributions seemed to be coming from Gln273, Leu99, Asn113, Gln252 and Asp256 in case of 
ZINC04177596, whereas in case of ZINC36617540, Pro109, Asp259, Pro270 and Gln273 were 
found to be contributing the most. 
Ligand ∆Evdw ∆Eelect ∆Ggas ∆Gsolv ∆Gbind 
B9 -26.9049±0.5113 -0.7503 ±0.2415 -30.6537±0.6095 9.5843±0.2877 -18.0694±0.4378 
ZINC36617540 -33.5008±0.3051 0.1831± 0.4217 -33.3177±0.5150 13.0906 ±0.4315 -20.2271± 0.2633 
ZINC04177596 -38.0273±0.4274 -2.4075± 0.3093 -40.4348± 0.6440 11.6866±0.3009 -28.7482± 0.4112 
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Figure 8.11. Per-residue energy decomposition for the top docked compound from the shape 




Figure 8.12. Per-residue energy decomposition for the top-docked compound from the 




It was also interesting to observe that Gln273 forms a hydrogen bond (average hydrogen bond 
distance 3.19 Å) with ZINC04177596, which could explain the high binding contribution from 
the Gln273 (Figure 8.11.). It is worth mentioning that all the above-mentioned residues that are 
involved in the interaction with the identified hits are located at HIV-Nef SH3 core domain. 
Thus, the identified hits are anticipated to play a key role in inhibiting Nef dimerization, which 
will ultimately affect HIV-Nef functionality. 
 
Figure 8.13. Depiction of the hydrogen bond and electrostatic interactions for the complexed shape 
similarity-based compound (ZINC04177596) with Nef (A), and pharmacophore-based compound 
(ZINC36617540) with Nef (B), respectively. The plots were generated using LigPlot package. 
 
 
8.6. Conclusive structural features of potential Nef inhibitors 
To add a further dimension to this study, we believed that informative chemical structural criteria 
for compounds to exhibit potential Nef dimerization inhibition should be presented herein. To 
195 
 
this end, we developed a combined pharmacophore map for the two top-ranked identified hits, 
ZINC04177596 and ZINC36617540, (as explained in section 8.4.2) to identify the crucial 
pharmacophoric features (Figure 8.14.). It is worth noting that the pharmacophoric groups were 
created based on the target-bound confirmations – target-bound confirmations proved to produce 
more reliable results as elaborated in our previous report16. Information from per-residue energy 
decomposition analysis and 2-D interactive ligand interaction plots (Figure 8.15 B and C) were 
also considered to identify these crucial residues surrounding the common pharmacophoric 
moieties. With this, we concluded a set of chemical structural features, as depicted in Figure 
8.15D, which could be crucial for the activity of potential Nef inhibitors. Such information could 
serve as a guide or a route map in the design of potential Nef inhibitors as anti-HIV compounds. 
 
Figure 8.14. Common pharmacophoric features of top ranked compounds from both 
pharmacophore based and shape similarity-based library. The two hits, ZINC04177596, 
ZINC36617540 were aligned before creating the pharmacophoric maps. Yellow, green, pink, white 






Figure 8.15. A Schematic representation showing the combined pharmacophoric features of 
ZINC04177596, ZINC36617540, A; 2-D interactive representation of ZINC04177596 and 
ZINC36617540 with Nef protein, B and C, respectively, and proposed chemical structural 
criteria of potential Nef inhibitors, C. HBa, HBd and HP denote for hydrogen bond donor, 




In the present study, the structural features of compound B9, the only known HIV-Nef protein 
dimerization inhibitor, was used as a template to perform hybrid ligand-based virtual screening 
for the search for novel compounds with potential HIV-Nef inhibitory activity. The compounds 
library was generated based on two approaches; shape similarity- and pharmacophoric similarity-
based virtual screening. Drug-like properties were used as filtering criteria for the search of the 
novel hits. This led to a result of 560 possible candidates from a shape similarity-based search 
and 650 possible candidates from the pharmacophore similarity-based search. The combined 
compounds library was then subjected to structure-based virtual screening using molecular 
docking to rank their binding affinities towards NEF protein. The best top-two candidates from 
each library were then selected for subsequent 5 ns MD and post-dynamic analysis. 
ZINC36617540 showed the best binding affinity from the pharmacophore-based library while 
ZINC04177596 showed the best from the chemical shape similarity-based library. Both 
compounds were found to bind prominently at the SH3 core domain of HIV-Nef. The calculated 
binding free energy (∆Gbind) showed that the identified hits have better binding affinities by ~ > 
10 kcal/mol when compared to the prototype inhibitor, B9. Such significant difference in the 
binding affinities between the identified hits, ZINC36617540 and ZINC04177596 and B9 
prompted us to propose a set of structural criteria that could be crucial for further optimization or 
design of novel Nef inhibitors. These sets of structural criteria were established based on a 
combined target-bound pharmacophoric maps of both hits as well as information gained from 
post-dynamic analysis.  
 
However further experimental investigation would boost the current report, information 
highlighted herein could serve as a cornerstone strategy towards the design of novel potential 
inhibitors against HIV-Nef protein.  
 
8.8. Acknowledgements 
The authors would like to thank the Centre of High Performance Computing in Cape Town 
(www.chpc.ac.za) for the computational facility and the National Research Foundation (NRF) of 
198 
 
South Africa and the School of Health Sciences, UKZN for the scholarships and financial 
support. 
 
8.9. Supplementary Material 
The RMSD and binding free energy profiles of compound B9 during the simulation time were 
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The first account on the dynamic features of Nef or negative factor, a small myristoylated protein 
located in the cytoplasm believes to increase HIV-1 viral titer level, is reported herein. The 
dimerization between two Nef subunits manipulates host cellular machinery and allows HIV to 
survive and replicate. Due to its major role in HIV-1 pathogenicity, Nef protein is considered an 
emerging target in anti-HIV drug design and discovery process. A Newly discovered compound 
B9 is believed to bind to the active site of HIV-Nef, which is located at the interface between 
two helical subunits, and interfere with protein dimerization. Here we report the first account on 
the dynamic features of HIV-Nef protein. In this study, comparative long-range all-atom 
molecular dynamics simulations were employed for apo and bound protein to unveil molecular 
mechanism of HIV-Nef dimerization and inhibition. Results clearly revealed that B9 binds at the 
dimeric interface of Nef protein and caused significant separation between residues involved in 
dimerization. Snapshots at a regular time interval along the time frame of molecular dynmaics in 
combination with increased inter-residue differences among orthogonally opposed residues, 
Asp108, Leu112, Gln104 confirmed a disruption in dimeric packing. Large differences in 
magnitudes were observed in case of radius of gyration (~1.5 Å), per-residue fluctuation (~2 Å), 
C-alpha deviations (~2 Å) which confirm a comparatively more flexible nature of apo 
conformation due to rapid dimeric association. Compared to the bound conformer, a more 
globally correlated motion in case of apo structure of HIV-Nef confirms the process of dimeric 
association. This clearly highlights the process of inhibition as a result of ligand binding. The 
difference in PCA scatter plot and per-residue mobility plot across first two normal modes 
further justifies the conformational flexibility and its inhibition in the presence of inhibitor.  
The in-depth dynamic analyses of Nef protein presented in this report for the very first time 
would serve crucial in understanding its function and inhibition mechanisms. Information on 
inhibitor binding mode would also assist in designing of potential inhibitors against this 
important HIV target.  
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Since its emergence in early 1980s the “global killer” acquired immunodeficiency syndrome 
(AIDS) has already proclaimed the lives of estimated 22 million people worldwide 1, 2. To date, 
the Human Immunodeficiency Virus type 1 (HIV-1), the instrumental agent in causing AIDS, is 
regarded as one the most challenging epidemic in the history of infectious diseases 2, 3. According 
to different documented reports, an estimated 34 million individuals live with HIV/AIDS 
worldwide 4, 5. Let alone in sub-Saharan Africa, an approximated 22.9 million individuals 
constitute the overall global estimate 4, 5. Despite the continuous global effort, no cure yet exists 
for HIV/AIDS. Currently, the most effective therapeutic regimes consists of a multiple drug 
"cocktail”, otherwise known as HAART, approved by food and drug administration (FDA), 
which consists of several antiretroviral, targeting different enzymes in HIV life cycle 6. These 
drugs mainly include: protease inhibitors (PIs), integrase (IN) inhibitors reverse transcriptase 
(RT) inhibitors, entry inhibitors and progression inhibitors 7.  
 
The development of resistant strains against almost all currently approved anti-retrovirals prompt 
researchers to find new drug targets, which can prove effective in reducing viral load from the 
host. The recently discovered HIV-Nef target, a small 27-35 kDa myristoylated protein, which 
plays a major role in HIV-1 pathogenicity 8. Nef localizes primarily in the cytoplasm, but also 
partially to the plasma membrane and is one of many pathogen-expressed proteins, known 
as virulence factors. When undergoes dimerization in HIV, Nef protein is able to manipulate the 
host's cellular machinery and thus allow infection, survival or replication of the pathogen 9. Nef 
stands for "Negative Factor" and even though the viral protein is a major component for HIV-1 
replication in infected hosts, Nef markedly elevates viral titers 5. As Nef is one of the accessory 
proteins of the HIV genome, thus it has a central role in the down regulation of host immunity.  
 
Because of its major role in HIV-1 pathogenicity, Nef protein has been proved to be a very 
important target in anti-HIV drug design and discovery process. Understanding Nef dimerization 
process and its inhibition mechanism is crucial for the design of potent inhibitors as anti-HIV.  
To date, a handful of small molecule inhibitors were identified using high throughput screening 
(HTS) which block the Nef dependent HIV replication. Among them, a diphenylpyrazolodiazene 
containing small molecule inhibitor, B9 (Figure 9.1.) appeared to be specifically potent (IC50 
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2.8 µm) at blocking Nef activity by preventing dimerization of the two Nef subunits 10, 11. The 
binding pocket of compound B9 with HIV-Nef dimeric interface proved as a future “hot spot” to 













Figure 9.1. 2D structural representation of diphenylpyrazolodiazene containing Nef inhibitor, B9. 
 
Molecular dynamics simulations and post dynamics calculations emerged as a close counterpart 
to experiment and helps in understanding the complex biological phenomena’s. Application of 
long-range molecular dynamics simulations to unveil folding-unfolding behavior of biological 
macromolecules paved a way to understand the complex process of macromolecular 
dimerization 12-16. Recent applications of enhanced post-dynamics approaches proved to be 
efficient in understanding the conformational landscape of biological macromolecules. Principal 
component analysis (PCA) or essential dynamics analysis is one of the widely used enhanced 
post-dynamics approaches to explore structural fluctuations among different biological systems 7, 
17. A large portion of overall fluctuation can often be accounted by a few low frequency 
eigenvectors with high Eigen values. If motion between two different macromolecules is similar 
then the Eigen vectors coming from individual trajectories should be similar to each other. For 
this reason, PCA has proved an efficient tool that can be used to compare motions of different 
macromolecules. Besides principal component analysis a number of post-dynamics analyses 
were also applied to understand the conformational behavior of biological systems 7, 18. Dynamic 
cross correlation analysis is one of those techniques, which has been applied to understand the 




In order to understand the dynamic landscape HIV-Nef dimerization process and its inhibition, 
comparative molecular dynamics simulations were employed for the apo and bound protein. A 
wide range of post-dynamic analyses were carried out in order to accomplish this task– these 
include; dynamic cross correlation (DCC), principal component analysis (PCA), radius of 
gyration (Rg), protein mobility plots as well as monitoring other several metrics.  
 
To our best knowledge, this is the first account of such comprehensive computational study on 
this crucial HIV target. Therefore, we believe that this report serves as a cornerstone towards the 
understanding HIV-Nef protein structure and dynamics and its inhibitory mechanism. The 
compilation of computational and bioinformatics tools presented herein could also be 
implemented within the drug discovery and development of more potent HIV inhibitors against 
Nef. 
 
9.4. Computational methods  
9.4.1. Protein structure preparation 
The crystal structure of HIV-Nef conserved core in complex with SH3 domain was retrieved 
from protein data bank (PDB: 1EFN) for subsequent simulations 21. The SH3 domain was 
deleted from the protein system to generate a native model of HIV-Nef core domain. The protein 
structure was prepared using Chimera22 molecular modelling suite. 
 
9.4.2. B9-Nef complex preparation 
The recent diphenylpyrazole-based HIV-Nef inhibitor, B9, was believed to bind at dimeric 
region of HIV-Nef 10. To generate an initial starting structure of B9-Nef complex, B9 was 
docked into the active site of HIV-Nef, which is located at the helical dimeric region 10, 11 of 
HIV-Nef (Figure 9.2.). Prior to docking, the ligand and protein systems were prepared as 
explained in our previous reports 23, 24. Autodock Vina25 was used to generate docked 





Figure 9.2. Graphical representation of HIV-Nef active site located at the junction of dimeric cleavage. 
 
Table 9.1. The active site residues and GRID box dimensions used to dock compound, B9 inside HIV-Nef 
active site. 
Protein System Active site residues* Grid Box dimensions 
HIV-Nef conserved core 
domain 
Gln104B, Gln107B, Asp108B, 
Asp111B, Leu112B, Pro122B, 






Number of Points 
X= 22.0 Å 
Y= 24.0 Å 
Z= 24.0 Å 
Centre Grid Box 
X= 44.0 Å 
Y= 18.0 Å 
Z= 37.0 Å 
* B and D refers to dimeric chains of HIV-Nef conserved core domain 
 
The active site of HIV-Nef conserved domain is highlighted in Figure 9.2 and Table 9.1 and 
was used to generate a grid box with a spacing set at 1 Å and an exhaustiveness of 8. The top 
docked conformation of compound B9 complexed with HIV-Nef was then visualized using 
ViewDock plugin26 integrated with Chimera22. 
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9.4.3. Molecular Dynamic (MD) Simulations 
 
All-atom molecular dynamics simulations were performed on both apo and B9 bound 
conformations of HIV-Nef using Amber12 7, 27. The GPU version of PMEMD engine provided 
with Amber 12 was used to perform all molecular dynamics simulations. The RESP procedure 
was used to generate atomic partial charges and geometry was optimized using Gaussian 09 at 
the HF/6-31G* level28. The ANTECHAMBER module was used to generate atomic partial 
charges for the ligand using GAFF force field29. The ff99sb force field implemented with Amber 
12 was used to describe the protein system30. The LEAP module integrated with Amber 12 was 
used to add missing hydrogens and heavy atoms and required counter ions to neutralize the 
system. Both the systems were immersed into an orthorhombic box with TIP3P31 water 
molecules such that no atom was within 10 Å of any box edge. Periodic boundary conditions 
were enforced and long-range electrostatic interactions were treated using particle mesh Ewald 
(PME) method32 with a direct space and vdW cut-off 12 Å. Prior to system preparations the 
minimizations, heating and equilibration steps were performed as described in our recent report7. 
Finally a 100 ns production run was performed in a NPT ensemble with target pressure of 1bar 
and a coupling constant of          2 ps.  
The trajectory in both cases were saved and analyzed in every 1 ps. The PTRAJ and CPPTRAJ 
modules33 integrated with Amber 12 were used for post-MD analysis e.g. RMSD, RMSF, Rg, 
distance, PCA. All visualizations and plots were carried out using Chimera22/VMD34 and Origin 
data analysis tool respectively. 
 
9.4.4. Dynamic Cross Correlation (DCC)  
The dynamic cross correlation between the residue-based fluctuations during simulation was 
calculated using the CPPTRAJ module integrated with Amber 12. The following equation 




Where, i and j stands for ith or jth residue and Δri or Δrj represents displacement vectors 
correspond to ith and jth residue. The cross correlation (Cij) varies within a range of -1 to +1 with 
lower and upper-limit indicates a fully anti-correlated and correlated motion during simulation 
time. In this instance the DCC calculations were carried out taking in account backbone Cα 
atomic fluctuations. 
 
9.4.5. Principle Component Analysis (PCA)  
Principle component analysis (PCA) is widely used in recent years to reduce dimensionality of 
data obtained from molecular dynamics simulations to extract dominant modes responsible for 
conformational7. PCA was performed on C-alpha atoms using PTRAJ and CPPTRAJ modules33 
integrated with Amber 12. The data were averaged over 1000 snapshots with an equal interval of 
100 ps in both cases. The first two principal components correspond to first two Eigen vectors of 
the covariance matrix7. The scatter plot showing the dominant conformational motion 
representative of each structure was created using Origin data analyses programme. The 
porcupine plots correspond to first two normal modes were created using ProDy interface35 
integrated with Normal Mode Wizard plugin of VMD34. 
 
9.5. Results and Discussion 
9.5.1. Binding mode of B9 with HIV-Nef 
The docked structure of inhibitor B9 inside the active site of HIV-Nef dimeric cleavage provided 
crucial information on ligand binding landscape inside the active site of HIV-Nef (Figure 9.3.). 
It can be observed that –NO2 group attached with the phenyl ring involved in formation of two 
hydrogen bond interactions with Gln104 and Gln107 residues of one subunit of HIV-Nef dimer. 
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Interestingly, compound B9 binds at the dimeric cleavage of HIV-Nef dimer possessing multiple 
common residues from both sub-units in its active site. The 2D interaction plot (Figure 9.4.) 
highlighted the position of inhibitor B9 in the HIV-Nef dimeric cleavage and common active site 
residues from each dimeric subunit. The binding mode clearly shows the presence of a 
hydrophobic/aromatic moiety, which is involved in proper binding of inhibitor in the dimeric 
groove, consists of some major active site residues involved in dimer packing e.g. Asp108, 
Pro122, Leu112. Figure 9.4 further highlights the position of pharmacophoric features, which 
are necessary for a proper binding of inhibitor within residues involved in dimer packing e.g. 
Gln104, Asn126, Gln107. The detailed pharmacophoric feature described in one of our recent 
communication in combination with a recently reported structure activity relationship study36 
may provide structural benchmark to develop novel small molecule inhibitors using a rational 
approach37. 
 
It is believed that binding of compound B9 in the HIV-Nef dimeric cleavage leads to inhibition 
of HIV-Nef dimerization. The docked structure of compound B9 was further used to obtain a 





Figure 9.3. Residue interaction plot of compound, B9 inside the active site of HIV-Nef. Green dotted lines 
denote hydrogen bond interactions. 
 
 
Figure 9.4. A. 2D interaction map of compound B9 at the dimeric cleavage of HIV-Nef. Yellow and light 
green indicates the location of residues in each helical subunit. B. Pharmacophoric feature of target bound 




9.5.2. MD simulations and post-dynamics analysis 
9.5.2.1. RMSD, RMSF and radius of gyration (Rg) 
 
Figure 9.5 highlights the time dependent root mean square deviation of backbone C-alpha atoms 
for both HIV-Nef free and ligand (B9) bound conformation. It was noticed that the backbone of 
both systems were well stabilized after a 30 ns time period. However, a larger magnitude (~2 Å) 
of fluctuation was observed in case of unbound conformation of HIV-Nef when compared with 
bound state. One possible explanation of this phenomenon is that the attachment of inhibitor 
molecules inside HIV-Nef active site leads to a conformational rigidity, which hampers 
conformational evolution of HIV-Nef, especially during the process of dimerization. 
 
Figure 9.5. C-alpha backbone RMSD for HIV-Nef free and ligand bound conformations. The average C-
alpha RMSD found to be 5.18 Å and 3.72 Å respectively for apo and B9 bound complex of HIV-Nef. 
 
 
To assess the effect of inhibitor (B9) binding on the conformational flexibility of the HIV-Nef, 
per-residue RMSF of C-alpha carbons were computed for both ligand bound and apo 
conformations. From per-residue fluctuation (Figure 9.6.) it can be clearly noticed that presence 
of inhibitor inside the active site of HIV-Nef highly affected the conformational flexibility of the 
overall protein structure, which reflects the inhibition of dimerization in presence of inhibitor. 
The significant difference (~2 Å) in average per-residue fluctuation clearly indicates a 
conformationally flexible nature of apo conformation, which might account for the disruption in 
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dimerization. Furthermore, a more flexible region was observed between residues 138-152 which 
are located in one of the dimeric helix section of Nef (apo conformation). The higher value in 
RMSF might be due to the process of dimerization, which involves flexible helical residues 
located at Nef dimers. Whereas, the presence of B9 in the helical region inhibits the process of 
dimerization that affects the overall RMSF of Nef-B9 complex, as highlighted by lower average 
RMSF as well as lower magnitude of per-residue fluctuation at the helical region. 
 
 
Figure 9.6. Residue based fluctuation of HIV-Nef free and inhibitor bound conformations of HIV-Nef during 
the simulation time. The average C-alpha per-residue fluctuation for apo and bound conformations were 
found to be 12.26 Å and 10.48 Å respectively. 
 
The overall fluctuations in RMSF further correlate with C-alpha RMSD fluctuations, which 
confirm a larger overall fluctuation in case of free conformation when compared with ligand 
bound conformation of HIV-Nef. Figure 9.7 highlights the deviation of C-alpha residues located 
at the helical region of HIV-Nef active site, which clearly indicates more flexible nature of 
residues in unliganded (apo) HIV-Nef system when compared with bound conformation. The 
apo conformation showed a higher value of C-alpha deviations at the Nef helical region with an 
average RMSD of 5.17 Å, whereas its B9 counterpart displayed a comparatively lesser deviation 
with an average RMSD of 3.71 Å. This significant difference in C-alpha RMSD’s (~2 Å) 
between helical region of native apo and bound conformations further highlights the helical 
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flexibility, which played a significant role in the process of dimerization. Thus it can be further 
postulated that attachment of inhibitor B9 in the helical active site of HIV-Nef leads to 
conformational rigidity, consequently impairs dimerization process.  
 
Figure 9.7. Deviation of C-alpha atoms of residues located at the active site helical region involved in the 
process of dimerization. The average RMSD’s between apo and B9-Nef complex found to be 5.17 Å and 3.71 
Å respectively. 
 
These findings were further supported by the findings observed from the radius of gyration (Rg) 
(Figure 9.8.).  
 
Figure 9.8. Radius of Gyration (Rg) of C-alpha atoms of HIV-Nef free and ligand bound conformation. The 




The shape and folding of Nef-bound and free conformations over the trajectory can be seen in 
terms of Rg. Throughout the simulation, the apo conformation of HIV-Nef showed 
comparatively higher Rg value as compared to B9-Nef complex. The native apo conformation 
displayed an average Rg of 20.64 Å whereas B9-Nef complex displayed a significantly lower Rg 
fluctuation with an average value of 19.04 Å. This larger breathing in Rg (~1.5 Å) in case of 
native apo conformation highly correlates with per-residue fluctuations and RMSD outcomes 
which justified an increased biomolecular flexibility of apo structure as compared to bound one. 
Binding of inhibitor B9 in the dimeric cleavage of HIV-Nef and its negative effect on dimeric 
flexibility confirms its inhibitory mechanism by hampering the overall biomolecular flexibility 
and dimer packing.  
 
9.5.2.2. Understanding HIV-Nef dimerization 
To further understand the dynamics of dimerization process, the distance between the 
orthogonally opposed residues11 in each dimeric subunit are monitored along the dynamic 
simulations. These residues are highlighted in Figure 9.9.  
 
 
Figure 9.9. Position of orthogonally opposed residues at the dimeric helix of HIV-Nef believed to be involved 
in the process of dimerization10, 11. 
 
Figure 9.10, 9.11, 9.12 and 9.13 clearly suggests that in case of apo protein the distances 
between the orthogonal residues are significantly less when compared with bound conformation 
of HIV-Nef. Snapshots along the pathway of molecular dynamics simulations for apo and B9 
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bound conformations of HIV-Nef further justified a lack of dimerization in case of Nef-B9 
complex (Figure 9.14.). The average distances between C-alpha atoms of orthogonally opposed 
Leu112, Gln104 and Asp108 residues in case of B9 bound conformation of HIV-Nef found to be 
11.24, 24.23, 17.32 and 32.38 Å respectively. Whereas, in case of apo conformation the 
magnitude of average distances were comparatively less as the average C-alpha distances 
between Leu112, Gln104 and Asp108 found to be 10.93, 11.62 and 13.73 Å respectively. These 
significant differences in distances among residues involved in dimer packing confirmed lack of 
dimerization in Nef-B9 complex. This fact further co-relates with the experimental outcome, 
which confirmed a disruption of Nef dimerization by B9 using a cell based assay10. 
 
Molecular dynamics simulations further revealed that another oppositely placed helical residue 
present at the Nef dimeric region, Tyr115 moves further apart from each other in the B9 bound 
confirmation and thus confirming the inhibition in dimer packing as a result of disruption 
between two Nef helices (Figure 9.12.). The occupancy of compound B9 inside the active site of 
HIV-Nef dimer was found responsible in increasing the average distances among residues 
(Table 9.2.) involved in dimer packing, suggesting inhibition of HIV-Nef dimerization, which 
further substantiates the lack of conformational flexibility as a result of inhibitor binding.  
 
 
Figure 9.10. Distance between C-alpha residues involving Leu112 residues from both subunits. The average 





Figure 9.11. Distance between C-alpha residues involving Gln104’s from both subunits. The average distance 
between two oppositely placed Gln104 residues found to be 24.63 Å and 11.62 Å for B9 bound and apo 




Figure 9.12. Distance between C-alpha residues involving Asp108 residues from both subunits. The average 




Figure 9.13. Distance between C-alpha residues involving Tyr115 residues from each monomer. The average 
distances were found to be 32.38 Å and 31.70 Å respectively for bound and apo conformations respectively. 
 
Table 9.2. Residues involved in dimer packing 11 and their average distances from each other during 
simulation time. 

















Figure 9.14. Snapshots of apo and B9 bound conformations of HIV-Nef at a certain time interval during MD 
simulation. The residues highlighted in ‘green’ are responsible in the process of dimer packing. A and B 




Understanding the evolution of residues involved in dimer packing by analyzing the time 
dependent snapshots of apo and B9 bound conformation of Nef in combination with post 
dynamics analysis e.g. distance, Rg, RMSD, RMSF provides a model to understand the process 
of dimer packing and explain how the inhibitor gained access to the Nef dimeric site and its 
evolution in dimeric region leads to a dimeric inhibition. These outcomes from a classical 
molecular dynamics simulation unveils the large conformational drifts of HIV-Nef during the 
process of inhibitor binding which will prove effective in designing novel Nef dimerization 
inhibitors. 
9.5.2.3. Dynamic Cross Correlation (DCC) analysis 
Figure 9.15 highlights the cross correlation map calculated for apo and bound conformation of 
HIV-Nef. It is evident from the correlation map that more globally correlated motion is observed 
in case of the free conformation of HIV-Nef, which further justifies the fact that in free 
conformation HIV-Nef went through a process of dimerization causing a more correlated 
residue-residue interaction. On the contrary, in case of bound conformation, a greater existence 
of negative correlated motions during simulation time was observed. This fact is further justified 
by observing a higher occupancy of positive Cij patches in case of free conformation as compared 
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to bound one. Such findings provide a solid conclusion on the mechanism of dimerization 
inhibition by B9. 
 
Figure 9.15. DCC map during simulation time taking in account Cα residues of HIV-Nef ligand bound (A) 
and free (B) conformations. 
 
9.5.2.4. Principal Component Analysis (PCA) 
To further understand conformational preferences for both ligand-bound and unbound 
conformations of HIV-Nef, principal component analysis was carried out taking in account C-
alpha residues of both the systems. Figure 9.16 highlights the dominant changes in motion 
across two principal components in case ligand-bound and unbound configurations of HIV-Nef. 
It was found that eigenvectors computed from individual trajectories were quite varied between 
the two systems, which further emphasize on the difference in the conformational landscape 
between the free and ligand bound conformation. The difference in magnitude of Eigen values 
coming from first principal components of both apo and bound conformations found to be ~0.05 
Å whereas this difference was ~0.02 Å in case of the second principal component. This 
difference in average Eigen values across first two principal components suggests a greater 




Figure 9.16. Projections of Eigen values during simulation period for ligand bound and apo (free) 
conformations of HIV-Nef along the first two principal components (PC1 and PC2).  
 
Moreover porcupine plots across two normal modes clearly indicates a closer distance between 
helical dimers in free conformation when compared with B9 bound conformation of HIV-Nef 
(Figure 9.17 and 9.18). Also it clearly indicates an overall change in direction of motion 
between bound and unbound conformation of HIV-Nef. 
 
Figure 9.17. Porcupine plots across two different normal modes showing the direction of motion of 




Figure 9.18. Porcupine plots across two different normal modes showing the direction of motion of ligand 
bound (B9) HIV-Nef system. 
 
 We also opted to monitor residue-based biomolecular flexibility across different normal modes 
in order to further understand the conformational flexibility and rigidity of the two systems, free 
and bound protein (Figure 9.19 and 9.20.).  
 
 
Figure 9.19. Comparison of mobility plot of unliganded and ligand bound conformation of HIV-Nef systems 




Figure 9.20. Comparison of mobility plot of unliganded and ligand bound conformation of HIV-Nef systems 
in normal mode 2. 
 
 
Interestingly it was noticed that the flexibility of the residues ranging from 100 to 120 were 
comparatively higher in case of apo conformation of HIV-Nef across first two normal modes. 
The average difference in fluctuation between apo and B9 bound conformation of HIV-Nef 
within residues 100-120 found to be ~100 Å (mode 1) and ~5 Å (mode 2) respectively. This 
region contained residues involved in dimer packing. Normal mode analysis not only highlights 
the fact that the process of dimer packing affects the overall flexibility but also substantiates the 
findings of RMSD, Rg, and RMSF parameters and further justifies the process of dimerization 
and its impact on overall protein flexibility. 
 
9.6. Conclusion  
Molecular dynamics simulation reveals a dimer packing and unpacking phenomena of HIV-Nef 
in its apo and inhibitor bound conformations. Small molecule inhibitors such as B9, which 
targets the dimeric helical area of HIV-Nef, inhibits the process of dimerization thus leading to a 
more conformationally rigid system with hampered dimerization process. The RMSF, radius of 
gyration and mobility plots generated during normal mode analysis for both the systems 
suggested a more conformational flexible nature of HIV-Nef dimer in the absence of an 
inhibitor. The increased magnitude of parameters e.g. Rg (~1.5 Å), C-alpha deviations at the 
dimeric helix (~2 Å) suggested a greater conformational flexibility of Nef apo conformation and 
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a flexible dimeric helix. On the contrary, B9 bound conformation of HIV-Nef found to be more 
conformationally rigid with a lesser inter-dimeric association this the simulation period. Location 
of inhibitor, B9 in the active site of two helical subunits act as barrier in the process of 
dimerization which can be easily understood by monitoring the distance among residues 
involved in the process of dimerization and as well as by visual inspection of snapshots 
generated during the long range molecular dynamics simulation. The difference in magnitude of 
the distance parameter for inter-residue connection among Asp108, Leu112 and Gln104 found to 
be 4 Å, 1 Å and 12 Å respectively. This first account report highlights important dynamic 
features of an important HIV target, which would also serve as an initial point in the process of 
designing novel compounds against HIV-Nef as anti-HIV drugs. 
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10. General conclusions and future study recommendations 
10.1. General conclusions 
 
The six major aims of this study were to: 
1. Chapter 4 - To design novel inhibitors with potential dual activity against HIV 
Protease (PR) and Reverse transcriptase (RT) enzymes: 
 
On the basis of structural information retained in known HIV-1 PR and RT inhibitors and 
understanding their respective binding mechanisms to specific targets, five novel leads 
were proposed as potential dual acting PR/RT inhibitors. Herewith, using a hybrid “loop 
docking”/MD strategy as well as per-residue interactions calculations, the five proposed 
structures exhibited better binding in comparison to prototype drugs. Amongst these 
novel leads, compound 2 with a bis-tetrahydrofuranyl moiety displayed the most 
inhibition activity against both PR and RT enzymes.  
 
2. Chapter 5 - To verify the activity of hydroquinone-based compounds as non-
nucleoside reverse transcriptase inhibitors (NNRTIs), as proposed by Bruccoleri: 
 
Previously, flexible hydroquinone-based compounds were proposed as potential mutant-
resistant NNRT inhibitors, but no experimental or computational work supported this 
proposal. Therefore, via an integrated in-silico computational framework that included 
de-novo design, structure-based virtual screening (SBVS), MD simulations and post-
dynamic per-residue binding energy decomposition analysis, the binding affinity as well 
as the interaction landscape, novel flexible hydroquinone-based compounds exhibited 
NNRT inhibitor activity, respectively. These proposed leads demonstrated improved 
binding affinity as compared to FDA-approved NNRTI prototype drugs (i.e.  rilpvirine, 
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nevirapine and efavirenz), however, the bioavailability profile of these compounds could 
hamper their uses as effective drugs.   
 
3. Chapter 6 - To identify novel CCR5 antagonists as potential HIV-1 entry inhibitors 
using integrated computational tools: 
 
Using an integrated in-silico computational approach, which included homology 
modelling, hybrid structure-based and pharmacophore-based virtual screening, MD 
simulations, per-residue energy interactions calculations and atom-based 3D-QSAR 
analysis, ten potential compounds were proposed as novel CCR5 antagonists or potential 
HIV-1 entry inhibitors. These ten novel leads via validated docking binding free energy 
calculations revealed better binding affinities with CCR5 as compared to the only FDA-
approved HIV-1 entry inhibitor, maraviroc. Per-residue energy interactions calculations 
on averaged MD structures demonstrated that hydrophobic active residues Trp86, Tyr89 
and Tyr108 contributed the most to inhibitor binding. The validated atom-based 3D-
QSAR model exhibited a high cross-validated rcv2 value of 0.84 using three principal 
components and a non-cross-validated r2 value of 0.941. It was also observed that nearly 
all compounds in the test set and training set yielded a good predicted value.   
 
4. Chapter 7 - To provide a more comprehensive insight into the precise impact of the 
M184I mutation on RT resistance to lamivudine: 
 
The underlying atomistic nature surrounding the mystery of the M184I single point 
mutation that interferes and in turn leaves HIV-1 RT totally resistant to lamivudine was 
investigated and accomplished using MD simulations, binding free energy calculations, 
PCA and RIN analysis, respectively. Results revealed that single point mutations at 
residue 184 of RT caused; (1) distorted orientation of lamivudine within the active site as 
a result of steric confliction between the oxathiolane ring of lamivudine and side chain of 
beta-branched amino acids Ile at position 184 and therefore, perturbs inhibitor binding, 
(2) a reduction in the binding affinity (~8 kcal/mol) compared to the wild type protein, 
(3) disparity in overall protein motions evident from PCA performed on both systems and 
237 
 
(4) alteration of the hydrogen bonding framework and atomic interactions with the 
inhibitor. 
 
5. Chapter 8 - To identify more potent potential HIV-Nef inhibitors by exploiting the 
structural features of B9 using an integrated computational tools framework: 
 
To date, only one compound, known as B9, has been reported as a potent Nef inhibitor. 
Herewith, using a hybrid ligand shape-similarity-and pharmacophore-based virtual 
screening tactic, in conjugation with MD and further post-dynamic analysis, we identified 
and proposed top ten compounds from each compound library as new potential novel 
leads targeting HIV-Nef with a detailed analysis of their respective binding modes. 
Furthermore, the top identified hit compounds from the shape similarity-based library 
(ZINC04177596, ∆Gbind= -28.7482 kcal/mol) and pharmacophore-based library 
(ZINC36617540, ∆Gbind= -20.2271 kcal/mol) possessed comparatively better binding 
affinities compared to the reference molecule, B9 (∆Gbind= -18.0694 kcal/mol). Also, 
both top identified hits; ZINC04177596 and ZINC36617540 demonstrated relatable 
binding modes, as the prototype antagonist B9, at the Nef active site. The prominent 
binding forces were hydrophobic and electrostatic interactions, which were responsible 
for holding these ligands tightly in place at the Nef dimer interface.  
  
6. Chapter 9 - To reveal the dimer packing and unpacking phenomena of HIV-Nef in 
its apo and inhibitor bound conformations: 
 
Molecular dynamic simulations revealed a dimer packing and unpacking phenomena of 
HIV-Nef in its apo and inhibitor bound conformations. The only known small molecule 
Nef inhibitor, B9, targeted the dimerc helical area of HIV-Nef and inhibited the 
dimerization process, and thus produced a more conformational rigid system with a 
hindered dimerization process. During normal mode analysis conducted for both protein 
systems, the generated RMSF, radius of gyration and mobility plots advocated a more 
conformational flexible nature of HIV-Nef dimer in the absence of the inhibitor. As 
mentioned earlier, the Nef inhibitor B9, located at the dimeric active site acts as a barrier 
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during the dimerization process, and thus is easily understood by observation of inter-
residue distance parameters involved in dimerization and also by visual inspection of 
snapshots generated during the long range MD simulations. The disparity in magnitude of 
inter-residue connection distance parameters amongst Asp108, Leu112 and Gln104 were 
found to be 4 Å, 1 Å and 12 Å, respectively.  
 
 
10.2. Future study recommendations  
 
1. Chapter 4: Herein we reported the main concept and structural scaffolds of proposed 
dual acting PR/RT HIV inhibitors. In future, more meaningful binding free energy results 
could be achieved by using experimental data as a point of reference. Also extensive 
study on the relative binding affinities of more drugs against different PR and RT 
subtypes. The proposed structural scaffolds generated in this study could be used as a 
starting point for screening of a wider set of substituents for further lead optimization. 
Thus, synthesis and biological testing of proposed scaffolds is advised. Furthermore, 
newly developed structures and can be subjected for more computational analysis, for 
instance, the parameters used to calculate binding free energy needs to be optimized for 
more meaningful results. In order to provide more understanding into the proposed and 
other newly generated substituents dual activities and enzyme dynamics, advanced 
computational techniques such as PCA, RIN, QSAR and Substrate Envelope Analysis 
(SEA). Moreover, the in-silico strategy introduced in this study could be useful in the 
process of drug design and development, not only against HIV, but also for a wide range 
of other biological targets. 
 
2. Chapter 5: Via an integrated in-silico computational framework, the results in this study 
attempted to provide a contribution towards verifying the activity of hydroquinone 
compounds initially proposed by Bruccoleri. However, the experimental aspect is 
lacking, therefore the proposed scaffolds from this study could be subjected to further 
synthesis and biological testing to provide experimental support to the above-mentioned 
proposal. These proposed leads demonstrated improved binding affinity as compared to 
FDA-approved NNRTI prototype drugs, but, the bioavailability profile of these 
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compounds could hamper their uses as effective drugs. Results obtained from this 
extensive study could assist medicinal and biochemistry researchers with further 
experimental investigations. Advanced computational techniques such as PCA, RIN, 
QSAR and Substrate Envelope Analysis (SEA) could be used to provide deeper insight 
into inhibitor activity and protein dynamics.  
 
3. Chapter 6: The results in this study contributed towards shedding light on the activity of 
a new series of lead compounds as potential HIV entry inhibitors. Information gained 
from this study and the new series of novel lead compounds could serve as a powerful 
tool in the drug design and development process. Further screening and biological testing 
could be performed to provide validation to the computational work. Other advanced 
computational techniques such as PCA, RIN, SEA and QM/MM could be conducted to 
provide deeper insight into the different inhibitors activities and protein dynamics as well 
as protein-inhibitor interactions at the atomic level.  
 
 
4. Chapter 7: The comprehensive analysis presented in this report could provide useful 
information in future for researchers for understanding the drug resistance mechanism 
against lamivudine. The results could also provide some potential clues for further drug 
design of novel inhibitors that are less susceptible to drug resistance and contribute to the 
development of anti-HIV thereapy. The findings of this report could provide potential 
markers for further synthetic and biological testing of more novel drugs that are less 
susceptible to drug resistance. 
 
5. Chapter 8: The results in this study contributed towards the discovery of more potent 
inhibitors targeting HIV-Nef through exploitation of the structural features of B9 by 
using an integrated computational tools approach. As a result of the significant difference 
in the binding affinities between the identified hit compounds, ZINC36617540 and 
ZINC04177596 and the reference prototype drug, this prompted us to propose a set of 
structural criteria that could be imperative for further lead optimization and design of 
more potential small molecules targeting HIV-Nef. Further experimental investigation i.e. 
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screening and biological testing by medicinal and biochemists would boost the 
proficiency of the current report.  Other advanced computational tools such as PCA, RIN, 
SEA, DCC and QSAR could be utilized to provide deeper understanding into inhibitor 
activity and protein dynamics as well as protein-inhibitor interactions at the atomic level.  
 
6. Chapter 9: This first account report highlights important dynamic features of an 
important HIV target, which would also serve as an initial point in the process of 
designing novel compounds against HIV-Nef as anti-HIV drugs. The validation and 
proficiency of this current report could be achieved by further experimental investigation. 
Also, potential Nef inhibitors could be designed that focused solely on targeting the 
dimeric helical site of the HIV-Nef protein and possibly by using the QSAR methodology 
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Abstract In silico pharmacophore and structure-based
drug design guided by binding mode analysis and molec-
ular dynamics simulations is an effective approach for
identifying novel potent and selective inhibitors. Herein,
we demonstrated a unique strategy for developing dual
acting inhibitors against HIV-1 protease and reverse
transcriptase via an integrated computational protocol that
relies on ‘‘loop docking’’ and molecular dynamics simu-
lations, the designed targets exhibited binding affinities
comparable to, and in some cases better than, known active
reference drugs.
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Introduction
Three main HIV-1 enzymes have been exploited as the
core of chemotherapy for AIDS treatment. These enzymes
are HIV-1 protease (PR), reverse transcriptase (RT), and
integrase (IN) (Pani et al., 2002). However, designing
inhibitors to target each single enzyme have proved a
successful strategy for treatment, the therapeutic effect of
these inhibitors is drastically hampered by many implica-
tions. Nucleoside RT inhibitors (NRTIs) exhibited high-
intrinsic toxicity (Schinazi et al., 2006), whereas, the less
toxic protease inhibitors (PIs), non-nucleoside RT inhibi-
tors (NNRTIs), and integrase inhibitors (INIs) are severely
compromised by the rapid emergence of resistant viral
strains (Young and Kuritzkes, 2002; Bacheler, 1999; Mbisa
et al., 2011).
A common tactic to overcome HIV disease resistant to a
single therapy is the use of multidrug therapy. Highly
active antiretroviral therapy (HAART) (Yeni, 2006) com-
bines NRTIs with NNRTIs or PIs and effectively reduces
HIV viral load which in turn considerably improves the life
quality of AIDS patients (Palella et al., 1998). Even
though, HARRT proved successful, to ensure the efficacy
of this primary treatment for AIDS, complete adherence—
which is very difficult to attain because of complicated
dosing and intolerable acute and chronic toxicities—is
essential. Failure to achieve adherence typically results in
viral rebound and, even worse, multidrug resistance.
To this end, we envisage a dual acting anti-HIV therapy
using a single drug that concomitantly inhibits two viral
enzymes that could result in lower toxicity, simplified
dosing, and improved patient adherence, therefore reducing
the possibility of drug resistance.
The concept of designing of multifunctional ligands has
been proposed before (Morphy and Rankovic, 2009).
Multifunctional ligands were classified into three catego-
ries on the basis of how the scaffolds were combined
(Morphy and Rankovic, 2009): (a) conjugate, if scaffolds
are linked by a linker, (b) fused, if they directly coupled
with no linker, and (c) merged, if the scaffolds are inte-
grated into a single structure sharing common feature.
Another classification based on the targeted protein binding
sites was also introduced. Targeted protein binding sites
could be: (a0) adjacent within a single protein structure
(Lewis et al., 2002; Munoz-Torrero and Camps, 2006), (b0)
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located in different proteins but recognize similar endog-
enous ligands (Gemma et al., 2006; Yamamoto et al.,
2002), and (c0) located in different proteins but recognize
unrelated ligands (Kawanishi et al., 1996; Ryckmans et al.,
2002; Groneberg et al., 1999). In this report, we propose
potential inhibitors based on the above-mentioned (c and
c0) classifications.
In this study, we aimed to design novel inhibitors with
potential dual activity against HIV PR and RT enzymes.
Our design is initially based on the pharmacophoric fea-
tures conserved in most potent FDA-approved PR and NRT
inhibitors (Fig. 1). Then, the pharmacophore-based created
scaffolds were subjected to structure-based screening
against the respective enzyme to estimate their binding
affinities.
In the current work, the strategy to design potential dual
acting inhibitors is assisted by an integrated in silico
approach that exploits the structural features of both the
inhibitor and the enzyme active site. With no doubt that the
most appropriate way to verify the activity of in silico
designed target is the experimental in vitro and/or in vivo
testing, however, the time and cost factors should be con-
sidered carefully before testing anticipated inhibitors.
Validated computational tools could serve as useful tools to
save time and effort in the drug design process. In this
report, we introduce a ‘‘tough’’ in silico approach that
relies on the use of docking calculations followed by
molecular dynamics simulations to accurately estimate the
binding affinity, as well as the stability of the inhibitor–
enzyme complexes. As a matter of fact, we believe that
docking calculations could be entirely misleading and even
using the same software, in many case, may result in dif-
ferent predictions. In order to ensure reliable docking
results, we embarked on a novel approach which we name
‘‘loop-docking’’ to enhance the docking calculations
predications (see Methods: in silico design and validation
Fig. 1 The design of dual acting inhibitors is based on the
pharmacophoric features of known inhibitors for each enzyme target
and the binding theme of these pharmacophoric groups with the
respective enzyme active site. Darunavir–PR complex (PDB code:
3QOZ) and Zidovudine–RT complex (PDB code: 3KLF) were used in




sections). Furthermore, the docked structures were then
subjected to molecular dynamics simulations to ensure that
these docked structures are stable enough over a reasonable
time scale. Docked structures that fail to exhibit stability
during MD simulations are subjected to further docking or
rejected. The ‘‘loop docking’’/MD strategy has been tested
and proved successful on 30 X-ray crystal structures of
various ligand–protein complexes (a manuscript that fully
describe this approach has been submitted and under
review). Herewith, we report the main concept and struc-
tural scaffolds of proposed dual acting PR/RT HIV inhib-
itors. Screening of a wider set of substituents for further
lead optimization is still running. Synthesis of these com-
pounds is quite feasible and most starting structures are
commercially available. Since the synthesis and testing of
the proposed inhibitors is still on-going, detailed informa-
tion about the synthetic procedure, structural analysis, and
biological testing will be revealed in a forthcoming pub-
lication. Previously, we have released the X-ray crystal
structure of the HIV PR subtype C (Ahmed et al. 2013), as
well as several reports on the synthesis, NMR and bio-
logical testing of a series of anti-HIV PR inhibitors
(Honarparvar et al., 2012; Karpoormath et al., 2012;
Makatini et al., 2011a, b, 2013). Also, we demonstrated an
extensive study on the relative binding affinities of nine
anti-HIV FDA-approved drugs against different PRs sub-
types (Ahmed et al. 2013).
The unique strategy adopted in this report could serve as
a powerful tool in the process of drug design and devel-
opment, not only against HIV, but also for a wide range of
biological targets as well.
Methods: in silico design and validation
Constructing of the proposed structures
and conformational ensembles
Proposed structures were constructed and energy mini-
mized using Avogadros software (Hanwell et al., 2012). To
ensure thorough conformational sampling of the ligand
candidates, low-energy conformations were generated for
each molecule using Omega v1.8b (Hawkins et al., 2010).
For each compound, conformers generated within a range
of 3.0 kcal/mol from the lowest energy conformer were
investigated.
Protein systems
Protein structures were obtained from the protein data bank
(http://www.rcsb.org/). The PDB codes 3QOZ and 3KLF
were used for PR and RT, respectively. Procedure for
enzyme model preparation for docking and MD simulations
is explained in details elsewhere (Makatini et al., 2011a;
Karpoormath et al., 2012; Honarparvar et al., 2012).
Docking calculations: ‘‘loop docking’’
The idea behind our in-house ‘‘loop docking’’ approach is
based on the fact that consecutive docking runs could
remarkably improve the docking energy and orientation.
From our experience with docking, we realized that in
many cases the best-docked structure could be a docking
artifact and does not represent the best docking orientation.
Therefore, we always opt to rerun the docking calculation
using the best-docked structure from initial docking as a
starting structure for a second docking run and so on. We
used a few scripts to allow this process to be automated.
This automated ‘‘loop docking’’ will continue until a
threshold value (d) is reached. The threshold value (d) is
the difference between the docking binding energy of the
last run and the preceding one. A threshold value of 0.05
was found to be appropriate. When this imposed value
reached, the docking stops and the best-docked structure is
selected. Autodock software (Morris et al., 1998) is used
for docking calculations. Details on docking set up and
parameters can be found in our previous reports (Makatini
et al., 2011a; Karpoormath et al., 2012; Honarparvar et al.,
2012).
Molecular dynamics (MD) simulations
As before (Ahmed et al. 2013), MD simulations were
performed for all inhibitor-enzyme complexes (eight sys-
tems in total) using Amber software (Case et al., 2005).
Results and discussion
Design plan: pharmacophore and structure-based
design
Our design began with the chemical knowledge of the
structural features of PR and RT inhibitors, as well as the
anatomy of the binding sites of both enzymes. First, we
carefully studied the binding mode for all up-to-date
resolved HIV PR and RT X-ray crystal structures of ligand–
enzyme complexes to determine the common and most
conserved pharmacophoric groups that critically involved in
the ligand binding. However, finding a specific feasible way
to help us easily analyze these ligand–enzyme binding
themes was not an easy task to accomplish. After many
trials, we came up with an efficient and viable procedure.
For each enzyme class, PR and RT, all X-ray crystal struc-
tures were aligned using Chimera software (Pettersen et al.,




Table 1 2D structures, the calculated binding energy, and chemical properties based on Lipinski’s rule of five









MWt (511.2), LogP(1.4), Ha (7), Hd(5)
-9.3 -7.1
2
MWt (547.2), LogP(-0.13), Ha (9), Hd(5)
-9.5 -8.3
3
MWt (524.5), LogP(1.7), Ha (8), Hd(5)
-8.5 -6.7
4
MWt (539.5), LogP(0.50), Ha (9), Hd(6)
-8.4 -6.5
a Calculated binding energy for DRV and AZT against PR and RT enzymes, respectively




ligands to determine the common structural and binding
components. Then, Ligplot software (Wallace et al., 1995)
was used to create a visual map of the most critical binding
interactions between the ligands and enzyme active site.
Information gained from this extensive structural and
binding analysis allowed us to define the most important
fragments for each class of inhibitors, PRIs and NRTIs (see
Fig. 1). For PRIs, a characteristic structural feature is that
hydrogen bond donors in the core of the ligand is important
to form a hydrogen bond with the active site Asp25/Asp250
residues. It has been shown that the interaction between the
two catalytic aspartates and the hydroxyl group is worth
more than 4 kcal mol (Appelt, 1993). Another feature is that
the PR enzyme S1/S10 subsites are mostly hydrophobic and
ligand with hydrophobic groups that can fill in theses sub-
sites have showed significant enzyme inhibitory activity
(Brik and Wong, 2003). Some studies have also reported
that inhibitors that interact with the flap residues could be
potential inhibitors (Damm et al., 2008).
The same previous procedure has been repeated for the
X-crystal structures of RT–NRTIs complexes to understand
the binding theme of these inhibitors and obtain informa-
tion on the most critical pharmacophoric moieties. Unlike
PR inhibitors, it turned out that the binding behavior of
NRTIs slightly varies from one crystal structure to another,
however, seven amino acid residues seemed to be mainly
involved in the binding with the inhibitors. These amino
acids are Arg72, Gln151, Met184, Ala114, Asp113,
Tyr115, and Phe116.
Based on all the above-mentioned compiled informa-
tion, we proposed four main structural scaffolds (see
Table 1) that we believe it could exhibit dual acting HIV
Fig. 2 Compound 2 in complex with PR and RT, a and b, respectively, showing the hydrogen bonding and electrostatic interactions with




PR/RT inhibitory activity. Lead optimization and expan-
sion phases, in which a larger set of compounds will be
evaluated, are on-going. As mentioned above, synthesis of
these proposed targets is quite feasible and almost all
starting structures are commercially available.
Docking and MD simulations
The docking binding free energies for the proposed struc-
tures (1-4) against PR and RT are shown in Table 1.
Docking of reference drugs, Darunavir and Zidovudine,
was also performed for comparison (Table 1).
The docked complexes were then subjected to MD
simulation for 5 ns to ensure the stability of the ligands in
the enzyme active sites. Form our previous experience with
docking, in many cases, we found that, even the best
docked structure flies away from the enzyme active site
within a few picoseconds of MD simulations. Therefore,
we believe that docking calculations that are not validated
by relatively a long MD run to ensure the stability of the
system is not reliable. Interestingly, for all the proposed
compounds–enzyme complexes, the average RMSD values
were below 2.3 Å and the variation of the potential ener-
gies falls within 1,000 kcal/mol and this is a good indica-
tion of the system stability. The PDB coordinates for all
docked complexes (eight in total) are provided with the
supplementary material.
As evident from Table 1, interestingly, structure 2
shows the best binding affinity toward PR and RT. This
might due to the inclusion the bis-tetrahydrofuranyl




moiety. The bis-tetrahydrofuranyl moiety is found in
Darunavir structure and as we anticipated, inclusion of this
moiety resulted in a structure (compound 2) with high-
binding affinity comparable with Darunavir. As also seen
from Table 1, all the proposed structures show better
binding affinity toward RT than Zidovudine. This obser-
vation might be explained that inclusion of hydrophobic
fragments in the structures increases hydrophobic interac-
tions with the enzyme pocket residues and hence, improved
the overall inhibitor binding.
Ligand–enzyme interactions
Post-dynamic complex structures were analyzed to ensure
that the proposed structures fit well in the enzyme active
pocket and, to some extent, exhibit similar interaction
trends as the reference drugs with their respective enzyme
targets. As evident from the hydrogen bonding and elec-
trostatic interactions plots (Fig. 2), all proposed com-
pounds showed, to a great extent, comparable interactions
as in the crystal structures of the prototypes, DRV and AZT
(all PDB coordinates are provided in the electronic sup-
plementary material).
Per-residue interaction
For further lead optimization and expansion, it is useful to
have a quantitative estimation of the contribution of each
amino acid residues in the enzyme active site toward ligand
binding. To accomplish this, we computed the per-residue
interaction MolDock scoring function (Thomsen and
Christensen, 2006). Insight obtained from per-residue
interactions will allow us to tailor inhibitors that can
strongly interact with those residues showed the most
contribution toward the binding. Per-residue interactions for
compounds 2 with PR and RT are shown in Fig. 3a and b.
From the hydrogen bonding interaction plots and per-
residue interaction calculations, inhibitors clearly exhibited
strong interaction with PR enzyme via hydrogen bond with
the active site residues Asp25/Asp250, a conserved inter-
action seen in all X-ray crystal structures of PIs-enzyme
complexes. Interestingly, compound 2 showed a strong
interaction with the flap residues, Ile50/Ile500. Inhibitors
that can interact with flap residues are believed to interfere
with the flap opening and closure process, hence enzyme
normal function (Damm et al., 2008). With respect to RT,
proposed structures showed hydrogen bonding as well as
hydrophobic interactions with active site pocket residues,
most importantly with Tyr115, Asp110, Arg72, and Ly219
(Figs. 2, 3). These interactions were also seen in the X-ray
crystal structure of the AZT–RT complex.
As evident from the docking, MD simulations and per-
residue calculations, the four proposed lead compounds are
expected to be potential dual acting inhibitors and good
starting point for further optimization and expansion.
The design strategy presented here could be imple-
mented in the drug design and development process not
only against HIV targets but also against a wide range of
biological systems.
Conclusion
Based on the structural information of known HIV PR and
RT inhibitors and the understanding of their binding
mechanisms to the targets, novel leads were proposed as
potential dual acting PR/RT inhibitors. Using hybrid
computational approaches involving ‘‘loop docking’’ and
molecular dynamics simulations and per-residue interac-
tions calculations, the proposed structures were found to
exhibit better binding affinities when compared to the
prototype drugs. Compound 2 with bis-tetrahydrofuranyl
moiety was found to be the most active compound against
both PR and RT. The structures presented in this work are
proposed as promising leads for developing potential drugs
against HIV/AIDS therapy. Moreover, the in silico strategy
introduced in this study could be useful in the process of
drug design and development.
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Abstract: Using integrated in-silico computational techniques, including homology 
modeling, structure-based and pharmacophore-based virtual screening, molecular dynamic 
simulations, per-residue energy decomposition analysis and atom-based 3D-QSAR 
analysis, we proposed ten novel compounds as potential CCR5-dependent HIV-1 entry 
inhibitors. Via validated docking calculations, binding free energies revealed that novel 
leads demonstrated better binding affinities with CCR5 compared to maraviroc, an  
FDA-approved HIV-1 entry inhibitor and in clinical use. Per-residue interaction energy 
decomposition analysis on the averaged MD structure showed that hydrophobic active 
residues Trp86, Tyr89 and Tyr108 contributed the most to inhibitor binding. The validated 
3D-QSAR model showed a high cross-validated rcv2 value of 0.84 using three principal 
components and non-cross-validated r2 value of 0.941. It was also revealed that almost all 
compounds in the test set and training set yielded a good predicted value. Information 
gained from this study could shed light on the activity of a new series of lead compounds 
as potential HIV entry inhibitors and serve as a powerful tool in the drug design and 
development machinery. 
Keywords: CCR5 antagonists; HIV-1 entry inhibitors; homology modeling; virtual screening; 
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1. Introduction 
The Human Immunodeficiency Virus type 1 (HIV-1) infection, the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS) [1], still remains a fatal human health-threatening disease [2]. An 
estimated 34 million people live with HIV/AIDS worldwide [3,4]. The overall global estimate is that 
approximately 22.9 million of these individuals live in sub-Saharan Africa [3,4]. 
In AIDS therapy, the fundamental strategy is to inhibit viral replication and hence, to slow down the 
destruction of the immune system and prolong the lives of infected individuals. Currently, a number of 
viral targets are being used to develop anti-HIV drugs; which are essential for viral replication and survival, 
and these include, protease enzyme (PR) [5], reverse transcriptase (RT) [6] and integrase (IN) [7].  
Several drugs which are currently in clinical use have been developed to inhibit these potential viral 
targets, and such as integrase inhibitors, reverse transcriptase inhibitors and protease inhibitors [8].  
Numerous concerns regarding the long-term side effects of antiretroviral drugs and the increasing 
transmission of resistant variants accentuates the requirement to identify new classes of drugs, which 
are able to efficiently suppress HIV-1 replication [2]. Therefore, there is an on-going need for novel 
therapeutics, which can prevent the entry of HIV-1 into its target cells [9,10].  
The entry of the HIV virus into its target cell is mediated by the specific interactions of the  
target cell itself, such as the interaction between gp120 viral envelope glycoprotein and the plasmatic 
membrane receptors [11]. In turn, these specific interactions produce conformational alterations in 
both the glycoprotein and in the membrane receptors that facilitates fusion of the HIV virus and the 
target cell. Numerous studies have evaluated the role of CD4 and its interaction with gp120 and 
concluded that the CD4-gp120 interaction is a crucial component, but is not adequate for the disease to 
become established [12,13]. 
Besides CD4, recently certain chemokine receptors (CCRs) belonging to the G-protein  
coupled receptor superfamily (GPCRs) have been identified as co-targets crucial for viral entry into 
target cells [9,14]. Different CCRs and counterpart chemokine ligands (RANTES, MIP-1alpha and 
MCP2) are responsible for signaling regulation within immune cells and therefore are potential target 
systems for preventing virus-cell fusion. Several studies have reported on the identification and 
characterization of diverse CCRs [15]. Besides a single CCR that is viral strain-dependent, the 
majority of CCR strains are R5 isolates, which are transmitted during sexual intercourse and act on 
CCR5 throughout the disease [15].  
CCR5 has proven to be an important pharmaceutical target in the contexts of HIV-1 and  
other inflammatory diseases. This chemokine receptor functions as an integral protein in HIV-1 entry 
into host cells by acting as a crucial co-receptor for the gp120 viral envelope glycoprotein [1].  
Furthermore, experimental data revealed the importance of CCR5 in HIV-1 transmission. It was 
reported that individuals that are homozygous for the 32-base pair deletion for the CCR5 allele 
produce a defective CCR5 co-receptor and are resistant to R5-tropic HIV-1 infection, however are 
otherwise generally healthy [16]. This fact has been an instigating factor in the past decade for 
identifying anti-HIV agents that specifically targets CCR5-mediated entry mechanism. Furthermore, 
this implies that functional inhibition of CCR5 may help protect against infection without provoking 
damage to patients. Thus, blocking viral entry using small-molecule antagonists selective for CCR5 
might provide a new and more effective type of anti-HIV drug. 
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Although, the concept of designing small molecule CCR5 antagonists has been investigated  
before [1,10,17]; to date, no structural information about the precise binding site of CCR5 with any 
FDA-approved inhibitor is available. Several studies have reported CCR5 modeling of “potential” hit 
leads using computational approaches, including virtual screening, molecular docking, molecular 
dynamic stimulations and pharmacophore modeling. Perez-Nueno et al., reported a detailed 
comparative report of ligand-based and receptor-based virtual screening methods to unveil potential 
HIV entry inhibitors for CXCR4 and CCR5 receptors [18]. It has been documented that  
structure-based virtual screening methods yield better results as compared to ligand-based  
approaches. Afantitis et al. and Aher et al. identified CCR5 antagonists derived from  
1-(3,3-diphenylpropyl)-piperidinyl amides using virtual screening and quantitative structure-activity 
relationships (QSAR) studies [19,20]. In a previous report by Kellenberger et al. structure-based 
techniques were used to model the physics of protein-ligand interactions in conjugation with combined 
2D and 3D structure-based techniques [21]. Researchers have developed new approaches of combining 
computational molecular modeling methodologies, for example, molecular docking, 3D-QSAR, 
comparative receptor modeling and virtual screening to discover potential CCR5 HIV-1 entry inhibitor 
drugs [1]. Xu et al. studied the detailed interactive relationship between CCR5 and its inhibitors using 
a docking-based/ 3D-QSAR strategy along with protein modeling and MD stimulation [2]. However, 
in other mechanistic studies of protein-ligand entry inhibitor interactions, investigators have used 
homology modeling, molecular docking and molecular dynamic stimulation techniques [1].  
To this end, in this report, via hybrid structure-based and ligand-based virtual screening, we aim to 
identify novel CCR5 antagonists as potential HIV-1 entry inhibitors. A human CCR5 homology model 
template and maraviroc, a known FDA-approved CCR5 antagonist (Figure 1), were used as 
prototypes. Virtual screening of ligand-based compound libraries were generated via two distinct yet 
complimentary approaches: (a) structural similarity-based compound generated library—this library 
generated compounds that bear a 2D structural similarity to the reference drug maraviroc, whereas the 
(b) Pharmacophore-based generated library—this library generated compounds that contained the 
pharmacophoric features of the reference drug structure. Merging these independent compound 
libraries allowed us to ensure that our generated hit lead library encompassed structural units with 
diversity, yet with mutual pharmacophoric and structural features. Furthermore, docking calculations 
were computed using the generated ligand-based compound libraries against the CCR5 enzyme. 
Figure 1. 2D Structure of the known FDA-approved CCR5 antagonist maraviroc. 
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To validate our docking calculations, the same docking approach adopted for the ligand-based 
libraries was then performed on a set of compounds with known experimental data obtained from 
inhibition assays against HIV-1 CCR5 and these results were compared against experimental data. 
Since molecular docking may not be a true reflection of the stability of an ligand-enzyme complex, 
therefore, in order to gain more insight into the stability of the resulted docked systems, the nature of 
the overall interaction themes between the generated ligands and the target protein, and the specific 
amino acids involved in ligand binding, we performed 1 ns MD simulations followed by extensive 
post-dynamic analysis.  
We took our study a step further by obtaining a set of 35 novel oxamino-piperidino-piperidine 
amide analogs with available IC50 (mM) data taken from literature for the development of our atom-based 
3D-QSAR model [1]. 
It is worth mentioning that the three dimensional (3D) CCR5 structure is not yet available. 
However, homology-modeling of CCR5 has been performed before [9]. Therefore, in this study, the 
actual human CCR5 homology model was developed using the crystal structure of CXCR4 as a 
structural template. Information gained from this study could shed light on the activity of a new series 
of lead compounds as potential HIV entry inhibitors. This study should serve as a powerful tool in the 
drug design and development machinery. 
2. Computational Methods  
2.1. Homology Modeling of CCR5  
In order for our molecular docking study to be executed, the crystal structure of human CCR5 was 
homology modeled using the human CCR5 protein sequence retrieved from the UniProt database [22] 
(Uniprot ID: P51681). The actual homology model of CCR5 was developed using the crystal structure 
of CXCR4 (PDB ID: 3ODU) as a structural template and using the Modeler software [23] add-on in 
Chimera [24]. Hydrogen atoms were included in our enzyme model, whilst all other important active 
site residues were identified using Chimera Multi-align Viewer [24].  
2.2. Maraviroc Structure Acquisition and Preparation 
Maraviroc, the known FDA-approved CCR5 antagonist, was obtained in a mol2 file format from 
the DrugBank [25–27]. This CCR5 antagonist had its geometry optimized and energy minimized using 
the MMFF94 force field found in Avogardros software [28]. Thereafter, for subsequent analyses, 
maraviroc was kept in the mol2 format. 
2.3. Ligand Library Generation 
2.3.1. Structural Similarity-Based Compound Library Generation 
Maraviroc was used as the template for generating the 2D shape similarity-based compounds library 
from the Zinc Database. The maraviroc structure was drawn using the MarvinSketch software [29]. 
This reference template was used uploaded and queried the Zinc Database for all structures that had 
greater than 60% shape similarity to maraviroc. The query search generated a total of 1,002 compound 
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hits. As explained in our earlier report, certain physiochemical filters were implemented to enhance the 
structural query process [3]. In this study, the default physiochemical filter was set at drug-like 
qualities. Only compounds with molecular weight between 150 and 500 kDa were selected—this 
resulted in 480 hits. Other criteria were imposed to ensure the inclusion of the maximum number of 
compounds, such as the compounds had to have an xlog P between 4 and 5, a net charge between 5 
and 5, rotatable bonds between 0 and 8, a polar surface area of between 0 and 150, have hydrogen 
bond donors/acceptors between 0 and 10, and polar desolvation between 0 and 1 kcal/mol whereas 
compounds must have an apolar desolvation between 100 and 40 kcal/mol. Thereafter, these 
compounds were downloaded as a single mol2 file format and were individually separated into mol2 
files using the Molegro Molecular Viewer (MMV) software suite [29]. These files were then converted 
into a pdbqt format using the built-in Autodock Vina feature in the Raccoon software [30]. 
2.3.2. Pharmacophore-Based Library Generation 
The pharmacophore-based compound libraries were generated using the chosen pharmacophoric 
regions as illustrated in Figure 2 and the ZincPharmer Database [31]. Also, keeping in mind that the 
desired compounds would be selected based on their probability of forming good interactions with the 
receptor. Furthermore, the Lipinski Rule of Five was imposed as the set criterion for screening compounds 
not only for confining conformational variations of the same ligand, but also for reducing any duplication 
The query search generated a total of 602 compound hits. All these compounds were downloaded as a 
single sdf file format and then separated and processed as explained above in Section 2.3.1.  
Figure 2. Maraviroc structure used as a template for pharmacophore-based and structural 
similarity-based compound library generation. Pharmacophore selection criteria—green 
depicts hydrophobicity, purple depicts aromatic and white depicts hydrogen donor. Arrows 
indicate that constraints have been imposed. 
 
2.4. Virtual Screening and Validation of Docking Protocol 
In our study, the known CCR5 antagonist (maraviroc) and the two respective ligand-based compound 
libraries were subjected to virtual screening against the CCR5 enzyme. The Autodock Vina [32] screening 
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software was used to conduct docking calculations. Although the Screening procedure was run using 
the software default settings; the exhaustiveness of the screening was fixed to the value of 8. The grid 
box used to define the screening site was verified by using the built-in functionality property found in 
Autodock Vina [24]. The grid box was defined around the following key amino acid residues, namely 
Phe85, Trp86, Trp 89, Leu104, Tyr108, Ile 198, Try251 and Glu283,and these resembled the active 
site residues found in the crystal structure of CXCR4 enzyme following the sequence alignment 
performed in Chimera. The X, Y and Z centres were defined as 11.01, 2.08 and 45.68, whereas the  
X, Y and Z size dimensions were defined as 58, 82 and 74, respectively. Autodock Vina screening 
results were produced in the pdbqt format. From each of the two compound libraries, the top ten 
compounds were selected on the basis of best binding affinities and visualized using the Viewdock 
feature in Chimera.  
2.5. Molecular Dynamics Simulations and Post-Dynamic Analysis 
The best-docked ligand-enzyme complexes that resulted from the structure-based and 
pharmacophore-based compounds library were then exposed to MD stimulations using the Amber 
software [33], following the procedure explained in our previous report [34] were performed using the 
We examined the post-dynamic nature of how ligands interacted with the CCR5 target protein within a 
range of 5 Å as illustrated by hydrogen bond and hydrophobic interactions using the Molecular 
Viewing Operator (MOE) program [35]. Likewise, residue contribution towards ligand binding was 
computed using the Moldock scoring functions [29]. 
2.6. Three-Dimensional (3D) QSAR Analysis  
A set of 35 novel oxamino-piperidino-piperidine amide analogs (Figure 3) with available IC50 (mM) 
data was taken from literature for the development of the atom-based 3D-QSAR model (Table 1) [1]. 
This 3D-QSAR study was performed in Discovery studio 3.5 [36]. The 1/logIC50 value of CCR5 was 
used in this study. Of the 35 compounds reported, 26 compounds were used as a training set and the 
remaining nine compounds were used as a test set, based on a random selection. The compounds in the 
test set have a range of biological activity values similar to that of the training set. The ligands were 
pre-aligned using a molecular overlay method and placed in a 3D grid space (Figure 4). The grid 
spacing was 1 Å. The energy potentials on every grid point were then calculated using a CHARMm 
force field which used the electrostatic potential and the Van der Waals potential and treated as 
separate terms. A +1e point charge is used as the electrostatic potential probe and distance-dependent 
dielectric constant is used to mimic the solvation effect. For the Van der Waals potential a carbon atom 
with a 1.73 Å radius is used as a probe. The energy grid potentials can be used as independent 
variables to create partial least-squares (PLS). Furthermore, the best 3D-QSAR model was validated 
by predicting activities of the 9 test set compounds. The 3D-QSAR was evaluated by cross-validated 
R2, Q2. The predicted 1/logIC50 at 6th PLS factor are tabulated in Table 1. 
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Figure 3. The 2D structures for the oxamino-piperidino-piperidine amide analogs used in 
the 3D QSAR of this work. 
 
Table 1. Dataset analyzed for 3D QSAR with experimental 1/logIC50, predicted 1/logIC50 
and residual value.  

































































































































































































































































































































































t = test set. The conformation of compound denoted in brackets ( ) [1].  
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Figure 4. Molecular alignments used in the present study.  
 
Figure 5. (A) Superimposed structures of 3ODU [16] and modeled CCR5 enzyme (blue) 
with CCR5 antagonist, maraviroc [24]; (B) The 2D sequence alignment of 3ODU and the 
homology model generated for our study. Yellow highlighting represents -helices and 
green highlighting represents -sheets. Sequences outlined in red lack 3D crystal structure. 
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3. Results and Discussion 
3.1. Homology Modeling of CCR5 
The actual homology model of human CCR5 was modeled using the 3ODU crystal structure as a 
structural modeling template. As outlined in Figure 5, both these proteins demonstrated good structural 
similarity in and around the active site residues, with most of the residues having relatively identical 
locations to each other. The Multi-align Viewer tool located in Chimera recorded a 42.11% shared 
similarity between the two proteins’ sequences; after modeling, the enzyme model had a zDOPE score 
of 0.91 with an RMSD of 1.1771 Å. Four differences were observed between the active site sequences 
of our modeled CCR5 and the 3ODU model template, which included Leu204 (3ODU) corresponding 
to Leu104 (CCR5), Trp85 corresponding to Trp86, and two residue gaps namely corresponding to 
Leu213 and Phe113 from 3ODU (Table 2), respectively. We assume that these noted differences have 
had very minimal effects in the docking study as result of the shared structural similarity between the 
Leu and Trp residues, respectively. Further investigation is required to verify this assumption.  
All non-modeled regions were removed from the active site in order to allow for emphasis on all 
crucial residues and their importance in the active site of CCR5.  
Table 2. Comparison of the active site residues between the modeling template (3ODU) 
and modeled structure. 





























# —Differing Residue; * —Residue Gap. 
3.2. Virtual Screening 
Results obtained from virtual screening for the pharmacophore-based and structure-based compound 
libraries are shown in Table 3. Our query of the Zinc Database for compounds bearing 2D shape 
similarity-based identity to the reference drug template generated 220 compound hits. However,  
our query of the ZincPharmer Database for pharmacologically related compounds generated  
120 compound hits. All compounds in the two generated compounds libraries (see Methods sections 
for details) were then docked into the active site of the CCR5 enzyme using Autodock Vina and 
thereafter, from each library, we selected the top 10 compound hit leads. As shown in Table 3 and 
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Figure 6, all top 10 ranked compounds from each library exhibited remarkably higher binding energies 
compared to Maraviroc ( 10.2 kcal/mol), with binding energies ranging from 12.2 to 11.6 kcal/mol 
for the 2D shape similarity-based identity library, whereas the pharmacophore-based library had binding 
energies ranging from 12.0 to 11.4 kcal/mol. 
As outlined in Figure 6, an unexpected observation revealed that compounds that were structurally 
similar had higher binding affinities on average compared to those compounds that were 
pharmacophorically-based. Although, not a huge variance amongst both libraries existed, however, this 
was an indicator about the particular importance of each specific pharmacophoric area required for CCR5 
antagonistic behavior. This observation might be attributed to the selected pharmacophore-based 
groups. A further investigation is required for the imperative role played by these pharmacophoric 
groups in terms of site-specific interactions and in return, how do these interactions affect inhibitor 
binding affinities and functioning. It was also worth mentioning that compounds 3, 5, 7 and 8 from 
both the structure-based and pharmacophore-based generated libraries demonstrated exact binding 
energies (Figure 6). Another interesting observation, not a large difference existed amongst the top  
10 binding energies compounds from both the structure-based and pharmacophore-based generated 
libraries with a difference of 0.60 kcal/mol between the highest and lowest ranked compounds 
(Figure 6). This observation might be attributed to the conservancy of the crucial pharmacophoric and 
architecturally shared properties “amongst these compounds allowing for “alleged stability”, and hence 
for well-maintained binding affinities. 
With the intention of finding the best compounds of this study, we integrated both the generated 
compound libraries and revealed the top 10 best-docked compounds (Figure 7 and Table 3). It was 
instantly observed that these compounds were remarkably larger in size as compared to maraviroc 
(Figure 7). Furthermore, majority of the compounds occupied the spaces between Tyr89, Trp94, 
Glu283, Leu104, Thr195, Tyr251, Phe109, Ile198 and Trp248 respectively, something which 
maraviroc did not achieve as a result of its smaller size (Figure 7). In this study, integration of these 
factors might be the contributing factors for the higher binding affinities as the total number of 
interactions with the active site was remarkably higher compared to those felt by maraviroc.  
From our docking calculations, it appeared that the virtual screening compound hits demonstrated  
good activity as CCR5 antagonists. Several factors might have contributed to these findings, however 
one of such importance to us was that the docking protocol implemented might have not been accurate 
enough to provide precise estimates of the different binding energies. In an effort to eradicate this 
factor, we opted to validate the docking method applied in this study. “Cross validation” was not 
employed to validate our docking results. This is an approach, where other docking programs are used 
to validate the data attained from the original docking software. Due to previous experience of using 
different docking software with various scoring functions would generate results that could be 
different and be misleading, we opted to disregard this docking validation approach. We strongly 
believe that the utmost rational mannerism for validation of docking calculations, or even any other 
computational tool, is to perform the calculations on a set of compounds with available experimental 
data and these results are then compare against known experimental data for validation.  
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Table 3. List of the top 10 screened compounds based on their docked binding energy. Compounds are ranked in order of highest to lowest 
binding affinity. 
Library Rank ZINC ID Structure 
Binding Energy 
(kcal/mol) 
xlogP H-bond Donors H-bond Acceptors Molecular Weight (g/mol) 
Ref R ZINC03817234 10.2 3.50 2 6 514.69 
S * 1 ZINC71849549 12.2 2.27 2 6 318.89 
P ** 2 ZINC00825224 12.0 4.11 3 5 397.488 
P 3 ZINC00634884 12.0 5.96 1 6 481.60 
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Table 3. Cont. 
Library Rank ZINC ID Structure 
Binding Energy 
(kcal/mol) 
xlogP H-bond Donors H-bond Acceptors Molecular Weight (g/mol) 
S 4 ZINC32760563 11.9 3.47 0 5 388.51 
S 5 ZINC32760533 11.8 3.44 0 5 388.52 
S 6 ZINC25010434 11.8 2.16 1 7 431.54 
P 7 ZINC00851466 11.8 5.52 3 10 536.38 
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Table 3. Cont. 
Library Rank ZINC ID Structure 
Binding energy 
(kcal/mol) 
xlogP H-bond Donors H-bond Acceptors Molecular weight (g/mol) 
S 8 ZINC71818945 11.7 3.35 0 6 434.58 
P 9 ZINC00895646 11.7 3.99 2 7 451.55 
P 10 ZINC00895634 11.7 3.54 2 7 438.53 
* Similarity-based library, ** Pharmacophore-based library, Ref-Maraviroc. 
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Figure 6. The top 10 ranked ZINC compounds from both the 2D similarity-based and 
pharmacophore-based libraries.  
 
Rank Structure-Based Pharmacophore-Based 
1 ZINC71849459 ZINC00634884 
2 ZINC32760563 ZINC00825224 
3 ZINC25010434 ZINC00851466 
4 ZINC32760533 ZINC00877991 
5 ZINC71818945 ZINC00895634 
6 ZINC11546940 ZINC00895646 
7 ZINC19698213 ZINC00895774 
8 ZINC25010439 ZINC01038388 
9 ZINC71849397 ZINC01080881 
Figure 7. Docking conformations of the known CCR5 antagonist (maraviroc) and the top 
10 ranked docked compounds from both the pharmacophore-based and structure-based 
libraries determined in this study, all-complexed with the CCR5 enzyme. 
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To this end, in order to validate our docking approach implemented in this study, we performed 
docking analyses on a set of compounds assayed using our docking method. The structures and 
experimental IC50 values were obtained from Binding database [37]. The binding energy of each 
compound was then plotted against its corresponding experimental IC50 value (Figure 8). As evident 
from the docking results (Figure 8), the docked energies are in great accordance with the experimental 
IC50. We observed that as the binding affinity increased (lower binding energy), the IC50 increased 
(Figure 8). We postulate that the larger the binding affinity, the more concentration is needed for 
complete enzyme inhibition. To us, this proves to be an interesting trend, since the top 10 ranked 
compounds which were obtained from both libraries (Table 3) had higher binding energies compared 
to any of those used in the assay. This implies that the docking approaches used in this work could be 
reliable enough to estimate the binding affinities for the top 10 ranked compounds (from both 
libraries—Table 3). 
Figure 8. The binding energies determined in our study and were compared against IC50 
values for the compounds assayed. The higher the binding affinity, the higher the IC50. 
 
3.3. Molecular Dynamics Simulations 
In order to gain more insight into the stability of the resulted highest ranked virtual screening hit 
complexes, the nature of overall interaction theme between the proposed ligands and the target protein 
and the specific amino acids involved in ligand binding, we performed 1 ns MD stimulations followed 
by extensive post-dynamic analyses on the ligand-enzyme complexes. 
MD stimulations of 1 ns were performed for the highest ranked virtual screening hit complexes 
(Figure 9), to ensure the stability of the ligand within the CCR5 active site. We also performed MD 
simulations on the reference ligand (maraviroc) bound to CCR5 (see Supplementary Material).  
From our previous experience with molecular docking, in many occasions, we experienced that even 
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MD stimulations. Therefore, we believe that docking calculations that are not validated by relatively a 
long MD run to ensure stability of the system might not be reliable. Interestingly, for all the 
compound-enzyme complexes, the average RMSD values were below 2.5 Å. In addition, the 
variability of the potential energies fell with 1000 kcal/mol and this suggested being a good indicator 
of the system stability.  
Figure 9. The highest ranked virtual screening hit lead complexes with CCR5 subjected to 
MD simulations. Structure-based compound (ZINC71849459) in complex with CCR5 
(Black). Pharmacophore-based compound (ZINC00634884) with CCR5 (Blue). 
 
3.4. Per-Residue Interactions 
In an effort to investigate the contribution of a single amino acid towards ligand (and/or antagonist) 
binding, we computed per-residue interactions using Moldock software [29] (Figure 10). The top 
ranked antagonist with the highest binding energy within each compound library was assessed, which 
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included ZINC71849459 from the structure-based identity library and ZINC00634884 from the 
pharmacophore-based library. We noticed that Lys197, Phe109, Trp86, Tyr89 and Try108 exhibited 
remarkably interactions with both of those docked ligands. However, Trp86, Tyr89, Thr105, and 
Tyr108 demonstrated especially better interactions with ZINC00634884 (pharmacophore-based library), 
whereas Lys197, Leu196 and Glu283 showed good interactions with ZINC71849459 (structure-based 
identity library). As shown in Figure 11, in order to gain a better understanding of the ligand-amino 
acid interactions occurring within CCR5’s active site, we generated a plot of the specific amino acid 
residues-ligand interactions using the MOE software [35].  
Figure 10. Per-residue interactions for the highest ranked compounds with the best binding 
energy from the structure-based and pharmacophore-based libraries. 
 
The MOE plot analysis of ZINC71849459 bound to CCR5 enzyme’s active site revealed that the 
ligand was especially well surrounded electrostatically by several amino acid residues within the active 
site (Figure 11A). However, it could be noted that the ligand ZINC00634884 bound to the active site 
was not well cradled electrostatically by the amino acid residues compared to the former (Figure 11B). 
An interesting observation was that not a single amino acid formed any hydrogen bonds between the 
protein and ligand for anyone of the two ligands investigated. As shown in Figure 11, on average the 
hydrophobic amino acid residues played crucial roles in protein-ligand interactions than the 
hydrophilic amino acid residues. Another important observation was that the stronger ligand-amino 
acid residue interactions exhibited here in Figure 11 matched to those outlined in Figure 10.  
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Figure 11. Pharmacophore-based compound (ZINC00634884) with CCR5 (A) and 
Structure-based compound (ZINC71849459) in complex with CCR5 (B), respectively, 
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3.5. Atom-Based 3D-QSAR 
The atom-based 3D-QSAR model was developed from the training set of 26 inhibitors (Table 1) 
and the test set of 9 inhibitors using molecular overlay alignments (Figure 3). This atom-based  
3D-QSAR model was built after model development and validation based on the internal predictions 
of the training set and the external predictions of the test set. PLS analyses of the CCR5 inhibitor 
training sets showed a high cross-validated rcv2 value of 0.84 using three principal components and 
non-cross-validated r2 value of 0.941. All of the parameters of these QSAR model showed certain 
reliability and feasible predictability to help us design new and high selectivity CCR5 inhibitors. From 
Figure 12, we can see that almost all compounds in the test set and training set yielded a good 
predicted value. The graphical plot of observed vs. calculated TPH1 inhibitory activity for both the 
training set as well as the test set is shown in Figure 12. 




In the present work, the structure of human CCR5 was homology modeled using the crystal 
structure of CXCR4 as a structural modeling template. The protein appeared to be modeled with a 
remarkably degree of accuracy, specifically at the active site where docking studies were performed. 
Our query of the ZINC database for drug-like compounds that shared 2D shape similarity-based 
identity and query of ZINCPharmer for pharmacologically related drug-like compounds to a known 
FDA-approved CCR5 antagonist called maraviroc. The entire top 10 ranked compounds from each 
library exhibited remarkably higher binding energies compared to the best-docked structure of 
maraviroc. Moreover, an unforeseen observation revealed that compounds that were architecturally 
similar had higher binding energies on average compared to those that were pharmacophorically-based.  
To validate our docking calculations, the same docking approach adopted for the ligand-based libraries 
was performed on a set of compounds with known experimental data attained from inhibition assays 
against HIV-1 CCR5 and the results were compared against experimental data. The docked energies 
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favorable predicted binding energies than the known drug maraviroc will have “better activity”  
(i.e., smaller IC50 values). To us, this proves to be an interesting trend, since the top 10 ranked 
compounds which were obtained from both libraries had higher binding energies compared to any of 
those used in the biological assay, therefore it stands to reason compound hits elucidated in this study 
exhibit humble activity as CCR5 antagonists. Also, this implies that the docking approaches used in 
this work could be reliable enough to estimate the binding affinities for other compounds to be studied. 
Furthermore, from our previous experience with molecular docking, and in numerous insistences, the 
reliability of a stable protein-ligand complex might not be a true reflection. Therefore, in order to 
obtain more insight on the stability of the resulted docked complexes, the nature of the overall 
interaction themes between the generated ligands and the target protein, and the specific amino  
acids involved in the ligand binding, we performed 5 ns MD simulations followed by extensive  
post-dynamic analyses on the ligand-enzyme complexes resulted from our docking simulations.  
We took our study a step further by obtaining a set of 35 novel oxamino-piperidino-piperidine amide 
analogs with available IC50 (mM) data taken from literature for the development of our atom-based 
3D-QSAR model. All of the parameters of the QSAR model showed certain reliability and feasible 
predictability to help us design new and high selectivity CCR5 inhibitors. Our novel identified leads 
have the propensity to be considered as potential CCR5 antagonists and moreover as potential HIV-1 
entry inhibitors. Information gained from this study could shed light on the activity of a new series of 
lead compounds as potential HIV entry inhibitors and should serve as a powerful tool in the drug 
design and development machinery. 
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